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 Abstract 
Efforts to increase the survival rate of patients suffering from bone metastases have 
been largely unfruitful. This is primarily due to the lack of appropriate preclinical 
models that make it possible to recapitulate the key steps of the human disease and 
eventually develop efficient therapeutic strategies. In this PhD thesis new avenues 
have been entered by developing tissue engineered constructs composed of 
biomimetic scaffolds and human mesenchymal progenitor cells and their matrix 
products to mimic functionally defined humanized organoids within immuno-
compromized murine hosts. Following this novel approach, it was demonstrated that 
it is possible to engineer a morphologically and functionally intact humanized bone 
organ in vivo. Human osteotropic cancer cells injected via the left cardiac ventricle 
homed to the humanized bone organs and developed bone metastases. Human 
haematopoietic stem cells were likewise able to home to the constructs resulting in 
the humanization of the bone marrow and human haematopoiesis. The model 
presented here could potentially satisfy the need for a preclinical platform in which 
both human cancer cells and human immune cells can be manipulated within a 
humanized microenvironment. These experiments are the first steps towards the 
development of individualized, patient-specific diagnostic and therapeutic models of 
bone metastasis.  
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 Chapter 1: Introduction 
1.1 THE CLINICAL PROBLEM OF BONE METASTASIS 
Cancer is the leading cause of death in economically developed countries and 
this is primarily due to the spread of cancer cells to distant organs [1, 2], with the 
skeleton representing the most common site to be affected [3]. Carcinomas of the 
thyroid, kidney or bronchial system commonly form bone metastases. While their 
incidence in post-mortem examinations is between 30-40%, tumours of the gastro-
intestinal tract rarely give rise to bone metastases [4]. The highest prevalence of bone 
metastases however, is found in breast and prostate cancer, accounting for up to two-
thirds to three-fourths of all cases of metastatic bone disease [5]. Post-mortem 
examinations were able to demonstrate that approximately 70% of patients dying of 
these cancers have at least one bony lesion [4]. The high prevalence of osseous 
lesions associated with these tumour entities is not only due to their high incidence 
and osteotropism, but also due to the frequently prolonged clinical course of patients 
suffering from these tumours [6]. The median survival of patients diagnosed with 
bone metastases from breast and prostate cancer is relatively long and can be 
measured in years. In contrast, the survival time of patients diagnosed with 
metastatic bone disease in advanced lung, colorectal or renal cancer is usually 
measured in months [1, 3, 7, 8] (Table 1.1). Generally, the prognosis of patients with 
disease that remains confined to the skeleton is considerably better than that of those 
with involvement of visceral organs [5]. Single lesions are associated with a better 
prognosis than multiple skeletal lesions and, at least for patients suffering from 
prostate cancer, the dissemination to the appendicular skeleton is synonymous with a 
more advanced stage of the disease [9-11].  
Introduction 13 
 Tumour 
entity 
 
 
 
5-year global 
prevalence 
(per 100.000) 
 
Global incidence 
(%) 
 
 
Incidence of bone 
metastasis (%) 
 
 
Median survival after 
development of bone 
metastases (months) 
 
 
Breast 210.7 10.9 65-75 19-25 
Prostate 130.4 7.1 65-75 12-53 
Colo-
rectum 
66.3 9.8 5 <10 
Lung 34.1 12.7 30-40 6-7 
Bladder 23.9 3.0 40 6-9 
Thyroid 17.5 1.7 60 48 
Melanoma 15.4 1.6 14-45 <6 
Kidney 15.1 2.2 20-25 6 
Table 1.1. Prevalence, incidence and prognosis of common solid tumours associated with metastatic 
bone disease. Table reprinted from Rudert et Holzapfel [12], © 2014, with kind permission from 
Springer Science and Business media. 
At the time of initial diagnosis of a solid tumour, most patients do not have 
clinical signs of distant metastases. After excision and local tumour control, these 
patients are per definition in complete clinical remission. During disease progression, 
early stage detection of bone metastases is difficult due to the refractory nature of 
bone tissue. In many cases, bone metastases are not diagnosed until patients suffer 
from so-called skeletal related events (SREs). These include pathological fractures, 
spinal cord compression, hypercalcaemia, bone pain requiring palliative radiotherapy 
and orthopaedic surgery [3]. However, a long time before bone metastases become 
clinically relevant, circulating tumour cells (CTCs) in the peripheral blood or 
disseminated tumour cells (DTCs) in the bone marrow can be detected [13]. DTCs 
can stay dormant for many years without developing overt skeletal lesions. During 
the course of the disease, only a very small subpopulation of metastasized cells 
acquires the ability to develop clinically relevant bone metastases. Nevertheless, 
there is increasing evidence that the general presence of CTCs can be associated with 
poor prognosis related to metastatic progression in the skeleton and other organs, 
respectively [14-16]. Bone marrow aspiration is already part of the routine screening 
for leukaemia but it hasn’t found its way into clinical practice for the routine 
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 diagnosis of solid tumours so far. More sensitive novel techniques are currently 
under investigation to enable the detection and characterization of DTCs or CTCs 
from solid tumours [13]. However, there is still a long way from bench to bedside as 
these techniques are at the moment not sensitive and reliable enough and do therefore 
not justify the additional costs [17]. Hence, bone metastases of breast and prostate 
cancer are still diagnosed at a rather advanced stage of the disease. 
From a clinical point of view, patients with overt signs of osseous lesions 
have entered a so far incurable stage of the disease. From then on, treatment options 
for cancer related bone disease are palliative. However, as the clinical course of 
patients with bone metastases from prostate or breast cancer is usually quite 
prolonged, metastatic bone disease should be seen as a chronic condition that has to 
be carefully managed in order to maintain an adequate quality of life of the affected 
patients. Due to the high prevalence and prolonged clinical course of metastatic bone 
disease in breast and prostate cancer, the economic burden is tremendous. 
Epidemiological studies suggest, that approximately 280.000 adults in the U.S. were 
living with bone metastases on December 31st 2008 [6]. Schulmann and Kohles 
estimated that the mean annual medical costs for this group of patients were $75,329 
compared to $31,082 for patients with cancerous disease without bone involvement. 
The authors also estimated the annual national burden for patients with bone 
metastasis to be $12.6 billion, suggesting that metastatic bone disease is a significant 
driver of overall cancer related costs [18]. In the future, these numbers will most 
likely rise as the incidence of tumour entities associated with higher age such as 
prostate cancer is expected to increase in parallel with longer life expectancy in 
developed nations [19].  
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Complications and SREs 
 
Spinal cord compression 
Nerve root compression 
Impaired mobility 
Pathological fractures 
Orthopaedic Surgery 
Bone pain 
Bone pain requiring radiotherapy 
Anaemia 
Hypercalcaemia of malignancy 
Infiltration of bone marrow 
 
 
 
 None  Any  Percent  
Breast (n=1130)  737  393  35  
Prostate (n=640)  518  122  19  
Other tumours (n=766) 639  127  17  
 
Metastatic bone disease is associated with high morbidity and can lead to 
severe complications that highly influence the quality of life of cancer patients. 
These complications are referred to as SREs and are used as composite endpoints in 
many clinical trials. SREs such as pathological fractures are associated with an 
increased mortality rate and are most common in breast and prostate cancer patients 
[20-23] (Table 1.2). 
 
 
 
 
 
Table 1.2. Left: Potential complications caused by metastatic bone disease. These complications are 
known as SREs. Right: Frequency of pathological fractures by tumour entity (adapted from [23]). 
Clinically relevant bone metastases are usually not treated under curative 
aspects as in many cases cancer has progressed to a systemic disease where multiple 
skeletal sites are involved. Most of the patients are conservatively treated using 
radiation or chemotherapy. However, in some rare cases - such as a single bone 
metastasis from a renal cell carcinoma - a curative surgical therapeutic approach can 
be justified where the affected bone is excised with wide resection margins and 
reconstructed with a prosthesis, allo- or autograft. Palliative surgical therapies aim to 
reconstitute the stability of the affected bone and preserve the patient’s mobility [24, 
25]. This leads to reduced pain levels and improves the patient’s quality of life. 
Recently, more and more treatment concepts have evolved that influence not only the 
replicating cancer cells but also their microenvironment. These novel treatment 
concepts have been developed in parallel to the growing understanding that processes 
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 such as tumour initiation, progression and metastasis are not only the result of 
genetic or epigenetic alterations of cancer cells but also significantly influenced by 
signals and factors provided by the microenvironment [26].  
1.2 PAGET’S SEED AND SOIL THEORY AND ITS SIGNIFICANCE IN AN 
HISTORICAL CONTEXT 
The organ distribution of metastases from a primary tumour is not random. In 
fact, the establishment of metastases within any organ or tissue requires reciprocal 
interactions between tumour cells, host cells and the microenvironment [27]. In a 
similar although metaphorical way this was first postulated by Stephen Paget in 
1889: “...Every single cancer cell must be regarded as an organism, alive and capable 
of development. When a plant goes to seed, its seeds are carried in all directions; but 
can only live and grow if they fall on congenial soil...” [28, 29]. By analysing 
autopsy records of 735 women with breast cancer, Paget could document a non-
random pattern of metastasis. He concluded that certain tumour cells with metastatic 
activity (the “seed”) would have a specific affinity for the milieu within certain 
organs (the “soil”) [28]. In other words, Paget suggested that metastases only 
develop when the “seed” and the “soil” are compatible.  
In 1928, James Ewing presented an alternative explanation for the preference 
of some cancer cells forming metastases in specific organs. He hypothesized that 
metastatic dissemination occurs by purely mechanical factors and the specific 
distribution pattern mainly is a result of the anatomical connections of the primary 
tumour within the vascular system. Organs that are the first drainage stations for 
tumour cell emboli would sustain the highest burden of tumour cell colonisation [30].  
Though, this viewpoint prevailed for many years, the exclusive validity of this 
hypothesis could clearly be refuted in the following decades.  Even more: Paget’s 
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 theory again gained popularity in the scientific community with the results of the first 
animal models analysing the distribution pattern of metastases. In 1952, Lucke et al. 
analysed the different growth behaviour of carcinoma metastases in the lungs and 
livers of rabbits. They found that liver metastases were larger and more numerous 
than the metastases in the lung. The authors could make these observations also in 
human autopsy studies, indicating that both mechanical and local factors of the host 
tissue are likely to determine metastasis development and growth behaviour after 
arrest of tumour emboli in the capillary system [31]. The same working group clearly 
demonstrated that not every tumour embolus is developing into a metastasis. Some of 
them do actually have the ability to pass through the capillary and consequently 
through the vascular bed of organs [32].  
Later on, J. Isaiah Fidler could isolate cells with different metastatic properties 
from the same parent tumour, indicating that not all cells in a primary tumour have 
the same potential to form metastases [33]. He and his working group also 
demonstrated that mechanical arrest of tumour cells in the capillary bed of distant 
organs indeed occurs, but subsequent growth and development of a metastatic lesion 
is markedly influenced by cells from the host organ [34, 35]. Furthermore, they 
demonstrated that there is even a specific distribution pattern for metastatic growth in 
different regions within one organ [36]. There were also other groups that made 
similar observations. Pilgrim et al. found different sizes of metastases, when 
injecting the same number of cells into the spleen and the kidney, respectively [37].  
In 1984, Tarin and co-workers reported the evidence of organ-specific 
metastasis in ovarian cancer patients after treatment with peritoneo-venous shunts 
due to peritoneal carcinomatosis. Unexpectedly, after treating the patients with the 
shunt, they found no greater load of metastases in the lung, despite the fact that its 
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 capillary bed captures the first draining of all the blood from the shunt between the 
peritoneum and the internal jugular vein [38].   All these findings corroborated 
Paget’s theory, indicating that metastatic growth is not only dependent on the 
characteristics of the neoplastic cells, but also on the microenvironment of the host 
tissue.   
1.3 CURRENT CONCEPTS OF THE PATHOPHYSIOLOGY OF BONE 
METASTASES AND NEW TREATMENT AVENUES 
Most researchers nowadays accept that there are elements of various theories 
one has to consider to understand the underlying principles of bone metastasis. After 
several decades of studying the genetic alterations involved in cancerogenesis, we 
are just starting to understand the biological principles behind the processes leading 
to skeletal metastasis. In 2003, Isaiah Fidler presented a revised definition of the seed 
and soil theory consisting of three principles [39]: i) Neoplasms are biologically 
heterogeneous and contain different subpopulations of tumour cells with different 
characteristics and a varying potential to form metastases. ii) The process of 
metastasis is selective for cells that succeeded the metastatic cascade, including steps 
such as invasion, embolisation, surviving in the circulatory system, cell arrest in the 
capillary bed, extravasation and proliferation in the organ parenchyma. Fidler 
pointed out, that “the successfull metastatic cell (the “seed”) has been likened to a 
decathlon champion who must be proficient in all ten events, rather than just a few” 
[40]. Development of metastases is only possible if the microenvironment of a 
specific organ provides special homeostatic mechanisms (the fertile “soil”) that the 
cancer cells can usurp. These physiologic interactions between cells and the host 
organ can promote survival, angiogenesis, invasion and growth of tumour cells. For 
the development of novel and effective treatment protocols against bone metastasis, 
it is therefore crucial to understand the different pathophysiologic mechanisms that 
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 are involved in the interplay of cancer cells and their homing site, the bone 
microenvironment. The first step in understanding these processes, however, is to get 
familiar with the physiological conditions and functional cellular interplay between 
cancer cells and the bone marrow milieu. 
1.3.1 Key cellular players within the bone marrow and development of the niche 
concept 
The importance of the bone marrow stroma for the maintenance of 
haematopoietic cells was firstly demonstrated in 1968 by Tavassoli and Crosby who 
transplanted autologous bone-free marrow in various ectopic sites in the rat [41]. 
After transient deprivation of the bone marrow, they observed a de novo bone 
formation with subsequent establishment of a sinusoidal network and finally a re-
population of the transplant by circulating haematopoietic stem cells (HSCs) [42]. 
The development of new bone in this system and the ability of the bone to maintain 
itself suggested that progenitors of skeletal tissues are included in the bone marrow 
[43].  
Friedenstein and Owen demonstrated that this osteogenic potential is attributed 
to the progeny of single bone marrow cell clones [44], a notion that later resulted in 
the concept of the so-called mesenchymal or skeletal stem cell (MSC) [45]. The 
findings of Crosby, Tavassoli and Maniatis, on the other hand, were the basis for the 
conceptualization of the haematopoietic stem cell niche by Schofield in 1978 [46]. 
According to the original concept, haematopoiesis is not possible without the 
regulating influence of specific microdomains of the bone marrow structure, even 
though HSCs per se possess the intrinsic capacity of self-renewal, multi-potency and 
long-term reconstitution [46].  
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 From an anatomic point of view, there are several regions within the bone 
marrow that are able to harbour haematopoietic stem cells: endosteal surfaces, 
sinusoids and stromal tissue [47]. The main regulating cellular components of the 
HSC niches are osteoblastic cells, haematopoietic cells, endothelial cells, adipocytes 
and stromal cells [48-53]. Several groups proved the case for the importance of these 
cell types for a functioning niche by demonstrating that pathologies of these cell 
systems usually come along with a likewise compromised haematopoiesis [54-57].  
Osteoblastic cells are well known for their regulatory role of HSCs. They 
produce several factors that are essential for haematopoiesis such as granulocyte 
colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating 
factor (GM-CSF) and leukemia inhibitory factor (LIF) [58, 59]. Deguchi et al. 
showed that mice deficient in the runt-related transcription factor 2 (RUNX2; also 
known as core-binding factor subunit alpha-1, CBFα1), a key factor associated with 
osteoblast differentiation, are not only characterized by a lack of intramembranous 
and endochondral bone formation but also by a complete absence of bone marrow 
indicating that osteoblasts play a pivotal role in the process of haematopoiesis [60].  
Zhang and colleagues demonstrated that an increase in N-cadherin+ bone lining cells 
by conditional inactivation of BMP receptor type IA (BMPRIA) resulted in an 
increase of HSC numbers in transgenic mice [49]. Calvi et al. used transgenic mice 
that express a constitutively active parathyroid hormone (PTH) receptor in 
osteoblasts to increase the number of osteoblastic cells, which in turn was associated 
with a higher number of HSCs.  PTH treatment of wild type mice was able to 
reproduce the effects seen in transgenic mice [61].  
While these studies support the role of osteoblasts as an important niche factor 
for HSCs, the importance of their specific differentiation status still remains unclear 
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 [47, 62]. Sacchetti and Corselli ascribed the ability to establish a HSC niche in vivo 
to a specific single cell type isolated from bone marrow, namely CD146+ clonogenic 
pericytes, a subset of mesenchymal progenitors with self-renewing capacity in vitro 
[62, 63]. In transplantation studies, they demonstrated that only these MSCs but not 
osteoblasts were able to establish a haematopoietic niche in vivo [62]. According to 
Paolo Bianco, CD146+ MSCs coincide with adventitial reticular cells (ARCs) 
residing in a perisinusoidal position and express not only genes typical for the 
osteogenic lineage such as alkaline phosphatase (AP) but also genes characteristic for 
vascular cells such as angiopoietin 1 [47]. Bianco calls this mesenchymal progenitor 
cell “a dynamic organizer of a complex system of effector cells” including its 
progenies such as adipocytes, osteoblasts and stromal cells [47].  It has been shown 
that mesenchymal progenitors are significantly involved in the production of stromal 
cell-derived factor 1 (SDF-1; CXC motif chemokine 12, CXCL12) and therefore 
control HSC homing and maintenance within the bone marrow [64].  
Sinusoidal endothelial cells also play a pivotal role for the proliferation, 
differentiation and migration of HSCs [65, 66]. Winkler et al. demonstrated that 
knockdown of E-selectin which is exclusively expressed by bone marrow endothelial 
cells, results in HSC quiescence and enhanced self-renewal potential indicating that 
E-selectin is a crucial factor of the niche by promoting HSC proliferation [66].  
1.3.2 Mechanisms that guide the homing of cancer cells to the bone marrow 
 To understand the pathophysiology of metastatic bone disease it is imperative 
to emphasize that there is a strong interdependence of cancer cells and the factors 
provided by their microenvironment. Interestingly, the particular cellular 
composition of the bone marrow contributes to the typical distribution pattern of 
metastatic lesions [67]. Cancer cells mainly spread to skeletal regions with a high 
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 content of HSCs reflecting the increased blood flow, high rate of haematopoiesis and 
specific factors provided by the microenvironment [68]. In adults, these regions are 
mainly represented by the vertebrae, the pelvis and the sternum. Metastases distal to 
the elbow and knee are distinctly uncommon (Table 1.3). In early childhood, 
haematopoiesis occurs also in the marrow of long bones such as the femur as in this 
age the conversion of red to yellow marrow is not yet completed. Therefore, bone 
metastatic disease in children does not infrequently involve both the axial skeleton 
and the appendicular bones. In 2012 Wang and Shen performed bone scan studies 
using 99mTc-methylene bisphosphonate in 144 patients with histologically proven 
prostate cancer and analysed the distribution features of metastatic bony lesions [69]. 
In early stages of the disease they found the highest proportion of bony lesions 
located in the spine. However, the more extensive the metastatic disease, the 
proportion changed in favour of other bones such as the pelvis, the thorax or the 
shoulder girdle. The particular distribution pattern of metastatic foci is easy to 
understand after dissecting the specific mechanisms that lead to the colonization of 
the bone marrow by cancer cells.  
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Table 1.3. Frequency distribution (%) of metastatic involvement of specific skeletal sites in patients 
with multiple bone metastases determined by bone scan studies. 
The cellular and molecular machinery within the bone marrow that guide 
homing and maintenance of cancer cells and HSCs is very similar [74]. During 
embryogenesis and also later during adolescence, HSCs migrate on highly specific 
cellular transit pathways. Guided by these pathways, they find their way from the 
bone marrow to locations within the body, where regeneration and healing is in 
process. Osteotropic cancer cells are able to use these transit pathways to colonize 
the bone marrow and compete with HSCs for their niche.  
Under physiological conditions, the SDF-1 – CXCR4 axis is the main control 
system for the homing and maintenance of haematopoietic stem and progenitor cells 
(HSPCs) within the bone marrow [75]. As outlined above, SDF-1 is highly produced 
by mesenchymal cells of the bone marrow microenvironment, whereas its receptor, 
CXCR4 is expressed by HSPCs, which enables them to be retained within the 
supportive niche in a gradient-dependent manner [76]. Osteotropic cancer cells 
eventually can mimic parts of the receptor profile of HSPCs including CXCR4 to 
 
 
[Reference] 
 
Prostate 
 
[70] 
Breast 
 
[71] 
Lung 
 
[70] 
Thyroid 
 
[72] 
Kidney 
 
[73] 
Spine 93 66 76 54 42 
Pelvis 89 50 68 50 48 
Ribs 83 58 71 31 48 
Skull 63 19 46 13 10 
Femur 49 15 41 21 23 
Humerus 34 9 29 11 10 
Shoulder 32 11 24 9 6 
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 establish footholds within the HSC niches [77, 78]. This pathway can serve as a 
target for drugs that block the interaction between SDF-1 and CXCR4 such as the 
CXCR4 receptor antagonist plerixafor (AMD3100). Plerixafor is used in the clinic to 
mobilize HSCs into the peripheral blood for the purpose of HSC transplantation [79]. 
Recent data has demonstrated that this drug could be a potential new therapeutic tool 
to treat bone metastases by mobilizing metastasized tumour cells from the bone 
marrow into the bloodstream and therefore sensitizing these cells to chemotherapy 
[80, 81]. Similar observations have been made in metastases bearing mice that were 
treated with G-CSF, a factor known to act as a potent mobilizer of HSCs [78]. This 
has led to the initiation of phase I and II clinical trials including patients suffering 
from metastases from solid tumours that were treated with CXCR4 antagonists [82].  
It has been hypothesized that specific changes in the molecular and cellular 
machinery of the bone marrow precede the arrival of cancer cells and lead to the 
development of the so-called pre-metastatic niche [83, 84]. Kaplan et al. showed that 
bone marrow derived haematopoietic progenitor cells expressing vascular endothelial 
growth factor receptor 1 (VEGFR1) home to secondary tumour sites in response to 
VEGF provided by primary cancer cells and form cell clusters followed by the 
arrival of VEGFR1 positive endothelial progenitor cells and cancer cells [85]. In this 
pre-metastatic niche, VEGFR1 positive cells maintain their primitive receptor profile 
(CD34, CD11b, c-kit and Sca-1) and keep their progenitor status. The VEGFR1 
positive haematopoietic progenitors were also shown to express very late activation 
antigen-4 (VLA-4, integrin α4β1) [85]. This molecule binds to fibronectin within the 
extracellular matrix (ECM) and to vascular cellular adhesion molecule 1 (VCAM-1) 
on stromal cells and mediates cell adhesion to the microenvironment [86, 87]. 
Kaplan et al. demonstrated that preventing the development of the pre-metastatic 
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 niche by treatment with Anti-VEGFR1 and Anti-VLA-4 resulted in a reduced cluster 
formation of VEGFR1 positive cells and eventually prevented metastasis [85].  Since 
Kaplan first propagated the term pre-metastatic niche, multiple other tumour derived 
soluble factors such as placenta derived growth factor (P1GF), tumour necrosis 
factor α and β (TNF- α, TNF-β), lysyl oxidase (LOX), G-CSF and versican have 
been identified as drivers of the pre-metastatic niche [88, 89]. 
1.4 RESEARCH PROBLEM  
As outlined above, patients suffering from bone metastases are still treated 
mainly palliatively and curative treatment options are missing. Not only appropriate 
in vitro but also in vivo model systems are strongly needed to recapitulate and study 
human diseases in order to develop novel diagnostic tools and therapeutic strategies 
[90]. However, recent data demonstrates that currently used models are not capable 
of recapitulating human diseases in a sufficient manner [91]. The value of current 
models is increasingly questioned as it has been demonstrated that more than 80% of 
new drug candidates that enter clinical trials are inefficient despite previous 
successful preclinical testing in rodents [92]. For the drugs that pass both preclinical 
and clinical studies it has been estimated that it takes more than 10 years and 
approximately 1$ billion to get their regulatory approval [93]. Given the time and 
costs it takes to develop a novel drug and introduce it into the clinic, the present 
process can be called no other than ineffective [91].  
It has been shown that traditional mouse xenograft models, patient derived 
xenograft models or genetically engineered mice alone are in many cases not 
sufficient to reliably predict results in human medicine [90]. One important 
limitation of these models is that the behaviour and growth of the grafted or 
genetically modified cells are investigated within a murine macro- and micro-milieu 
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 [94-96]. However, it is well known that interspecies differences exist between human 
and murine cellular systems and their molecular repertoire [97, 98] [91]. The level of 
conservation between humans and mice is highly variable for different chemokines 
and adhesion molecules including cases where a certain chemokine exists in one 
species but not in the other one [99]. Furthermore it has been shown that some 
murine chemokines such as IL-3 and GM-CSF do not bind to their corresponding 
human receptors and the other way round [100, 101]. This can significantly influence 
the results of drug testing studies. The fully human monoclonal antibody Denosumab 
for example binds with a high affinity to human receptor activator of NF-κB ligand 
(RANKL), but not to its murine counterpart. It therefore inhibits the differentiation 
and survival of human but not murine osteoclasts [102]. For the preclinical 
assessment of the drug’s pharmacokinetic and pharmacodynamic properties and 
safety profile, transgenic mice had to be developed that express chimeric 
murine/human RANKL [103].  
However, even if the protein of interest shares the same amino-acid sequence 
between humans and the model organism, it might be the case that there is no direct 
correlation between the functional cross-reactivity of proteins of both species. The 
following example makes this issue more clear and demonstrates that it is not only 
important to consider that both species express the target gene, but also that the 
biological function of the cells that express the gene should ideally be conserved 
between the species. In 2006, a phase I clinical trial was conducted for the testing of 
the humanized monoclonal antibody TGN1412 which is directed against the human 
CD28 antigen to activate regulatory T cells. The drug was developed with the aim to 
treat diseases such as lymphoma or rheumatoid arthritis since in these cases the 
activation of regulatory T cells was supposed to be useful [104]. Cynomolgus and 
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 rhesus monkeys were used to test the compound, as these primates possess a 100% 
sequence homology for the extracellular domain of the CD28 receptor [105]. 
Preclinical testing revealed that the compound was safe in these non-human 
primates, suggesting that similar responses were to be expected in humans. However, 
when the first small dose of this drug was administered to all six patients who didn’t 
take the placebo, a cytokine release syndrome was triggered resulting in systemic 
organ failure. Further analyses of this unexpected dramatic event revealed that the 
effector memory subset of the human lymphocytes was most likely to be responsible 
for the cytokine release. Finally, it was shown that in cynomolgus monkeys this 
particular subset of lymphocytes lacks CD28 and was therefore not responsive to the 
drug [106].  
A potential solution for these problems is the development of humanized 
mouse models that involve not only single human cell suspensions but integrate 
entire humanized organ systems. In these systems, incorporated human stromal cells 
can provide the factors needed for the maintenance, survival or proliferation of 
human parenchymal cells of interest. This approach can be extended to the use of 
human cancer cells that are known to be likewise dependent on factors provided by 
their microenvironment. The remarkable advancements in the field of tissue 
engineering, stem cell biology and biomaterials science over the last decade may 
now make humanized mouse models possible that were previously thought all but 
impossible and more closely recapitulate the biological processes seen in humans 
[107] [91]. In parallel to the development of novel in vitro models, the tissue 
engineering & regenerative medicine (TE&RM) community can enter new avenues 
by developing tissue engineered constructs composed of biomimetic scaffolds and 
human cells and their extracellular matrix products to generate functionally defined 
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 humanized organoids within immuno-compromized murine hosts.  Using these 
techniques, different humanized stromal components can first be engineered in vitro 
and then implanted into the host animal to assemble chimeric tissue/organ interfaces 
and investigate the behaviour of human cells within their native microenvironment 
[91]. This novel concept finally allows researchers to account for interspecies 
differences in their disease models. 
1.5 HYPOTHESIS AND THESIS AIMS 
Hypothesis: A functionally defined and morphologically intact humanized 
bone organ can be engineered and specifically modified to stay viable after 
transplantation into immuno-compromized mice. This organ should enable 
reproducible modifications of the haematopoietic stem cell niche in order to make 
the homing of human osteotropic cancer cells and human haematopoietic stem cells 
possible.   
This research hypothesis has been tested by pursuing the following aims over the last 
three years: 
Aim 1: Development of a morphologically intact tissue engineered 
humanized bone organ incorporating human stromal cells and their matrix 
products to study the species-specific homing of human prostate cancer cells to 
bone.  
Aim 2: Incorporation of human parenchymal cells into the tissue engineered 
humanized bone organ to establish a functional peripheral lymphatic organoid 
capable of human haematopoiesis. Aim 2 can be divided into 2 parts: 
a) Development of a functional haematopoietic system capable of long-term 
reconstitution. 
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 b) Humanization of the haematopoietic compartment to enable human 
haematopoiesis.  
1.6 ACCOUNT OF RESEARCH AND PUBLICATION OUTPUT 
The first step in this PhD project was to perform a comprehensive literature 
review about existing humanized models of bone metastasis. This work was 
published in the international journal “Cancer Metastasis Reviews” [5 year IF: 9.076, 
JCR journal ranking 20/200 in oncology] and forms chapter 2 of this thesis. It 
describes advantages and limitations of existing xenograft models of bone metastasis 
and gives an overview about promising new developments in the field. After 
reviewing the literature and analysis of our first preliminary experiments, it became 
clear that traditionally used humanized xenograft assays of bone metastasis are not 
able to sufficiently mimic vital human bone as a homing station for human cancer 
cells. By successfully completing Aim 1 of this PhD project, it was demonstrated that 
a vital and morphologically intact humanized bone organ incorporating a murine 
haematopoietic system can be developed using tissue engineering strategies. More 
importantly, it was shown that human prostate cancer cells inoculated via the left 
cardiac ventricle can reproducibly home to the tissue engineered humanized bone 
constructs. This novel model made it for the first time possible to study the species-
specific homing of human prostate cancer cells to bone. The results of these 
experiments were published as an original paper in the international journal 
“Biomaterials” [5 year IF: 8.911, JCR journal ranking 1/32 in materials science and 
biomaterials], which forms chapter 3 of the thesis. In October 2014, this work was 
decorated with the “Basic Research Award” of the German Society for Orthopaedics 
and Trauma. It is endowed with 20.000 Euro and awarded for outstanding original 
scientific work in the field of orthopaedics or trauma.   
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 To develop the model further, we aimed to engineer a humanized bone organ 
capable of producing human blood elements. In the last decade, several 
transplantation assays have been used to generate humanized mice incorporating 
human cellular and/or humoral immune elements. In chapter 4, we review the 
idiosyncrasies of the existing assays and outline our roadmap to create humanized 
lymphoid organs capable of haematopoiesis that might be used for studies of tumour 
immunology in the future. This extensive review was published in the international 
journal “Stem Cells” [5 year IF: 8.328, JCR journal ranking 4/68 in haematology]. In 
Aim 2 of this PhD project, it was demonstrated that the engineered humanized bone 
organs are capable of hosting a functional bone marrow compartment with a cellular 
composition similar to mouse bones. Moreover, we showed that the engineered 
humanized bone organs are indeed capable of hosting transplanted human HSCs and 
support human haematopoiesis. These analyses resulted in an original article 
published in the journal “Biomaterials” [5 year IF: 8.911, JCR journal ranking 1/32 
in materials science and biomaterials].  
The main body of the thesis consists of the above mentioned journal articles 
and can be found in the following sections. Due to formatting requirements for thesis 
by publication, the format of the published articles was slightly changed. The 
reference lists of the papers were combined to one single file and can be found in the 
bibliography at the end of the thesis.  
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 2.1 ABSTRACT 
The determinants and key mechanisms of cancer cell osteotropism have not 
been identified, mainly due to the lack of reproducible animal models representing 
the biological, genetic and clinical features seen in humans. An ideal model should 
be capable of recapitulating as many steps of the metastatic cascade as possible, thus 
facilitating the development of prognostic markers and novel therapeutic strategies. 
Most animal models of bone metastasis still have to be derived experimentally as 
most syngeneic and transgeneic approaches do not provide a robust skeletal 
phenotype and do not recapitulate the biological processes seen in humans. The 
xenotransplantation of human cancer cells or tumour tissue into 
immunocompromised murine hosts provides the possibility to simulate early and late 
stages of the human disease. Human bone or tissue-engineered human bone 
constructs can be implanted into the animal to recapitulate more subtle, species-
specific aspects of the mutual interaction 
2.2 INTRODUCTION 
Bone metastases significantly influence the quality of life and performance 
status of cancer patients (Figure 2.1). Although new drug technologies have brought 
enthusiasm to the field by reducing bone pain and the incidence of skeletal related 
events, their positive effects on the median survival rate seem to be only marginal 
and treatment remains palliative in most cases [108-111]. We and others reason that 
the development of an effective therapeutic regimen is impeded by the lack of 
adequate animal models that are able to recapitulate the biology of the disease in 
humans [112, 113]. 
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Figure 2.1. Clinical case of a 49 year old female patient with breast cancer metastasis to bone: Ablatio 
mammae with dissection of the axilla (level I and II) was performed (primary tumour stage: pT4d 
pN2a G3 L1 V1 R1; ER 12/12; PR 12/12; c-erbB2 3+). Radiographic examination shows a 
pathological fracture of the right proximal femur (A) which was treated by proximal femoral 
replacement (B). Gross examination of the specimen revealed a lobulated metastatic lesion within the 
medullary canal leading to destruction of the cortical bone (C). Microscopically (H&E staining) 
infiltrative tumour strands could be found leading to osteclast recruitment on the bone surface (D). 
Immunohistochemistry of the primary tumour tissue revealed significant specific staining of Her2-neu 
(E), oestrogen- (F) and progesterone receptors (G) (Score: 3+). The postoperative therapy regimen 
included irradiation of the proximal femur and the breast as well as hormonal therapy. [Figures were 
kindly provided by the Wilhelm Sander Therapy Unit for Bone- and Soft Tissue Tumours, Technical 
University Munich, Germany]. 
Regardless of the approach, an animal model should be reproducible and its 
investigative period should be relatively short in order to be effective and affordable. 
Furthermore, it should closely mimic the clinical situation in humans and be capable 
of recapitulating as many steps of the metastatic cascade as possible (Figure 2.2), 
thus facilitating the development of prognostic markers and novel therapeutic 
strategies. In an ideal model, normal epithelial tissue would spontaneously undergo 
metaplasia and develop carcinoma in situ at the primary site, which would 
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 consecutively progress to adenocarcinoma. This would then metastasize to bone and 
lead to osteoblastic, osteolytic or mixed lesions characteristic for the specific tumour 
type. Although no current platform can replicate all aspects of the human disease, 
models of bone metastasis that reproduce some stages of the disease have yet yielded 
important insights. Though any “model” is imperfect by definition, it can be 
appropriate if it can provide controlled conditions in which a given hypothesis can be 
tested. It is essential that researchers are familiar with the advantages and 
disadvantages of the specific model. Only then they can work within those 
parameters [114].   
 
Figure 2.2. Main steps in tumour initiation, progression and bone metastasis: Vascularisation must 
occur to supply the tumour mass with nutrients. This is mediated by several parallel mechanisms 
including angiogenic factors secreted by the surrounding tissue [115]. Transformation into an invasive 
phenotype by epithelial-to-mesenchymal transition (EMT) enables cancer cells to break through the 
basal membrane, invade the stroma and enter venules that offer little resistance to penetration 
(intravasation). After entering the systemic circulation, most tumour cells are rapidly destroyed, but 
some sidestep the immune system by forming aggregates with platelets and leukocytes [17]. Arrest in 
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 capillary beds of the bone marrow is facilitated by mechanical entrapment and mediated either by 
adhesion to endothelial cells or to parts of the subendothelial basement membrane [116]. After 
extravasation cancer cells may undergo mesenchymal-to-epithelial transition (MET) and assimilate 
into the bone/bone marrow microenvironment. They are competent to enter a prolonged period of 
latency in which disseminated tumour cells can remain dormant for months or even years. However, a 
subset of these cells is able to complete their evolution into an organ-specific overt metastasis [117]. 
[Figure produced using the image bank at www.servier.com with permission from Servier Medical 
Art] 
In general, three broad approaches have been employed to investigate bone 
metastasis in vivo. These include syngeneic (spontaneous, inducible or 
transplantable) models of metastasis, genetically engineered models and xenograft 
models [113, 118, 119]. Each of these has inherent advantages and limitations. 
Xenograft models have been developed to mimic the clinical conditions. In this 
platform human tumour tissue or human cancer cells are inoculated into a rodent 
host, usually murine, that is immunocompromised to prevent tissue rejection by the 
immune system. However, this also presents a major limitation of xenograft models, 
as the effects of an intact immune system on tumour cell growth, dissemination and 
bone colonization cannot be displayed [120]. This can have a significant impact on 
the clinical relevance of the data generated. Nevertheless, most known mechanistic 
insights into the process of human bone metastasis have been derived from xenograft 
models.  
This article reviews the idiosyncracies of different xenograft assays of bone 
metastasis and provides an overview about the techniques used to date. There will be 
a special focus on humanized xenograft models of bone metastasis and on the 
technical questions that remain to be answered when using this platform. As the 
knowledge about the key mechanisms of breast and prostate cancer metastasis to 
bone is of utmost clinical relevance, we will place a special emphasis on these two 
tumour entities.  
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 2.3 HUMANIZED XENOGRAFT MODELS TO STUDY BONE 
METASTASIS 
Conventional xenograft models fail to mimic the human bone 
microenvironment as the intrinsic homing site of the inoculated cancer cells. 
Moreover, certain signalling pathways between human cancer cells and murine 
stromal cells may not occur due to interspecies signalling incompatibilities. A 
refinement to humanize the intrinsic homing site of metastatic cells is the 
implantation of functional human bone or tissue engineered bone constructs into the 
host animal to recapitulate more subtle, species-specific aspects of the mutual 
interaction between human cancer cells and human bone [121-123]. Recent studies 
could show that the surrounding stroma of the primary tumour can also be at least 
partially humanized [124, 125], making it possible to analyse the specific biologic 
modifications that cancer cells have to undergo in response to signals received from 
the surrounding stroma not only at the homing site of the cancer cells but also at the 
primary tumour site. These modifications improve the value of xenograft models 
when used to predict drug efficacy against a panel of human tumours within a given 
histology. If it were possible to reconstitute all parts of the human bone 
microenvironment with its haematopoietic cell system, at least a partial human 
immunity could be conferred to the murine host which would make xenograft models 
even more suitable for studying human biological processes. 
2.4 THE RATIONALE BEHIND HUMANIZED MOUSE MODELS 
The first immunodeficient mouse models analysing human tumour growth 
were based on nude mice homozygous for a mutation in the forkhead box N1 
(Foxn1) gene. Though nude mice are T cell deficient, they exhibit an intact B cell 
function and a high activity of natural killer cells. While they were shown to support 
human tumour growth, no successful engraftment of haematopoietic cells or tissue 
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 could be demonstrated [126]. Systematic progression of genetic modifications has 
now led to a variety of immunodeficient mice that can be used for the development 
of human-mouse chimeras for bone metastases research [96].  
In 1983 CB17-Prkdcscid  (abbreviated SCID, severe combined 
immunodeficient) mice were developed which lack mature T and B cells [127]. 
These mice are homozygous for the so-called scid mutation, a mutation at the protein 
kinase, DNA activated, catalytic polypeptide (Prkdcscid). This provided the 
opportunity in which grafted human haematopoietic tissue or cells can proliferate, 
differentiate, function and maintain their physiological anatomical features at least to 
a certain degree. In 1992 Kyoizumi and co-workers  showed that human foetal bone 
implanted into SCID mice sustained active human haematopoiesis in vivo, yet they 
demonstrated that the human bone marrow space was progressively replaced by 
murine haematopoietic cells over time [128]. One explanation for this could be a 
phenomenon known as leakiness. In SCID mice a spontaneous rearrangement of T 
and B cell receptors can be observed during ageing, leading to the generation of 
mature T and B cells. Moreover high levels of innate immunity and natural killer cell 
function limit the engraftment of parts of the human haematopoietic system [129].   
In an attempt to further reduce innate immunity and increase the engraftment 
and function of human haematopoietic tissue or cells, Shultz et al. developed 
NOD.CB17-Prkdcscid (non-obese diabetic, abbreviated NOD-scid) mice. As 
compared to SCID mice they have an additional deficiency of the innate immune 
system with a reduced level of natural killer cell activity allowing for a higher 
engraftment rate of human cells and tissues [130].  Several studies could clearly 
demonstrate that the main barriers to the successful transplantation of human bone 
and haematopoietic cells into SCID mice are the host natural killer cells and 
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 macrophages [131, 132]. Since their development in 1995, NOD-scid mice have 
undergone several genetic modifications that improved their utility in simulating 
human tumour growth and haematopoietic activity. However, a functional human 
immune system could not be established mainly because of a low but present residual 
innate immune system in these mice. Another important issue which should be taken 
into consideration when using NOD-scid mice is their relatively short life span 
(mean 8.5 months) compared to other laboratory mice (18-30 months). This is a 
consequence of spontaneously developing thymic lymphomas due to the presence of 
a provirus, Emv-30, on chromosome 11. In turn, this tumour makes long-term drug 
testing studies impossible [130, 133]. Nevertheless, the NOD-scid model has been 
the gold standard in xenograft models of bone metastasis for the last 15 years.  
Attempts to backcross nude and NOD-scid mice have been already successful 
resulting in a mouse that has the characteristics of NOD-scid mice, but is hairless and 
lacks the life shortening provirus. Like many of the newer strains of 
immunocompromised mice, this strain is only available at laboratories where it was 
developed [134]. Recently established mouse strains which are homozygous for 
targeted mutations at the interleukin-2 receptor (IL-2R) γ-chain locus could help to 
further humanize bone metastasis models in the future. These so called NSG (NOD-
scid gamma, e.g. NOD.Cg-Prkdcscid ILrgtm1Wjl/SzJ) mice enable greater 
engraftment rates of haematopoietic cells and might allow the growth of tumours that 
previously have not grown in immunocompromised mice [135]. This is primarily due 
to the lack of T and B cells and a further reduction in innate immunity with an 
absence of natural killer cells [136]. Some studies have shown that irradiation of 
newborn NSG mice with several hundred cGy and subsequent transplantation of 
human haematopoietic stem cells led to the generation of human B- and T-cells, 
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 platelets and red blood cells [136, 137]. Because the Il-2rg knockout prevents the 
development of thymic lymphomas, the life span of NSG mice is higher than in other 
SCID strains, enabling the analysis of long-term drug effects and complex cell 
interactions [136].   
However, limitations remain even with the NSG model, as there is a lack of 
some human-specific cytokines required for human cell development. Furthermore, a 
fully functional human immune system could not be established due to a relative 
absence of HLA expression on stromal cells of the mouse, which is important for the 
positive selection of human T cells. Future advances in the development of 
transgenic NSG mice could at least overcome some of these limitations [96, 138]. 
More recently, a new NSG mouse strain (NSG-HLA-A2/HHD) with homozygous 
expression of HLA I heavy and light chains has been developed. Transplantation of 
human haematopoietic stem cells into newborn NSG-HLA-A2/HHD mice resulted in 
the establishment of functional HLA-restricted T-lymphocytes [139].   
Selecting the appropriate mouse strain is essential to enable the creation of a 
system in which the host’s immunity does not impede the engraftment of tumours, 
bone or haematopoietic cells from human origin. However, immunocompromised 
mice are only the precondition to enable the development of a humanized system. If 
it were feasible to implant all components of the human bone microenvironment and 
ensure their viability for the life span of the host, it would make xenograft models 
much more suitable for predicting drug responses in the clinic. In such a humanized 
system, human bone marrow stromal cells, haematopoietic cells and tumour cells are 
influenced by growth factors from both the murine host and the transplanted human 
cell complex. Therefore it is important to recapitulate the physiology of human bone 
as accurate as possible. 
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 2.5 RECAPITULATING THE PHYSIOLOGY OF HUMAN VITAL BONE 
When results of humanized xenograft models of bone metastasis are interpreted 
and conclusions are drawn, researchers have to keep in mind that the origin, the 
quality and the amount of transplanted bone and bone marrow can significantly 
affect the outcome of these studies. The tumour take rate is not only dependent on 
the mouse strain or the human cancer cells used but also on the inherent 
characteristics of the transplanted bone.  
There are several sources of human bone graft material (Appendix A, Table 
A.1 & Table A.2) all with inherent advantages and limitations. In 1995 Shtivelman 
and Namikawa [140] first described the use of human foetal bone in a xenograft 
assay of bone metastasis and subsequently many other research groups followed this 
approach. Most of them used male femora or humeri from foetuses of a gestation age 
between 16 and 22 weeks [119, 122, 141-143]. Reports describing the biology of the 
implanted foetal fragments suggest that the tissue was viable and adequately 
vascularised after 4 weeks of implantation into SCID mice [119, 122] and could 
sustain active human haematopoiesis [128, 140]. In some countries human foetal 
bone is commercially available. Though species-specific homing of the inoculated 
human tumour cells to the implanted foetal bone could be demonstrated, this 
approach has limitations and conclusions should not be extrapolated to adult human 
bone. The composition of foetal bone differs significantly from adult bone by the 
presence of a large number of stromal cells and the absence of lymph follicles and 
plasma cells in the marrow. In foetuses with a gestation age of 16 to 22 weeks the 
ossification centre is located only in the diaphysis while the epiphyses as well as the 
metaphyses consist mainly of hyaline cartilage [144]. Foetal bone marrow does not 
replace the liver and spleen as the primary site of haematopoiesis until the third 
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 trimester. Suffice it to say that the resultant haematopoiesis is foetal with, for 
example, the erythroid lineage expressing haemoglobin F and the B-cell lineage co-
expressing CD10 and CD19 [145, 146].  Previous studies have shown that adult and 
foetal haematopoietic progenitor cells differ with respect to proliferation rate, 
differentiation capacity and response to certain growth factors [147-149].  
These constraints have prompted researchers to use adult rather than foetal 
bone in xenograft models [121, 123, 124, 150-157]. The first attempts to successfully 
recapitulate the physiology of adult vital bone in SCID mice failed due to their 
residual non-specific immune system [158].  Heike et al. found that adult human 
bone did not stimulate an angiogenic response in SCID mice without any additional 
treatment [159]. However, Boynton and Sandhu could maintain bone viability and 
human haematopoiesis after pre-treatment with anti-asialo GM1 sera or total-body 
irradiation [131, 160]. Heike and co-workers showed that a continuous 
administration of human cytokines (rhSCF, rhIL-3, rhGM-CSF and rhG-CSF) at the 
site of bone implantation via an osmotic pump was also able to prevent degeneration 
and fibrosis of the bone marrow compartment [159].  
In 2001 NOD-scid mice were shown to be better recipients for human adult 
bone than SCID mice [123]. After transplantation of adult human bone chips into 
NOD-scid mice, histological analyses were performed at 4 and 16 weeks. Though, 
the implanted bone fragments showed signs of necrotic and fibrotic changes in the 
bone marrow compartment at 4 weeks, all implants had recovered at 16 weeks and 
contained viable osteocytes and surrounding vessels of human origin as shown by 
specific staining for human CD34. Moreover, use of a human specific monoclonal 
antibody for HLA-DP, -DQ and –DR class II indicated that human cells or matrix 
were present within the bone marrow of the transplant.  Levels of human IgG in the 
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 peripheral blood, quantitatively determined using ELISA methods, were low at two 
weeks after implantation but increased between 2 and 4 weeks and reached a plateau 
thereafter [123]. In 2004 Hubin et al. found similar results [161]. After implantation 
of adult bone into NOD-scid mice, human osteoblastic cells survived and remained 
functional for up to 9 weeks as demonstrated by osteoid deposition on the surface of 
the bone trabeculae. Immunohistochemistry revealed the presence of human vessels 
surrounding the transplanted human bone. Blood, spleen and bone marrow of the 
animals were retrieved at different time points post-transplantation. 
Human CD45+ cells were undetectable at 8 weeks but emerged at 9 weeks into 
the blood (0.65 % of circulating mononuclear cells), spleen (0.23 %) and bone 
marrow (<0.1 %) of some mice and were still detectable at 12 weeks. Given the low 
counts, the authors could not exclude the possibility that the numbers were within the 
error margins of the flow cytometric analysis used. However, haematopoietic foci 
containing some cells of the myeloid lineage were found in the implanted bone 
suggesting that the human bone fragments could sustain lympho- and granulopoiesis. 
Others have also shown that after transplantation of human adult bone, the 
bone and the bone marrow compartment seem to undergo an adaptive phase in which 
the rate of new human bone formation and the activity of human haematopoiesis 
remains low for the first few weeks but recovers at later time points when 
multilineage human haematopoiesis, viable bone and osteoid formation could be 
observed [125].  This may be related to the process of neovascularisation, which is 
essential for the viability of the graft. Kuperwasser and colleagues [121] determined 
the species origin of the endothelial cells of the blood vessels in the centre and the 
periphery of the bone implants using monoclonal human-specific CD34 antibodies. 
Vessels within the graft were human CD34+, whereas the vessels in the periphery 
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 stained negative. The authors suggested that the human vessels inside the graft 
remained viable, but recruitment of mouse vasculature was necessary to supply the 
implanted bone.  Although the bone matrix was found to be viable after 12 weeks by 
detection of newly synthesized osteoid and osteocytes inside the lacunae, the bone 
marrow spaces were filled to a high degree with adipocytes and fibroblasts and only 
few T- and B-cells were present. Flow cytometric analysis on single-cell preparations 
of spleen cells using human CD19 and human IgG specific for human B-cells 
indicated that only 4% of the cells stained positive at 4 weeks after bone 
transplantation; this increased to 16.5% after 10 weeks. This implies that in this 
model the mechanisms of B-cell homing are intact [121]. These results were 
confirmed by other research groups using similar materials and methods [153, 155]. 
Summarising these findings, researchers analysing the activity of human 
haematopoiesis and the viability of bone should keep in mind that the process of 
neovascularisation of bone grafts needs several weeks.  
Though, research groups could find evidence of active human myelo- and 
lympho-poiesis after implantation of human bone into SCID or NOD-scid mice [121, 
128, 140, 161], there have been no reports of human xenoreactivity, which would 
lead to the development of a graft-versus-host reaction. This is assumed to be due to 
a negative selection on mouse MHC antigens in the dysplastic thymus [96]. 
However, it could be shown that the marrow of the human bone implant containing 
human immune cells resulted in an immune response against the colonies of 
inoculated cancer cells. This graft-versus-graft reaction was assumed to be due to the 
histoincompatibility between human cancer cells and human bone, both originating 
from different individuals [121].  The finding of human immune cells in the vicinity 
of bone metastasis and the relatively weak metastatic propensity observed after 
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 injection of cancer cells into the circulatory system suggested to two research groups 
[121, 140] to irradiate the mice implanted with human bone before administration of 
the cancer cells. After sublethal γ-radiation there was an increase of the number and 
size of metastases to human bone. Furthermore, no immune cells surrounding the 
cancer cells were detected [121]. However, it is far from proven that the residual 
innate immunity of the SCID [140] or NOD-scid [121] mice used in these studies 
does not also play a role in the observed immune response towards the human cancer 
cell colonies and the human bone. It is noteworthy that in these experiments the 
whole mouse was irradiated, not only the implanted human bone.  
To recapitulate the physiology of human vital bone in immunocompromised 
mice, not only viable osteocytes and osteoblasts, but also an active and proliferative 
haematopoietic cell system has to be transferred. To date we know that metastatic 
cancer cells can usurp the homing pathways of haematopoietic stem cells to establish 
footholds in their microenvironment. The establishment of a premetastatic niche 
seems to be indispensable for the development of future metastasis. It is assumed that 
growth factors released by the primary tumour induce the proliferation of 
haematopoietic bone marrow progenitors expressing VEGF-receptor 1+ and other 
markers of their progenitor status. These haematopoietic cells distribute within the 
circulatory system and preferentially home to areas of increased fibronectin 
expression within the bone microenvironment, paving the way for metastatic cells by 
forming niches where they can home [84, 85].  Recently it could be shown that 
disseminated tumour cells directly compete with haematopoietic stem cells (HSC) 
for the occupancy of the HSC niche and that changes in the size of the niche alters 
tumour cell dissemination [78]. Furthermore, the biological composition of the bone 
marrow microenvironment accounts for the typical distribution pattern of metastatic 
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 lesions seen in humans. It is well known that overt metastases develop mainly in 
skeletal regions where the heamatopoietic activity persists into old age [67, 68]. To 
recapitulate the disease in humans as closely as possible, one has to know the 
distribution pattern of the red bone marrow in the human skeleton to choose a bone 
graft which can recapitulate both the bone and the haematopoietic niche [47]. 
Moreover, a sufficient amount of proliferative bone marrow in the graft could lead to 
the development of a partially functional human immune system in the mouse. For 
xenograft models of bone metastasis many groups used chips [121, 124, 151, 156, 
162] or morcellised bone [153, 155, 157] obtained from the femoral head during 
arthroplasty. However, the epiphyseal conversion to fatty marrow occurs in early 
childhood [163], while haematopoietic marrow resides in the axial skeleton into old 
age. Therefore, the amount of red haematopoietic bone marrow in adults is 
significantly higher in the pelvis, ribs, skull and vertebrae than in the femoral head 
(Figure 2.3). While this assumption has been initially based on anatomical studies 
performed in the middle of the last century [164, 165], it has recently been confirmed 
by novel imaging modalities such as (18)F-fluoro-L-thymidine PET and high-
resolution MRI [166, 167].   
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Figure 2.3. Xenotransplantation of human bone into mice is not able to recapitulate vital human bone: 
Photograph showing a femoral head obtained from a 73 year old male patient who underwent total hip 
arthroplasty. The specimen was placed in a petri dish and the bottom was filled with sodium chloride. 
After cutting out cylindrical trabecular bone cores, yellow fatty bone marrow was clearly visible at the 
resection plane and fat was swimming at the surface of the liquid phase. Only few blood spots could 
be detected at the resection plane (A). Micro-CT analysis of the femoral bone core after 14 weeks of 
implantation into the flank of NOD/SCID mice showed no signs of new bone formation and a low 
bone volume to total volume (B). Histological analysis (H&E) revealed avital trabecular bone. The 
bone marrow spaces were filled with lipocytes and fibrous tissue. Bone marrow micro-vessel density 
was low (C). The osteocyte lacunae of the trabeculae were empty. No osteoblasts on the surface of the 
trabeculae could be detected which would indicate new bone formation via osteoid deposition (D).  
Other groups used cancellous bone obtained from ribs of patients undergoing 
thoracic surgery due to lung cancer [123, 150, 152, 154]. Even though the amount of 
proliferative marrow is assumed to be high at this location, bone from cancer patients 
could be altered by the pathology or previous treatment [160, 161]. Though, bone 
from the same donor can maintain its characteristics in immunocompromised 
recipients, donor age and morbidity can affect the outcome after transplantation of 
human bone into a murine host [131, 160]. Hubin et al. used the posterior iliac crest 
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 as a source of human bone. However, this  might raise ethical concerns, because in 
patients undergoing hip surgery a second trauma has to be created when obtaining 
bone from the posterior iliac crest [161]. A novel approach is to use morcellised bone 
obtained from the acetabular ground. These samples can easily be obtained from 
patients undergoing cemented total hip arthroplasty, as the reamed acetabular bone is 
normally a by-product of this procedure. This approach does not cause any additional 
morbidity and provides bone with a high content of red proliferative bone marrow 
(Figure 2.4).   
 
Figure 2.4. Growth factors support the maintenance of the viability of human bone transplanted into 
mice: From the same patient as depicted in Figure 3, small trabecular bone fragments from the pelvis 
were obtained during reaming of the acetabular ground (A). Micro-CT analysis after 14 weeks of 
implantation showed trabecular bone with a high bone volume to total volume. Numerous foci of 
newly apposed bone were evident at the surface of the fragments (B). Histological analysis (H&E) 
revealed vital bone with a high micro-vessel density and haematopoietic foci (C). Implanation together 
with BMP-7 was able to induce the development of haematopoietic bone marrow (D) 
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 The use of human tissue engineered bone constructs (hTEBCs) can be a highly 
attractive alternative to human adult bone, allowing control of the shape, size and 
porosity. Human TEBCs are predictably reproducible, consistent and not limited in 
supply like foetal or adult human bone. Furthermore, the amount and viability of 
cells seeded onto the scaffold can be monitored before implantation into the host. As 
only cellular components are transferred, there is only a little risk of infectious 
disease transmission as compared to the implantation of bone [112, 168-172].   
Schuster et al. [170] were the first to use this approach in bone metastasis 
research. They used hydroxyapatite-impregnated collagen sponges which were 
loaded with commercially available immature osteoblasts or osteoblasts isolated 
from patients who underwent bone marrow aspiration, respectively. After culture in 
osteogenic medium they were subcutaneously implanted into male SCID mice. Four 
weeks after bone transplantation, PC-3 human prostate cancer cells were directly 
injected into the bone construct. Histological analyses revealed mature bone and 
tumour masses in all transplanted bone constructs.  Unfortunately, the authors did not 
provide any information about the composition and the viability of the bone 
constructs [170].  
Moreau et al. created hTEBCs using silk fibroin protein sponges covalently 
coupled with BMP-2 and seeded with bone marrow stromal cells obtained from 
patients who underwent bone marrow aspiration [169]. Scaffolds were kept in culture 
for 1 day or 4 and 7 weeks, respectively. Three months after orthotopic implantation 
of SUM1315 breast cancer cells expressing green fluorescent protein and luciferase, 
the implanted bone constructs were histologically analysed. Two of six animals 
sustained metastases in one day cultured scaffolds, whereas no metastases could be 
detected in the scaffolds that were cultured for 4 or 7 weeks. Xenogen images of the 
Review paper 1: Humanised xenograft models of bone metastases revisited: Novel insights into species-specific 
mechanisms of cancer cell osteotropism 50 
 lungs and the skeleton of mice bearing metastases were negative for bioluminescent 
signals in early stages, which led the authors assume that the metastatic spread was 
exclusive to the implanted human bone constructs. However, subsequent papers by 
the same group indicated metastases in the mouse skeleton at later stages [172, 173]. 
The authors stated that their results were contradictory to the assumption that the 
most mature bone would yield the greatest metastatic spread. They concluded that 
the rich proportion of stem cells in the immature scaffolds could positively affect 
metastasis due to the existence of a pre-metastatic niche for the breast cancer cells 
[169]. However, the stromal and fibroblastic cells found in the constructs were not 
clearly shown to be human [172]. Therefore, in this model the species-specific 
homing of breast cancer cells to a bone construct has still to be proven.  
At present the authors’ interdisciplinary group is creating a xenograft model of 
bone metastasis in which human tissue engineered bone is transplanted into 
immunocompromised mice (Figure 2.5) [112]. These are steps towards a tailored 
human bone construct which can serve as a homing site for human metastatic cancer 
cells. However, there are still major problems that have to be solved in order to fully 
humanize these constructs. So far, this platform is only able to model the human 
bone matrix. The bone marrow and vasculature found in these constructs are of 
mouse origin. In the future, these tissue engineered bone constructs have to be 
provided with a human bone marrow compartment and a vascular network that 
ideally would precede new bone formation. Recently, using a syngeneic rat model, 
Yu et al demonstrated that co-culturing of endothelial cells with osteoblasts can 
improve osteogenesis in tissue-engineered bone grafts and can prevent ischemic 
necrosis [174]. Some of these bone tissue engineering concepts have already been 
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 transferred from bench to bedside which shows the capability of this approach to 
successfully engineer living bone [175-179]. 
 
Figure 2.5. A tissue engineered approach to grow vital human bone in mice: Melt electrospun 
polycaprolactone scaffolds coated with calcium phosphate were seeded with human primary 
osteoblasts and cultured in vitro under osteogenic conditions for 8 weeks. These constructs were then 
loaded with fibrin glue and rhBMP-7 and implanted subcutaneously into the flanks of NOD-scid mice. 
FDA-PI staining before implantation revealed a significant amount of viable osteoblasts filling the 
pores of the scaffold (viable cells are coloured green, dead cells red) (A). Necropsy after 14 weeks of 
implantation showed a well-vascularised tissue engineered bone construct. The main feeding arterial 
branches descend from the thoracodorsal artery (B). Micro-CT analysis showed trabecular structures 
within the ossicle and a cortex-like outer surface (C). Cells of human origin were identified by 
immunohistochemical staining of nuclear mitotic apparatus protein 1 (NuMa) using human-specific 
antibodies that do not crossreact with mouse tissue (human cells are coloured brown, mouse cells pale 
blue). Most of the osteocytes within the newly formed bone matrix were shown to be of human origin 
(D). 
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 2.6 METHODS OF CANCER CELL DELIVERY AND THEIR IMPACT ON 
THE DISTRIBUTION PATTERN OF BONE METASTASES 
Currently there is no xenograft model, which is capable of replicating all 
aspects of the metastatic cascade because experimental metastasis assays omit the 
first steps of the metastatic process, which involves the malignant transformation of 
normal epithelium. In general three different approaches to cancer cell xenografting 
can be differentiated [113]. The first involves the implantation (orthotopic or 
heterotopic) of cancer cells into specific organs or tissue resulting in the growth of a 
local tumour, which eventually metastasizes to the skeleton. The second approach 
circumvents local tumour growth and intravasation by inoculating (intravenous, 
intraarterial or intracardiac) cancer cells into the vasculature of the host. In the third 
platform cancer cells are directly injected into bone. The value of the later approach 
might be questionable and some might say it is a primary tumour model rather than a 
metastasis model, but bypassing steps of the metastatic cascade leads to a reduction 
in statistical variability. Studying later steps of the metastatic cascade is not 
complicated by factors associated with the growth of the primary tumour or multiple 
metastases. As a result, such studies are less time-consuming, less expensive and 
symptoms caused by primary tumour masses or multiple metastatic foci can be 
alleviated allowing for a longer follow up (Figure 2.6).  
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Figure 2.6. Different tumour cell xenografting techniques and their ability to depict certain stages of 
the metastatic cascade. The more steps of the cascade are recapitulated, the more complex is the 
specific model. 
The method of cancer cell xenografting significantly affects the distribution 
pattern of experimental metastases. Though injection of cancer cells into the 
circulatory system leads to a wide distribution throughout the host’s body, the cells 
will be trapped mainly in the first capillary bed after the injection site. However, this 
does not necessarily mean that the organ, which represents the first capillary bed and 
contains the highest number of disseminated tumour cells is sustaining the highest 
load of overt metastases [32, 39]. In fact the establishment of metastases within any 
organ requires reciprocal interactions between tumour cells, host cells and the 
microenvironment [27]. In a similar although metaphorical way this was already 
postulated by Stephen Paget in 1889 [28, 29], when he proposed his “seed and soil”-
theory. Nevertheless, the site of inoculation can enhance the probability of 
developing metastases in a specific organ or part of the body.  
Intra-arterial injection of cancer cells in a murine host is technically demanding 
and has been performed mainly in rats as their body size makes it easy to dissect and 
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 cannulate certain arteries [180-182]. By injecting tumour cells into only one 
extremity the risk of co-morbidity caused by multiple metastases can be kept low and 
hence a longer follow up of the tumour growth is possible. This in turn allows the 
analysis of long-term effects of certain anticancer drugs. In bone metastasis assays 
three different intra-arterial injection techniques have been described so far. Neudert 
et al. [182] used a technique in which the common femoral artery of both legs was 
fully ligated after injection of MDA-MB-231 human breast cancer cells via a 
polyethylene catheter. This resulted in the development of metastatic lesions in the 
distal femur and the proximal tibia within 18 days after inoculation, with a success 
rate of 95-100% and without additional co-morbidity. Interestingly the authors could 
find only a transient rise of serum creatinine kinase levels after ligation of the artery. 
No relevant macroscopic or microscopic necroses were found in muscle tissue upon 
euthanasia and no impact of ligation on bone structure, metabolism or chemical 
composition could be detected [182]. By injecting the same cancer cells into the 
superficial epigastric artery, Bauerle et al. could show that a permanent ligation of 
the femoral artery is not a sine qua non condition. By using this technique they 
observed a tumour take rate of 93% while metastatic lesions occurred exclusively in 
the femur, tibia and fibula of the animals. This approach even allowed a follow up of 
the metastatic lesions for up to 110 days [180, 181]. Halpern and co-workers could 
show that the preparation of the femoral artery for tumour cell inoculation is also 
possible in mice [183]. They ligated the inferior pedicle of the superficial epigastric 
artery and threaded a hydroxyapatite scaffold within its distal end. Six weeks after 
scaffold implantation they injected PyMT cells (isolated from a mammary tumour in 
a transgenic mouse) into the femoral artery of the same extremity. Based on 
bioluminescent imaging the tumour take rate was 100%. Tamura and co-workers 
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 used the carotid artery of rats to place a polyethylene catheter in the thoracic aorta 
and to inject c-SST-2 rat breast cancer cells [184, 185]. Though ligation of the 
carotid artery is necessary for this procedure it could be shown that this does not 
affect the wellbeing of the rats because they recover from the partial ischemia in a 
few minutes due to the existence of the circle of Willis [186].  
Injection of human cancer cells into the circulatory system is the most 
commonly used cell delivery method in humanized xenograft models of bone 
metastasis (Figure 2.7). The pattern and kinetics of cancer cell dissemination are 
dependent on the method chosen to inoculate the cells into the vasculature. The 
number of cells will depend on the inoculation method but also on the metastatic 
potential of the certain cell line. There is a critical limit of the number of cells that 
can be injected (Appendix A, Table A.1 & Table A.2). Too many cells can result in a 
high mortality as can cell aggregates that cause emboli in the lungs [123]. It has 
become widely accepted that the majority of cancer cells injected via the lateral tail 
vein end up in the lungs, trapped in the capillary beds of the alveoli, whereas the 
intracardiac injection route via the left ventricle targets the entire circulatory system 
but is usually aimed towards the development of bone metastases [187]. However, 
recent studies by Goodale et al. showed that cancer cell distribution is a dynamic 
process which is much more subtle than initially assumed [188]. They characterized 
the dissemination and kinetics of MDA-MB-435HAL cancer cells in female nude 
mice after different inoculation techniques using flow cytometry and laser scanning 
cytometry. Blood, lymph nodes and bone marrow samples collected at different time 
points were immunomagnetically enriched and labelled with human leukocytic 
antigen-FITC, CD45 antibodies and propidium iodide. The authors demonstrated that 
after injection into the lateral tail vein, circulating tumour cells were initially high, 
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 decreased rapidly by one week before increasing to a peak by 7 weeks. 
Simultaneously they showed a slow increase of disseminated cancer cells in the bone 
marrow and lymph nodes during the observation period, suggesting that cancer cells 
may distribute in the circulatory system originating from lung metastases which were 
established after initial delivery. Following intracardiac injection, circulating cancer 
cells increased with a peak at 4 weeks and cancer cells in the bone marrow remained 
at a moderate level until peaking at 5 weeks. Overall, intracardiac injection led to a 
significant higher number of cancer cells in the bone marrow than tail vein injection 
[188].  
 
Figure 2.7. Recapitulation of the human bone metastastic process: Humanized bone constructs were 
engineered as it is shown in Figure 5. After 14 weeks of in vivo bone growth, PC-3 prostate cancer 
cells transfected with the firefly luciferase gene were injected into the left cardiac ventricle (A). 
Bioluminescence imaging visualised the homing and proliferation of the human cancer cells in the 
human bone constructs (strong signal in both flanks) (B). Histological analysis (H&E) showed tumour 
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 strands consisting of PC-3 cells which seemed to have a mesenchymal like phenotype when observed 
in the vicinity of the human bone trabeculae (C). Many TRAP-positive staining osteoclasts (red cells) 
could be found on the surface of the trabeculae within the Howship’s lacunae indicating the osteolytic 
nature of PC-3 cells (D). 
These results should be kept in mind when planning the timeline of xenograft 
assays of bone metastasis. Furthermore, researchers have to be aware of the fact, that 
the development of metastases is also dependent on the tropism of the cancer cells. 
Both intracardiac and tail vein injection require experience and a careful handling of 
the animal. The injectable volume via the intracardiac route is usually limited to 100 
µl, whereas the intravenous route allows for a maximum of 200 µl (Appendix A, 
Table A.1 & Table A.2). The inoculation technique should be validated immediately 
after injection by bioluminescent imaging or by a gamma camera detecting co-
injected luminescent agents or radioactive substances. If the signal occurs throughout 
the whole body the cells were injected into the left ventricle, a signal in the lungs 
suggests an injection into the right ventricle. The later will lead to similar results as 
via tail vein injection.  
The first humanized xenograft model which could prove that orthotopically 
implanted human tumour cells can metastasize to implanted human bone grafts was 
introduced by Kuperwasser et al. in 2005 [121]. Human bone cores obtained from 
patients undergoing total hip replacement were implanted into the flank of female 
NOD-scid mice. After four weeks, different human breast cancer cell lines were 
transplanted into the mouse mammary fat pad using Matrigel™ as a carrier material. 
Only the use of the human breast cancer cell line SUM1315 resulted in metastases of 
the implanted human bone with a take rate of 20% at 8-12 weeks after cell 
inoculation. Metastases of the mouse skeleton were excluded using whole body x-ray 
analyses. Therefore, the authors assumed a species-specific osteotropism of this cell 
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 line. However, further analyses such as bioluminescent imaging or histological 
analyses of the mouse skeleton were not performed in order to exclude the existence 
of micrometastases in the mouse bone [121]. The same group reported a take rate of 
33.3% after 12 weeks using the same inoculation method and cell line but a tissue 
engineered human bone construct instead of a human bone chip [169]. To date, these 
results have not been reproduced by other groups.  
In a recent study Xia et al. demonstrated that tissue-specific interactions 
between human breast cancer cells and host tissues can influence the behaviour of 
tumours growing at the orthotopic site [162]. They showed that human breast cancer 
cells displayed a higher tumorigenicity when implanted into human breast tissue at 
the orthotopic site than cells implanted without human primary tissue [162]. In a 
subsequent study they implanted primary human breast tissue into the mammary fat 
pad of NOD-scid mice three weeks after implantation of a human bone chip. One 
week later they inoculated SUM1315 human breast cancer cells into the human 
breast tissue. After 10-12 weeks they could detect metastases in the human bone in 7 
of 10 animals, whereas no metastases in the mouse bone were found, indicating a 
species-specific process of bone metastasis [124]. While the implantation of human 
breast cancer cells into the mammary fat pad reliably produced metastases to 
implanted human bone, this could not be shown for the orthotopic implantation of 
human prostate cancer cells [121]. Nevertheless, orthotopically implanted PC-3 and 
LNCaP C4-2b human prostate cancer cells were able to colonize the skeleton of the 
host animal [189-191]. However, other research groups could not detect spontaneous 
metastases in bone after orthotopic implantation of human prostate cancer cells and 
have expressed their concern in this regard [192-194]. Taken together, this could be 
related to either a short observation period [194], to a relative paucity of blood flow 
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 at the primary site of implantation [189], to insufficient detection modes [193] or to 
the residual immune system of the host animal. Another possibility is that cancer 
cells generated at different primary sites select for cellular populations with different 
metastatic preferences [189]. Drawbacks of the orthotopic route of cancer cell 
inoculation include the long period of time needed for the development of bone 
metastases and the possibility of cancer cells leaking into the peritoneal cavity 
following surgery. The latter can contribute to the development of metastases in 
intra-abdominal organs and therefore can lead to wrong conclusions. Nevertheless, 
the orthotopic route of cancer cell inoculation reflects a more physiologic process of 
bone metastases than any other approach.  
Another platform comprises the injection of human cancer cells directly into 
the implanted bone or the mouse skeleton. In a strict sense this is more a primary 
tumour model than a metastasis assay and it allows only the analysis of the growth 
pattern of the cancer cells within the bone not the analysis of certain homing 
mechanisms. Moreover, the injury and subsequent remodelling mechanisms caused 
by direct injection of the cancer cells may contribute to the initial development of the 
tumour and may influence the phenotype of the metastasis as this might become 
more osteoblastic in nature due to the bone-healing process.  However, with this 
inoculation method tumour take rates between 70-100% can be achieved, which 
makes it an ideal model to study drug effects on the growth rate of the tumours [122, 
141, 142, 150, 152, 195, 196]. Animal numbers can be kept low and the power of 
statistical analyses can be estimated more easily than in other inoculation methods.  
Yang and co-workers used a similar model to investigate the metastatic 
potential of the human breast cancer cell line MDA-MB-231. They showed that 
subcutaneous co-transplantation of these cells together with human bone fragments 
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 resulted in tissue specific metastasis to an initially tumour free bone fragment on the 
contra-lateral side. The same working group also transplanted tumour-bearing bone 
samples from patients suffering from bone metastasis caused by breast cancer into 
the flank of female NOD/SCID mice together with tumour free bone samples on the 
contra-lateral side. An interesting finding was that patient derived breast cancer cells 
were able to colonise the tumour-free bone core on the contra-lateral side [153]. 
2.7 OUTLOOK 
The definition of the primary study outcome has a major impact on studies of 
humanized xenograft models of bone metastases. The mostly widely used primary 
outcome is the tumour take rate. However, after analysis of the current literature it 
should be noted that there are significant differences regarding the definition of this 
variable. Novel detection modes and imaging modalities make it possible to detect 
even single cells at secondary sites [197]. This prompts the question “how is a 
metastasis defined?”. After xenografting, the majority of cells fail to colonize tissues 
and if they do, most of them fail to form metastatic colonies. Even cells that exhibit a 
metastatic capacity, only about 0.01% or less develop metastases which makes the 
process of metastasis very ineffective [198, 199]. This does not mean that 
disseminated tumour cells are not associated with a potential danger to establish an 
overt metastasis, since they have accomplished most of the antecedent steps of the 
metastatic cascade [200]. In the clinic one would not treat any patient in a remissive 
state of the disease though one would know that there are disseminated cancer cells 
in secondary tissues. As most of the xenograft models of bone metastasis try to 
recapitulate the conditions seen in the clinic and seek to promote new treatment 
strategies, single cancer cells in the human bone or bone construct should not be 
understood as a true metastasis. On the basis of these considerations we advocate the 
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 definition of a metastasis given by Danny R. Welch: “The dissemination of 
neoplastic cells to discontiguous nearby or distant secondary (or higher order) sites 
where they proliferate to form an extravascular mass of incompletely differentiated 
cells” [200].  
It has become increasingly clear that novel animal models of human bone 
metastases are needed that more closely recapitulate the conditions seen in the clinic 
and offer the possibility to develop efficient anticancer drugs. In the last years the 
major argument against the use of xenograft models of bone metastases was the lack 
of a human immune system and a human secondary tumour site. However, recent 
developments clearly show that it is possible to further humanize these models and 
this process is still ongoing. Though, patient derived tissue xenografts from cancer 
patients have been used for decades, they are just now being appropriately 
characterised and used for drug testing assays as individualised therapies become 
more and more important in the clinic [201]. Several companies offer primary 
tumour tissues as an alternative to conventional cancer cell lines that have been 
grown on plastic or otherwise propagated as cell cultures. Patient-derived tumour 
xenografts are kept at low passage numbers and it has been shown that they are 
biologically stable when passaged in mice. On the contrary, commonly used in vitro 
cultured cancer cell lines have adapted to grow outside the natural tumour 
environment, they show a high rate of mutations and phenotypic drift and therefore 
differ significantly from the primary tumour cells [202]. Thus, in the near future 
individualised models may become reality where cancer cells and the cells of the 
secondary tumour site, both originating from the same patient, are implanted into an 
immunocompromised animal to predict drug effects in one particular patient.  
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 3.1 ABSTRACT 
The development of effective therapeutic strategies against prostate cancer 
bone metastases has been impeded by the lack of adequate animal models that are 
able to recapitulate the biology of the disease in humans. Bioengineered approaches 
allow researchers to create sophisticated experimentally and physiologically relevant 
in vivo models to study interactions between cancer cells and their microenvironment 
under reproducible conditions. The aim of this study was to engineer a 
morphologically intact humanized organ bone which can serve as a homing site for 
human prostate cancer cells.  Transplantation of biodegradable tubular composite 
scaffolds seeded with human mesenchymal progenitor cells and loaded with rhBMP-
7 resulted in the development of a chimeric bone construct including a large number 
of human mesenchymal cells which were shown to be metabolically active and 
capable of producing extracellular matrix components. Micro-CT analysis 
demonstrated that the newly formed ossicle recapitulated the morphological features 
of a physiological organ bone with a trabecular network surrounded by a cortex-like 
outer structure. This microenvironment was supportive of the lodgement and 
maintenance of murine haematopoietic cell clusters, thus mimicking a functional 
organ bone. Bioluminescence imaging demonstrated that luciferase-transduced 
human PC3 cells reproducibly homed to the humanized tissue engineered bone 
constructs, proliferated, and developed macro-metastases. This model allows the 
analysis of interactions between human prostate cancer cells and a functional 
humanized bone organ within an immuno-incompetent murine host. The system can 
serve as a reproducible platform to study effects of therapeutics against prostate 
cancer bone metastases within a humanized microenvironment. 
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 3.2 INTRODUCTION 
Adenocarcinoma of the prostate is the most frequently diagnosed cancer among 
men in the industrialized world and the second leading cause of cancer death [203]. 
Advanced prostate cancer (PCa) with castration-like levels of serum testosterone is 
known for its proclivity to develop skeletal metastases. Post-mortem examinations 
have demonstrated that 90% of patients diagnosed with PCa have evidence of bone 
metastases [204]. To date, treatment options for these patients remain at best 
palliative resulting in a 5-year relative survival rate of less than 25% [205]. 
Approximately half of the patients with advanced PCa experience at least one 
complication related to the development of bone metastases within a two-year 
timeframe [206]. These complications, also referred to as skeletal-related events 
(SREs), are associated with a poor prognosis [207]. Taxane-based therapy in 
combination with corticosteroids has become the standard of care in patients with 
PCa metastases but a relapse is likely within the first year after chemotherapy [208]. 
Resistance to therapy is thought to occur through molecular alterations in the bone 
microenvironment leading to an increased proliferation of cancer cells [78, 209]. 
Several therapeutic strategies have therefore been developed to target not only the 
cancer cell itself but also its microenvironment. While substances such as 
Denosumab or bisphosphonates have already proven their clinical utility by reducing 
the number of SREs, they have demonstrated only marginal effects on the overall 
survival rate [206, 210].  
To allow a more reliable preclinical evaluation of new anticancer drug 
candidates and improve the efficacy of therapeutic strategies against PCa bone 
metastases, novel in vivo models are needed to mimic the cellular and molecular 
phenomena of the human disease under reproducible conditions. Transgenic and 
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 syngenic animal models can answer specific questions about the disease, but usually 
lack a robust skeletal metastatic phenotype and cannot be used to predict drug 
efficacy against a panel of human tumours within a given histology [113]. Therefore, 
most insights about the biological mechanisms of human PCa bone metastasis are 
still derived from xenograft models [211]. In these models, human cancer cells are 
inoculated into immuno-incompetent mice to recapitulate various aspects of human 
tumourigenesis and responsiveness of human tumour cells towards anti-cancer 
therapeutics. However, there are major differences between both species in terms of 
organ physiology, regulatory proteins and cancer susceptibility inter alia [212]. 
Humanizing the host organism with human stroma-derived cells prior to engraftment 
of human PCa cells mimics the interactions between human cancer cells and their 
native microenvironment, thus significantly improving the value of xenograft models 
[213].  
Despite attempts by researchers to simulate the human bone microenvironment 
as the physiological homing site of human cancer cells by xenotransplantation of 
human bone fragments into murine hosts [123, 154, 156], this approach has not 
resulted in a sufficient mimicry of the characteristics of vital human bone. The 
implanted fragments are poorly vascularized and the bone marrow compartment is 
mainly filled with adipocytes and connective tissue instead of haematopoietic cells 
[121, 158, 161]. Although a series of genetic and epigenetic alterations of cancer 
cells may be necessary for initial carcinogenesis, it is nowadays widely accepted that 
for the development of overt metastases a permissive niche is required [84, 85]. 
Disseminated cancer cells directly compete with haematopoietic stem cells (HSCs) 
for the occupancy of their niche and changes of the microenvironment alter cancer 
cell dissemination [78]. Being able to create humanized bone constructs with a 
Research paper 1: Species-specific mechanisms of human prostate cancer metastasis in tissue engineered bone 67 
 functional bone marrow compartment would allow the conditions seen in the clinic 
to be recapitulated more closely [69].  
We and others reason that tissue engineering approaches which are usually 
focused on the regeneration of damaged tissue structure and function [175, 214], are 
able to galvanize research on cancer and metastasis [112, 215]. In the present study, 
we have engineered a humanized replica of a morphologically intact and functional 
organ bone consisting of human cells and matrix proteins. We use this reproducibly 
tailorable model to study species-specific homing mechanisms of human PCa cells to 
bone. 
3.3 MATERIALS AND METHODS 
Scaffold preparation and primary cell culture: Tubular medical-grade 
polycaprolactone (mPCL) scaffolds were produced by melt-electrospinning 
following an in-house protocol (Figure 3.1A) [216]. Scaffolds were coated with 
calcium phosphate to promote cell adhesion, osteogenic differentiation in vitro and 
bone formation in vivo [217]. Human mesenchymal progenitor cells (hMPCs) were 
isolated from bone samples obtained from male patients undergoing hip arthroplasty 
as approved by the ethics committees of the Queensland University of Technology 
and the Prince Charles Hospital, Brisbane (approval no. 0600000232). All samples 
were collected under informed consent and in accordance with the World Medical 
Association’s Declaration of Helsinki. Cells were isolated and cultured on the 
scaffolds as previously described by our group [218]. After sterilization of the mPCL 
tubes, they were seeded with 3 x 105 hMPCs and cultured until they were covered by 
a dense cell sheet [216] (Figure 3.1B). After 4 weeks of static culture, mPCL 
scaffolds were transferred into the vessel of a bi-axial rotating bioreactor (QuinXell 
Technologies, Singapore) for another 4 weeks of dynamic culture to increase fluid 
Research paper 1: Species-specific mechanisms of human prostate cancer metastasis in tissue engineered bone 68 
 velocity (Appendix B, Movie B.1) [219]. The vessel was filled with 500mL 
minimum essential medium (α-MEM, Life Technologies, Australia) and 
supplemented with 10% fetal bovine serum (FBS, Life Technologies), 0.1 µM 
dexamethasone (Sigma-Aldrich, Australia), 150 µM phosphoascorbic acid (Sigma-
Aldrich) and 10 mM β-glycerophosphate (Sigma-Aldrich) and media change was 
performed every 2 weeks. 
Characterization of the scaffold/cell-constructs: Prior to implantation into 
animals, 2 mm disks were stamped out of the cell-seeded scaffolds to analyze cell 
viability and morphology. Surface analysis was performed by scanning electron 
microscopy (SEM) (Figures 3.1C, D). Samples were fixed with 3% glutaraldehyde in 
0.1 M sodium cacodylate buffer (pH 7.3) for 1 h at 4°C. Fixed specimens were then 
washed twice in ddH2O before being dehydrated in an ethanol series (25%, 50%, 
70%, 90% and 100% ethanol). Samples were critical point-dried (Denton Vacuum, 
USA), mounted on SEM aluminum stubs and gold-coated in a SC500 Bio-Rad 
sputter coater (Bio-Rad, USA) before examination with a FEI Quanta 200 scanning 
electron microscope (FEI, USA). To assess cell morphology, samples were fixed 
with 4% PFA, permeabilized with 0.2% Triton X-100 in PBS for 20 min at RT, then 
incubated with 0.8 U/mL rhodamine415-conjugated phalloidin and 5 μg/mL 4’,6-
diamidino-2-phenylindole (Life Technologies) for 1h at room temperature (RT) 
(Figure 1E). Cell viability was analysed by staining for fluorescein diacetate (FDA, 
Life Technologies) and propidium iodide (PI, Life Technologies) (Figure 3.1F). 
Specimen were rinsed twice with PBS and incubated with FDA staining solution (2 
μg/mL) at 37°C for 15 min in the dark. Then they were rinsed again with PBS and 
incubated with PI staining solution (20 μg/mL) for 2 min, washed and visualized 
with a Leica SP5 confocal microscope (Leica, Australia). 
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Figure 3.1. Characterisation of cell-seeded scaffolds prior to implantation. (A) mPCL with a molecular 
weight of 50kD was used to produce tubular scaffolds by melt-electrospinning. (B) Light microscopy 
during culture showed clusters of hMPCs (asterisk) overgrowing the pores between calcium 
phosphate-coated mPCL fibres (arrow). (C) Prior to the in vivo experiments, 2mm disks were stamped 
out of the scaffolds by using a disposable biopsy punch. These discs were used for further analyses. 
(D) SEM imaging prior to implantation into the animals demonstrated that hMPCs had formed dense 
sheets (asterisk) covering the complete scaffold and filling the open spaces between the fibres 
(arrows). (E) Seeded cells were shown to exhibit an osteoblast-like morphology with a spindle-
shaped, elongated cell body and thin filopodiae (f-actin stained in red, nuclei in blue) (F) Viability of 
the cells was assessed by staining living cells with fluorescein diacetate (green) and dead cells with 
propidium iodine (red). More than 90% of the seeded hMPCs were shown to be viable before 
implantation into the murine host.   
Implantation of the scaffold/cell-constructs: All animal studies were conducted 
in conformity with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes and approved by the Animal Ethics Committee of the 
Queensland University of Technology (approval no. 1300000025). Four week old 
male NOD-scid mice (strain name: NOD.CB17-Prkdcscid/J; stock number: 001303) 
were purchased from the Animal Resources Centre (Canning Vale, Western 
Australia) and housed at the animal facility of the Pharmacy Australia Centre of 
Excellence. All animals were maintained under specific pathogen-free, temperature-
Research paper 1: Species-specific mechanisms of human prostate cancer metastasis in tissue engineered bone 70 
 controlled conditions and supplied with sterilized food and water ad libitum. Animals 
were used for experiments after a 2 week acclimatization phase. An incision of 
approximately 5mm was made on each flank of the animal and two subcutaneous 
pockets were created using blunt dissection. Before implantation, the hollow tubular 
scaffold/cell constructs were filled with 30 μL rhBMP-7 (1 μg/μL, Olympus Biotech 
Corporation, USA) embedded in 60 μL fibrin glue (TISSEELTM kit, Baxter 
Healthcare, Australia). Constructs were implanted after polymerization of the fibrin 
glue to ensure the maintenance of their tubular form.  
PCa cell culture: Due to their cellular characteristics, the human PC3 cell line 
was chosen as it exhibits a high metastatic capacity and lacks androgen receptors. 
Therefore, these cells are suitable to mimic a castration-resistant disease status. 
Metastatic lesions formed by PC3 cells are mainly osteolytic without any 
surrounding osteoblastic response [220]. As a negative control we used human 
epithelial non-tumourigenic MCF10A cells. Both cell lines were obtained from the 
American Type Culture Collection (ATCC, USA), transduced to express luciferase 
using a pLenti6/V5-D-TOPO lentivirus (Life Technologies) and selected for 2 weeks 
using blasticidin (InViVoGen, USA). Culture was performed in α-MEM 
supplemented with 10% FBS, 100 IU/mL penicillin (Life Technologies) and 100 
μg/mL streptomycin (Life Technologies).  
PCa animal studies: After implantation of the cell-seeded constructs, animals 
were kept for 14 weeks to allow mineralized tissue formation which was monitored 
via x-ray analysis (Kodak Image Station FX, Eastman Kodak Company, USA). Six 
animals were used for intracardiac injection of 5x105 Luc-PC3 cells suspended in 
100 mL PBS, whereas the other 6 mice received 5x105 Luc-MCF10A and served as a 
control. Homing and growth of the inoculated human PCa cells were monitored 
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 weekly via bioluminescence imaging (BLI, IVIS Spectrum 200, Perkin Elmer, USA). 
Animals were imaged 15 min post intraperitoneal injection of 100 µL (7.5 mg/mL) 
luciferin (PerkinElmer, USA). Four weeks after intracardiac injection, mice were 
sacrificed by CO2 asphyxiation. The humanized tissue engineered bone constructs 
(hTEBCs), mouse bones and organs were excised. Ex vivo BLI imaging was 
performed 20 min after Luciferin injection. Images were analyzed with the Living 
Image Software (Perkin Elmer) using a threshold set at 10% around each 
bioluminescent source to determine the amount of photons emitted within a given 
time. Signals higher than 200 counts were considered positive. Explanted specimen 
were fixed in 4% PFA for 24h at 4°C and transferred into 70% ethanol for 
subsequent analyses.  
Micro-CT: After recovery, hTEBCs were analyzed with a high resolution μCT 
scanner (μCT 40, Scanco Medical AG, Switzerland) and scanned at a voxel size of 
16μm. Samples were evaluated at a threshold of 150, a filter width of 0.8 and a filter 
support of 1. X-ray attenuation was correlated to the sample density with a standard 
curve generated after scanning hydroxyapatite phantoms with a known mineral 
density. Bone volume (BV, mm3), total volume (TV, mm3) and bone volume fraction 
(BV/TV %) were calculated according to guidelines described by Bouxsein et al. 
[221].  
Histology/Immunohistochemistry: Fixed samples were decalcified with 10% 
EDTA (pH 7.4) at RT for 6 weeks. Haematoxylin/Eosin (H&E) staining was 
performed on paraffin sections using a standard protocol [222]. For 
immunohistochemical analyses, sections were deparaffinised, rehydrated and 
incubated with 3% H2O2 (Sigma-Aldrich). Cells were permeabilized with 0.1% 
Triton X-100 in PBS for 6 min to target intracellular proteins. For antigen retrieval, 
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 the sections were either incubated with Proteinase K (Dako, Denmark) for 10 min at 
RT or with sodium citrate buffer (pH=6) at 95°C for 4 min, before blocking with 2% 
BSA (Sigma-Aldrich) for 30 min. Sections were then incubated with the primary 
antibody solution or with the matched non-immune antibody control, followed by the 
secondary antibody EnVision+ Dual Link System-HRP rabbit/mouse (Dako) coupled 
with horse radish peroxidase (Dako). Diaminobenzidine (Sigma-Aldrich) was used 
for chromagen development. Sections were counterstained with Mayer’s 
haematoxylin (Sigma-Aldrich) and analyzed using an Olympus BX-51 microscope 
(Olympus, Australia).  
Acid etching of resin-embedded samples: Specified ossicles were embedded in 
poly(methyl-methacrylate). The mineral phase was removed by mild acid-etching to 
leave a resin cast of the non-mineralized tissue behind. Samples were polished by 
sequential wet sanding with 400, 600 and 1200 grit sandpaper. The final polish was 
achieved with 1.0 alpha alumina powder using a soft cloth polishing wheel. The 
surface was then etched with 37% phosphoric acid for 2-10 sec, washed with sodium 
hypochlorite and rinsed with ddH2O [223]. Dried blocks were coated with gold 
sputter and analysed with a FEI Quanta 200 SEM.  
Tartrate resistant acid phosphatase (TRAP) staining: Sections were 
deparaffinised, rehydrated and washed for 5 min in de-ionized water. Then samples 
were incubated for 20 min at RT in 0.2 M acetate buffer consisting of 0.2 M sodium 
acetate (Sigma-Aldrich) and 50 mM sodium L-tartrate dehydrate (Sigma-Aldrich) in 
ddH2O. Then sections were transferred to the same acetate buffer to which 0.5 
mg/mL naphtol AS-MX phosphate disodium salt (Sigma-Aldrich) and 1.1 mg/ml 
Fast Red TR salt 1,5-napthalenedisulfonate salt (Sigma-Aldrich) has been added 
previously. Samples were incubated at 37°C for 2h,  rinsed in deionized water, 
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 counterstained with haematoxylin and mounted with an aqueous medium (Clear-
Mount, ProSciTech, Australia). 
Statistical analyses: Test statistics for the μCT and BLI data did not follow a 
normal distribution. Therefore, the Wilcoxon rank sum test was used to evaluate 
differences between the metastasis and the control groups. The level of significance 
was set at p ≤ 0.05.  
3.4 RESULTS 
3.4.1 Chimeric ectopic bone constructs recapitulate morphological features of a 
functionally intact organ bone 
Necropsy revealed that the hTEBCs were well integrated into the subcutaneous 
tissue without any fibrous encapsulation (Figure 3.2A). Histology (H&E) 
demonstrated that the newly formed ossicles recapitulate the morphology of a 
physiological organ bone with a cortex-like outer structure surrounding a trabecular 
network. The tissue was very well-vascularised and the intertrabecular spaces were 
filled with proliferative bone marrow (Figure 3.2B). Histologically, the bone marrow 
composition was very similar to the one found in bones of age-matched control 
animals (Appendix B, Figure B.1). Well expanded and preserved sinusoids were 
filled with erythrocytes and surrounded by haematopoietic progenitor cells of 
different lineages indicating a high haematopoietic activity. The presence of 
osteocytes in the lacunae, cuboidal cells on the surface of the trabeculae and 
multinucleated cells in resorption pits indicated that the organ was viable and 
actively remodelling at least for the time of implantation (Figure 3.2C). Collagen 
type-II positive hypertrophic cartilage cell clusters within dense immature tissue 
located mainly in the centre of the constructs indicated bone formation via the 
endochondral pathway (Figure 3.2D). Osteocytes within the newly formed bone 
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 matrix were visualized by acid-etching of resin embedded samples (Figure 3.2E). A 
high degree of interconnecting cytoplasmic extensions suggested a functional 
syncytial network (Figure 3.2F). Immunohistochemistry using human-specific 
antibodies demonstrated that the newly formed bone organ was a chimera, formed by 
human and murine mesenchymal cells. The bone tissue incorporated a high 
proportion of human mesenchymal cells (Figure 3.2G), which were shown to be 
metabolically active and contributed to the formation of the bone organ (Figure 
3.2H). Vascular structures and cellular components of the bone marrow were shown 
to be host-derived.  
 
Figure 3.2. Humanized ectopic bone constructs recapitulate morphological and compositional 
characteristics of a physiological organ bone. (A) Macroscopically, the tissue engineered ossicle 
(asterisk) had a dark red colour. Extensive neovascularisation (arrows) was evident around the 
construct. (B) Histology (H&E) revealed a cortex-like outer structure (arrows) consisting mainly of 
mature bone matrix which surrounded a network of intercommunicating trabeculae. Immature bone 
islets were located in the centre of the constructs and were identified as ossification centres (asterisk). 
(C) Bone marrow spaces included cellular components of proliferative haematopoietic marrow. Well-
expanded sinusoids filled with red blood cells (asterisk) were scattered within the marrow cavity and 
were surrounded by haematopoietic cells of different lineages. Megakaryocytes were identified as 
large cells with lobulated nuclei which were attached to the perisinusoidal wall (arrows). (D) 
Immunohistochemical staining for Collagen type-II revealed the evidence of hypertrophic hyaline 
cartilage cell clusters (white arrows) within immature dense tissue indicating endochondral 
ossification. These ossification centres were surrounded by mature trabecular structures (black 
arrows). (E) Mild acid-etching of the mineralized phase visualized an abundance of osteocyte cell 
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 bodies within the newly formed bone. (F) SEM analysis demonstrated a high degree of 
interconnecting cytoplasmic extensions indicating an intact syncytial osteocyte network. (G) 
Mesenchymal cells scattered within the bone matrix and the fibrous tissue were both of murine (blue, 
white arrows) and human (brown, black arrows) origin as shown by staining for human nuclear 
mitotic apparatus protein 1 (NuMa). (H) Staining for human Collagen type-I demonstrated that the 
newly formed organ was a chimera consisting of both human (brown, black arrow) and murine (pale 
blue, white arrow) extracellular matrix proteins.  
3.4.2 The engineered humanized bone organ serves as a target site for 
metastatic PCa cells 
After injection of Luc-PC3 cells into the left cardiac ventricle, animals were 
followed weekly via in vivo BLI over 4 weeks to determine metastatic tumour load. 
The first metastatic lesions were detectable one week after intracardiac injection. The 
highest radiance increase/increase in metastatic tumour load was found between 
week 3 and 4. After 4 weeks, BLI showed a summarizing signal, making it 
impossible to detect single lesions in different organs (Figure 3.3A). At the 
experimental endpoint, the engineered ossicles, mouse bones and organs were 
excised and imaged separately ex vivo to quantify the metastatic tumour take rate in 
different organs or tissues. The mean radiance per tumour bearing ossicle was 5.8 x 
104 photons per second per centimetre squared per steradian [p/s/cm2/sr]. The 
radiance in the control group was 0 p/s/cm2/sr (p < 0.001) (Figure 3.3B). The mean 
total flux was 1.9 x 106 photons per second [p/s] in the metastasis group and 0 p/s in 
the control group, respectively (p < 0.001). Metastases were also found in the mouse 
organs and skeleton. The highest metastatic tumour load was detected in the spine, 
lungs and liver (Figure 3.3C). 
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Figure 3.3. Human PC3 cells inoculated via the left cardiac ventricle reproducibly home to hTEBCs. 
(A) Weekly BLI showed the first localized signal at the left flank one week after cancer cell 
inoculation. After 4 weeks multiple metastatic foci resulted in a summarizing signal. (B) Ex vivo 
imaging revealed a high tumour take rate with a mean radiance of 5.8 x 104 p/s/cm2/sr per hTEBC. In 
the control group the mean radiance was 0 p/s/cm2/sr (p < 0.001). (C) Representative images of mouse 
bones (top panel) and organs (bottom panel) revealed the highest metastatic tumour load in the axial 
skeleton, liver and lungs. [bars showing maximum radiance signals in p/s/cm2/sr]. 
3.4.3 PC3 cells proliferate and recapitulate their typical metastatic growth 
pattern within the humanized microenvironment 
At the experimental endpoint, hTEBCs were analysed via quantitative μCT. As 
demonstrated histologically, the newly formed bone was shown to recapitulate the 
radiographic features of a physiological organ bone with a cortex-like outer structure 
surrounding a trabecular network (Appendix B, Movie B.2). The mean bone volume 
fraction (BV/TV %) in the control group was 26.2 ± 5.6%. This was significantly 
higher than the mean bone volume fraction of the ossicles in the metastasis group 
which was 15.0 ± 5.8% (p < 0.001) (Figure 3.4A). Homing and proliferation of 
intracardially inoculated PC3 cells resulted in the development of osteolytic 
metastases leading to a decreased bone volume fraction of the hTEBCs. The 
qualitative morphological analysis of the samples confirmed these results (Figure 
3.4B). The hTEBCs in the control group maintained their structure with an intact 
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 cortical shell, whereas the bone constructs in the metastasis group exhibited areas of 
extensive bone loss with destruction of their morphological entity. In the metastasis 
bearing ossicles, the surface of the trabeculae, which were in direct contact with the 
tumour mass, had an irregular profile with resorption pits occupied by large 
multinucleated cells. TRAP staining verified the presence of numerous osteoclasts 
actively degrading the bone matrix. On the contrary, in the ossicles of the control 
group, there were hardly any TRAP-positive cells detectable (Figure 3.4C).  
 
Figure 3.4. Human PC3 cells recapitulate their typical osteolytic metastatic growth pattern within 
hTEBCs. (A) Quantitative μCT analysis revealed a significantly higher bone volume fraction (BV/TV 
%) in the ossicles of the control group. (B) Qualitative μCT analysis showed extensive osteolyses in 
the metastases bearing ossicles. (C) The surface of the bone matrix which was in direct contact with 
metastatic PC3 cells (white arrows), was covered by TRAP-positive osteoclasts residing in resorption 
pits (red cells, black arrows).  
Histology (H&E) revealed the presence of metastases in 10 out of 12 ossicles 
(Figure 3.5A). The tumour margins were clearly confined by a front of TRAP-
positive cells (Figure 3.5B). Immunohistochemical staining for human nuclear 
mitotic apparatus protein 1 (NuMa) demonstrated that the bone marrow compartment 
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 was progressively replaced by human PCa cells (Figure 3.5C). The morphology of 
PC3 cells inside the hTEBCs varied from a rounded epithelial-like to a spindle-
shaped mesenchymal phenotype with different intermediate forms. Staining for 
human Ki67 revealed the presence of proliferating cancer cells in the centre of the 
metastatic lesions (Figure 3.5D). 
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 Figure 3.5. Engineered humanized bone provides a niche for metastasizing human PCa cells. (A) 
Histological analysis (H&E) showed a macro-metastatic lesion (dotted line) leading to a destruction of 
the outer cortical shell and trabecular structures. Higher magnification (lower panel) revealed 
remnants of bone matrix (black arrows) and osteoclasts in resorption pits (white arrows). (B) 
Corresponding section stained for TRAP demonstrated the osteoclast front (red cells) preceding the 
expanding tumour mass. (C) Immunohistochemical staining for human NuMa indicates that metastatic 
PC3 cells (brown, white arrows) progressively replaced the ossicle’s marrow components. (D) 
Proliferating cancer cells (brown, black arrows) were identified in the centre of the metastatic lesions 
by staining for human Ki67 (higher magnification area is indicated). [Lower panels are higher 
magnifications of upper panels]. 
3.5 DISCUSSION 
Our results show that a tissue engineering approach can overcome the 
limitations of traditional xenograft models of bone metastasis by developing a 
humanized organ bone within a murine host. We demonstrated that the hTEBC 
remains viable and functional at least for the duration of the experimental protocol 
and provides a humanized niche for human PC3 cells to home to, proliferate, and 
develop macro-metastases. In contrast to traditional xenograft models of bone 
metastasis we used a highly reproducible and standardized bone engineering 
protocol, which allows an in-process control of the pre-cultured constructs before 
implantation. This is a conditio sine qua non when planning a series of animal 
experiments with the same model to work on different hypotheses.  
So far, only two other groups have used a bone tissue engineering platform in a 
xenograft model of bone metastasis [169, 170]. Though, they showed that the 
engineered constructs allow human tumour growth, they failed to recapitulate a 
physiologically relevant bone organ and were not able to prove whether the 
implanted human cells survive and contribute to the niche formation.  
Schuster et al. [170] used hydroxyapatite-impregnated collagen sponges seeded 
with human osteoblasts. After subcutaneous implantation into male scid mice, human 
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 PC3 cells were injected into the constructs. Subsequent histological analyses 
revealed tumour masses in all implants. Although new trabeculae had formed, the 
authors were not able to show the establishment of a functional bone marrow niche. 
Furthermore, the group did not provide any information about the composition, the 
viability or the species origin of the newly formed bone [170].  
Moreau et al. [169] aimed to create ectopic tissue engineered bone constructs 
in NOD-scid mice using silk fibroin protein sponges covalently coupled with BMP-2 
and seeded with human bone marrow-derived stroma cells [169]. SUM1315 breast 
cancer cells were implanted orthotopically into the mammary fat pad of the mice and 
formed tumours after homing to the newly formed ectopic construct. However, 
histological analyses did not show the morphological characteristics of a functional 
organ bone. In fact, histology revealed only calcified scaffold structures surrounded 
by fibrous connective tissue with no evidence of newly formed trabeculae or bone 
marrow. Furthermore, the construct was interspersed with large portion of the 
scaffold material interfering with a physiological coherent tissue structure [169]. In 
this context we would like to point out that the process of calcification should not be 
confused with the process of ossification. Calcification simply denominates the 
production of calcium based salts within tissue, whereas ectopic ossification 
describes the formation of a marrow-containing organ bone via the endochondral 
pathway [224].  
We and others reason that for the study of interactions between cancer cells 
and a physiologically relevant bone microenvironment the formation of a functional 
bone marrow niche is essential [84, 85, 213]. Interestingly, no previous xenograft 
model of bone metastasis has been able to successfully recapitulate a physiological 
bone marrow niche [121-123, 154, 169, 173]. However, the establishment of a pre-
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 metastatic niche seems to be indispensable for the development of metastatic lesions 
[78]. Recent studies demonstrated that metastatic cancer cells can usurp the homing 
pathways of HSCs to establish footholds in their microenvironment [78, 84, 85]. 
Disseminated cancer cells directly compete with HSCs for the occupancy of the HSC 
niches and changes in the size of the niche alters cancer cell dissemination [78].  
In this study, we demonstrated that a tissue engineered humanized organ bone 
can be a suitable niche for both endogenous murine haematopoietic cells and 
inoculated human PC3 cells. Previous studies failed to prove whether the implanted 
human mesenchymal cells contribute to the formation of the constructs [169, 170]. 
We showed that the implanted hMPCs survive and are metabolically active as shown 
by staining for human extracellular matrix proteins. This humanized system provides 
a platform to further investigate the effects of therapeutics that target both the cancer 
cells and their microenvironment. Finally, with this model it is possible to test drugs 
such as the human monoclonal antibody Denosumab which has been shown to 
inhibit bone resorption only in humans not in rodents due to a species-specific 
binding to RANKL [103]. Tissue engineering of a morphologically and functionally 
intact humanized HSC niche and the development of a “blood producing humanized 
organ bone” within a murine host is the basis for a potential maintenance or 
amplification of human HSCs in this system. Our study paves the way for future 
experiments in which we will perform reconstitution assays with human HSCs that 
can populate their humanized tissue engineered niche. If these HSCs were able to 
differentiate, it would be for the first time possible to analyse interactions between 
human PCa cells and human immune cells within a humanized bone 
microenvironment. This could increase the value of xenograft models of PCa bone 
metastasis in the future.  
Research paper 1: Species-specific mechanisms of human prostate cancer metastasis in tissue engineered bone 82 
 While the implantation of human breast cancer cells into the murine mammary 
fat pad has been shown to result in metastatic lesions in transplanted bone constructs 
or human bone fragments [121, 169], the development of a humanized orthotopic 
xenograft model of PCa bone metastasis has not yet been successful. Several studies 
have failed to detect spontaneous bone metastases after implantation of human PCa 
cells into the murine prostatic capsule [192-194]. This could be related to either a 
short observation period, a relative paucity of blood flow at the primary implantation 
site, insufficient detection modes or to the residual immune system of the host animal 
[189, 213].  Therefore, we used the intracardiac route of cancer cell inoculation in 
our tissue engineered model. However, we and others have demonstrated that a 
bioengineered humanized primary tumour microenvironment can result in an 
increased metastatic capacity of human PCa cells [211, 225]. This may help to create 
a fully humanized xenograft model of PCa bone metastasis in the future.  
3.6 CONCLUSION 
In summary, we have accomplished to bioengineer a humanized organ bone, 
which recapitulates morphological features and biological functions of the HSC 
niches. We have shown that human mesenchymal cells are not only incorporated in 
this organ but are indeed metabolically active and contribute to the development of 
the humanized microenvironment. Human PCa cells reproducibly home to these 
humanized bone organs, proliferate, and develop macro-metastases. This model 
allows the analysis of interactions between human PCa cells and a vital humanized 
bone organ within an immuno-incompetent murine host. Finally, the bioengineered 
humanized model of PCa bone metastasis presented here will help to improve our 
understanding of the relevant biological processes seen in humans.  
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 4.1 ABSTRACT 
Despite positive testing in animal studies, more than 80% of novel drug 
candidates fail to proof their efficacy when tested in humans. This is primarily due to 
the use of preclinical models that are not able to recapitulate the physiological or 
pathological processes in humans. Hence, one of the key challenges in the field of 
translational medicine is to “make the model organism mouse more human”. To get 
answers to questions that would be prognostic of outcomes in human medicine, the 
mouse’s genome can be altered in order to create a more permissive host that allows 
the engraftment of human cell systems. It has been shown in the past that these 
strategies can improve our understanding of tumour immunology. However, the 
translational benefits of these platforms have still to be proven. In the 21st century, 
several research groups and consortia around the world take up the challenge to 
improve our understanding of how to humanize the animal’s genetic code, its cells 
and, based on tissue engineering principles, its extracellular microenvironment, its 
tissues or entire organs with the ultimate goal to foster the translation of new 
therapeutic strategies from bench to bedside. The present article provides an 
overview of the state of the art of humanized models of tumour immunology and 
highlights future developments in the field such as the application of tissue 
engineering & regenerative medicine (TE&RM) strategies to further enhance 
humanized murine model systems.  
4.2 INTRODUCTION 
For many decades, the laboratory mouse has been the key surrogate model 
system to provide insights into the development and treatment of human diseases 
such as cancer. However, in the light of recent clinical trial failures of novel drug 
candidates, the value of mouse models to translate research findings from bench to 
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 bedside has been increasingly questioned [90]. While significant insights into the 
molecular and cellular basis of human cancer biology are derived from small animal 
models, it is well known that considerable differences exist in terms of organ 
physiology, cellular dynamics and regulatory proteins, when mice are compared to 
humans [213, 226]. Relying solely on syngeneic murine models poses the risk of 
translating therapeutic strategies into the clinic that lack proven mechanisms. Even 
though animal studies might suggest novel drug candidates to be efficient, more than 
80% of these drugs fail when tested in humans [92]. To get answers that are more 
predictive of results in human medicine, major basic and translational research 
efforts are directed towards the humanization of the model organism mouse [99]. 
This can be achieved by incorporation of human transgenes into the host animal or 
transplantation of functional human cells, tissues or entire organs [94]. However, 
humanizing a mammalian species is not a clear-cut assignment due to the 
multifaceted interaction of biological components and spatial scales. 
The term “humanized mouse” first became popular after the publication of the 
paper “Humanized mice: are we there yet?” from Macchiarini et al. in 2005 [227], 
which summarizes the application spectrum of these model organisms in biomedical 
research. Since then, humanized mice have been increasingly used for the study of 
human biological processes, malignancies or disorders [94-96]. Though these model 
systems are of high value for the research community, they also have their inherent 
limitations and the expectations that humanized mice are the “Rosetta Stone” of 
translational research have not been fulfilled yet [228]. Scientists are still working on 
the improvement of our understanding of how to humanize the animal’s genetic 
code, its cells and extracellular microenvironment, its tissues or entire organs to 
foster the translation of new therapeutic strategies from bench to bedside. A 
Review paper 2: Humanized models of tumour immunology in the 21st century: Convergence of cancer research 
and tissue engineering 87 
 humanized mouse is an immuno-compromized hybrid model organism, a chimera, 
which is murine enough to provide a vital host environment for xenotransplanted 
cells but at the same time is not too much human so that a graft versus host disease is 
triggered. Without any doubt, this approach has the potential to answer specific 
questions in human medicine and particularly in cancer research, however at the 
moment, the humanization of the mouse and the development of a translatable model 
system is a process rather than a finalized product, since the success of this model 
system is growing in parallel with technological advancements in genetics, 
proteomics, stem cell research, tissue engineering & regenerative medicine 
(TE&RM), inter alia (Figure 4.1). Despite their promises and potential for 
translational medicine, the generation of humanized mice has raised ethical issues 
and moral confusion within the public and the research community. Therefore, 
scientists have to continuously question their own experimental approaches to ensure 
that their respect for both human and animal dignity is maintained [229]. Ethical 
guidelines have to be continuously refined in parallel to the technical advances 
available. This will ensure that research protocols are both ethically sound and 
advance health care.  
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Figure 4.1. The main obstacle in creating humanized mice: One of the major challenges within the 
biomedical research community in the 21st century will be to solve problems of highly complex and 
integrated biological systems. Validated humanized mouse models hold great promise for improving 
preclinical drug testing and unravelling biological mechanisms of the human disease. However, the 
true potential of this platform can only be uncovered by an integrative effort of different research 
disciplines. 
4.3 CREATING “NICHES” FOR THE ENGRAFTMENT OF HUMAN 
CELLS 
One of the most widely used methods in cancer research is the transplantation 
of human xenografts into murine hosts to investigate human tumour growth, 
invasion, progression and metastasis. Co-transplantation with human immune system 
elements allows the analysis of species-specific interactions between human tumour 
cells and a humanized immune system. This requires the use of immuno-
compromized hosts that readily integrate xenografts and do not reject human cancer 
cells. The ability to successfully transplant human cells that can be reproducibly 
maintained and amplified within the murine system was first made possible with the 
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 discovery of athymic nude mice in 1966 [230]. These mice are homozygous for a 
mutation in the forkhead box N1 (Foxn1) gene resulting in T cell deficiency. Though 
they were shown to support human cancer cell engraftment and tumour growth, they 
are not suitable to host functional human cells or tissues as they exhibit an intact B 
cell activity and functioning innate immunity [126]. In 1983 Bosma et al. reported a 
spontaneous autosomal recessive mutation in the Prkdcscid gene (protein kinase, 
DNA  activated catalytic polypeptide), which severely impairs lymphopoiesis in 
affected C.B-17 mice [127]. The severe combined immunodeficiency syndrome 
occurring in the C.B-17-Scid mouse is clinically very similar to the disease found in 
humans and analogous in the mode of inheritance with impaired rearrangement 
processes at the JH region. The lack of both T and B cells associated with this 
mutation allowed for the successful transplantation of human derived haematopoietic 
stem cells (HSCs) [231], peripheral blood mononuclear cells (PBMCs) [232] and 
fetal tissues [233]. However, engraftment rates were still low due to the remaining 
high level of innate immunity and due to a process known as “leakiness”, which is 
the production of functional T and B cells during ageing [95].  In 1980 Makino et al. 
described non-obese diabetic mice (NOD) that are characterized by an impaired 
innate immunity [234]. Crossing NOD and Scid strains resulted in a mouse with 
defects in both the innate and adaptive immunity. The diabetic phenotype was not 
relevant any more as the onset of diabetes in NOD mice is predominantly T cell 
dependent [130]. This so-called NOD/Scid mouse developed by Shultz et al. in 1995 
has served as the gold standard for the engraftment of functional human cells for the 
last two decades. However, some limitations still remained even with this strain, 
namely the limited longevity due to the development of thymic lymphomas and the 
reduced but yet prevailing leakiness [96].  
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 While the above-mentioned mouse strains are mainly the result of sophisticated 
breeding strategies, state-of-the-art platforms use genetic engineering to decrease 
immunity and increase the level of humanisation within these strains. In the 1990es, 
RAG-1 and RAG-2 mutant mice were genetically engineered that lack the ability to 
perform V(D)J rearrangement resulting in a Scid phenotype without leakiness [235, 
236]. Other targeted mutations were performed at the β2 microglobulin and perforin 
genes to prevent the development of natural killer (NK) cells [227, 237, 238]. 
Nevertheless, problems such as residual innate or adaptive immunity or the 
development of lymphomas in mice with Scid background still prevented the 
sufficient engraftment of functional human cells. These problems were not overcome 
until the development of immuno-deficient mice homozygous for a targeted mutation 
in the interleukin-2 receptor γ chain gene (IL-2rg) which encodes a transmembrane 
receptor subunit for signal transduction of IL-2, IL-4, IL-7, IL-15 and IL-21. These 
cytokines are essential for the function of leukocytes [239]. Mice carrying this 
mutation are characterized by severe impairment of T and B cell development, 
complete lack of NK cells and poor lymph node development [240]. Consequently, a 
series of highly immuno-deficient mice have been developed in the 2000s by 
combining the IL-2rγnull gene with mice carrying the Rag1null, Rag2null or Scid 
mutation resulting in even more profound immunological defects (reviewed in detail 
by Shultz et al. [95] and Ito et al.[138]).  Mice containing the IL-2rγnull mutation 
allow multi-lineage haematopoietic cell engraftment after transplantation of human 
HSCs [95, 241, 242]. They have proven their efficacy in analysing human 
immunological processes or key steps involved in human tumour growth or 
metastasis and have therefore become the new standard for humanized mouse models 
[95].  
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 4.4 MODELING HUMAN CELLULAR AND HUMORAL ANTI-IMMUNE 
RESPONSE 
Studies have demonstrated that a higher number of human cancer cells exhibit 
tumourigenic potential when transplanted into 2rγnull mice than into NOD/Scid mice 
[243]. This is mainly due to the more biologically permissive conditions found in 
2rγnull mice.  To recapitulate the clinical conditions more closely and to model the 
human anti-tumour immune response, immuno-compromized mice can be engrafted 
with both human cancer cells and functional human immune cells [244-247]. In 
2010, there were still only a limited number of papers published in which effects of 
human immune systems on human tumours were investigated within a murine host. 
However, within the last years and in parallel with the development of more 
permissive hosts, more and more groups have adopted these innovative concepts for 
their specific research questions.  
One method to generate humanized mice is to transplant human PBMCs. This 
does not require highly sophisticated cell isolation techniques and leads to a stable 
engraftment of activated T cell populations. Engrafted IL-2rγnull mice usually 
develop a robust xenogeneic GvHD after a few weeks only which is even accelerated 
when the mice are irradiated prior to cell transplantation [248]. Despite the 
transplantation of human PBMCs allows only a limited investigative time window, 
the model has already yielded significant insights into human tumour immunology 
[245, 249-251]. In 2009, Ito et al. [251] transplanted human lymphoma cells 
subcutaneously into 6-8 weeks old NOD/Shi-Prkdcscid Il2rctm1Sug/Jic mice. After 
28 days, they treated those mice with either 1 x 107 adult PBMCs alone or in 
combination with KM2760, a chimeric anti-CCR4 monoclonal antibody, for 2 
weeks. KM2760 was shown to mediate robust antibody-dependent cellular 
cytotoxicity and resulted in a significant increase of human tumour-infiltrating NK 
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 cells in mice bearing lymphomas [251].  Wulf-Goldenberg and co-workers [245] 
injected newborn NOD/C.B-17-Scid mice with 5 x 106 cord-blood mononuclear 
cells intrahepatically after γ-irradiation with 1Gy. After 5 weeks, T cell engraftment 
was observed and mice were subcutaneously transplanted with human SW480 colon 
carcinoma cells. While the engrafted human mononuclear cells alone had only a 
slight negative effect on tumour growth when compared to non-engrafted mice, 
treatment with a bispecific EpCAM/CD3 antibody was able to enhance the anti-
tumoural effect of human immune cells [245]. In a similar study performed by 
McCormack et al. [252], the efficacy of bifunctional ImmTAC-NYE, a T-cell 
receptor specific for NY-ESO-1 fused to an anti-CD3 scFv, was tested in a xenograft 
model in which 20 x 106 CD45+CD3+ PBMCs were intravenously injected before or 
after subcutaneous engraftment of NY-ESO-1 positive tumours. In both, the 
preventive and treatment group, there was a significant effect of the reagent when 
compared to PBS injected mice [252]. Guichelaar et al. [250] investigated the anti-
tumour response of human PBMCs with or without human Tregs in a humanized 
mouse model.  They injected Luciferase-labelled human myeloma cells into the 
circulatory system of adult Stock (H2d)-Rag2tm1FwaIl2rgtm1Krf mice. After 2 to 5 
weeks of tumour cell injection, 1 x 107 PBMCs were injected intravenously to induce 
both a graft versus tumour reaction and GvHD. In another experimental group, the 
authors co-transplanted 1 x 107 Tregs. As expected, a high engraftment rate of CD4+ 
and CD8+ T cells was found after 2 weeks of PBMC transplantation and 50% of the 
mice died after 4 weeks due to GvHD. Co-transplantation of Tregs however, resulted 
in a significantly longer survival rate by inhibiting GvHD while not suppressing the 
graft versus tumour reaction [250]. Human PBMC xenograft tumour models can also 
be used for the preclinical testing of human T cell therapies. Peripheral human T 
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 cells can be isolated and specifically targeted against an array of human tumour 
antigens by genetic transfer of antigen-specific receptors such as chimeric antigen 
receptors (CARs) [249, 253-256] or the heterodimeric T cell antigen receptor (TCR) 
[257]. This platform makes it possible to test the efficacy and safety profile of 
targeted T cell therapies in vivo. However, it has to be emphasized that the 
translational value of these studies is limited as true anti-tumoural T cell responses 
can hardly be differentiated from allogeneic graft versus tumour activity due to 
HLA-mismatch between human T cells and cancer cells. Furthermore, the 
xenogeneic GvHD occurring in these models can also influence the outcomes of 
these studies.  
A more complex method is the transplantation of CD34+ human 
haematopoietic stem and progenitor cells into the murine host [258]. Here, the 
technological approaches are quite diverse and only a few well-controlled studies 
comparing the efficacy of different isolation methods, culture conditions or 
engraftment routes can be found in the literature [259-261]. Human CD34+ cells can 
be isolated from cord blood, bone marrow, peripheral blood and fetal liver. Isolation 
is usually performed by Ficoll separation and subsequent incubation with human 
CD34 magnetic selection beads. Currently, human cord blood cells are seen as the 
gold standard since they are readily available and result in higher engraftment rates 
as compared to cells isolated from adult bone marrow [259]. Werner-Klein et al. 
recently found that although more CD34+ cells per number of mononuclear cells can 
be isolated from bone marrow than cord blood, approximately 2 x 105 CD34+ bone 
marrow cells are needed to achieve engraftment levels equivalent to 4.8 x 104 cord 
blood cells [259]. The group also demonstrated that in adult mice there is no 
statistical qualitative or quantitative difference in reconstitution capacity between 
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 cord blood cells transplanted via the intra-femoral, intra-hepatic or intravenous route 
[259]. When neonatal mice are used, the intra-hepatic route is recommended [261], 
as the liver is the main haematopoietic organ at birth [262]. For bone marrow cells, 
no significant differences were found when transplanted by intra-femoral injection 
into adults or intra-hepatic injection into newborn mice [259]. In 1998, Tagawa et al. 
[263] reconstituted 6-8 week old C.B-17-Scid mice intraperitoneally with 5 x 106 
human CD34+ cells. Although the engraftment rate was low, the authors 
demonstrated that IL-2 producing gastric carcinoma cell growth was effectively 
inhibited by the engrafted human cell system [263]. Aspord and colleagues [264] 
injected 3-6 x 106 CD34+ cells obtained from peripheral blood of healthy donors 
intravenously into sublethally irradiated NOD/C.B-17-Scid/β2m-/- mice. Four weeks 
later, the mice were subcutaneously engrafted with Hs578T breast cancer cells. 
Repeated injections of T cells autologous to the previously injected CD34+ cells 
resulted in accelerated tumour growth. The authors demonstrated that this effect was 
mediated by CD4+ T cells [264]. In more permissive strains such as 2rγnull mice, 
transplantation of HSCs allows higher engraftment rates [261] and stable multi-
lineage de novo reconstitution after only a few weeks [137] including CD4+ and 
CD8+ T cells [265, 266]. This model was used by Wege et al. who co-transplanted 3 
x 105 human CD34+ cord blood cells together with human breast cancer cells into 
the liver of IL-2rγnull mice [244, 247] to demonstrate that tumour growth was 
accompanied by tumour cell specific T cell activation. However, as stated above, the 
observed activation of human T cells might have also been induced by a MHC 
mismatch between the transplanted human haematopoietic and malignant cell 
populations [244].  There are still fundamental limitations that reduce the 
applicability of this platform. Despite the numbers of human T cells and myeloid 
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 cells that can be found in the bone marrow of 2rγnull mice are higher than in any 
other mouse strain used before, their numbers are still very low in the blood [97]. 
Furthermore the percentage distribution of B and T lymphocytes and myeloids is still 
very different to the one found in humans [97]. The reconstituted human immune cell 
system found in the blood consists mainly of B cells with only a very little amount of 
myeloids, whereas in humans the immune cell system in the blood consists in large 
parts of myeloid cells [97]. The established adaptive immune system is naive [95] 
and an appropriate antigen-specific T cell response is not possible as human T cells 
cannot be educated through HLA restriction within the mouse thymus [97].  
Furthermore, human B cells that develop within the murine host are immature 
without appropriate antibody switch from IgM to IgG after immunization or infection 
[267]. Even after rigorous depletion of T cells, there is a risk of GvHD caused by de 
novo generated T cells, though the onset of the wasting disease can be expected at a 
later time point than after transplantation of PBMCs. The lifespan of the animals 
reconstituted with CD34+ cells is dependent on their strain and age, the number and 
reconstitution capacity of the transplanted cells, the route of transplantation and 
adjuvant interventions such as conditional irradiation [268]. In currently used highly 
permissive 2rγnull mice, first clinical signs for GvHD can be expected when 
bleeding of the mice reveals anaemia and engraftment levels of more than 60% of 
human CD45+ cells [268].  
Most recently, it has been demonstrated that human specific cytokines are 
necessary for the generation of functional human immune cells and their proper 
hierarchical organization as some human cytokines are absent in the mouse system or 
characterized by low homology with murine cytokines [97]. These issues are 
currently being addressed by knock-in of human orthologous genes [269-271] or 
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 insertion of non-orthologous genes into the IL-2rγnull mouse genome [272-274] 
encoding for human specific cytokines or HLA antigens. Another commonly used 
method is the knock-out of murine genes encoding for MHC class I or II molecules 
[248, 273]. These technologies are designed to enhance human innate and adaptive 
immunity within the host by expression of human specific factors such as M-CDF, 
GM-CSF, IL-3, SIRPα and SCF, to decrease the risk of graft versus host disease 
(GvHD) and support the development of human HLA restricted T cells [275]. 
Recently, Rongvaux et al. [268] used Rag2−/−IL2rg−/− mice to knock in genes 
encoding for human IL-3, M-CSF, GM-CSF, thrombopoietin and to insert SIRPα 
into the murine genome. Intrahepatic transplantation of CD34+ fetal liver cells after 
sublethal irradiation resulted in a previously undocumented high engraftment rate for 
CD33+ myeloid cells that were able to infiltrate human melanoma tumour xenografts 
in a manner resembling the human disease [268].  
The third method used to engraft mice with a human immune system is the 
Bone-Liver-Thymus (BLT) model. In this platform, developed independently by two 
different groups in 2006 [276, 277], fetal liver and thymus tissue is implanted under 
the kidney capsule and CD34+ cells, autologous to these tissues, are co-transplanted 
into the murine host. The fetal tissues usually engraft well within the liver and 
develop a functional humanized organoid. In general, the same limitations apply for 
this platform as for the sole transplantation of CD34+ cells described above. 
However, the MHC molecules expressed by the implanted human tissues make a 
selection process of human lymphocytes possible. This results in the development of 
functional human T cells capable of an antigen-specific immune response and a 
higher engraftment rate of human cells in the peripheral blood than in any other 
model [97, 276, 277]. Vatakis et al. used this model to create a platform in which the 
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 anti-tumoural activity of genetically modified human HLA-restricted CD8+ T cells 
can be tested [278]. Fetal liver and thymus tissue was implanted under the kidney 
capsule of 6-8 weeks old IL-2rγnull mice together with 6 x 106 autologous CD34- 
cells and 106 autologous CD34+ cells transduced to express HLA-A*0201-restricted 
melanoma-specific T cell receptor (HLA-A*0201+MART+) [278, 279]. After 4 
weeks, mice were sublethally irradiated and transplanted with 1-5 x 105 transduced 
CD34+ cells obtained from the same fetus to support full reconstitution. The mice 
were then subcutaneously implanted with HLA-A*0201+MART+ and HLA-
A*0201-MART+ melanoma cells, respectively. Growth inhibition and tumour 
necrosis was only observed in HLA-A*0201+MART+ tumours. This observation led 
the authors conclude that the anti-tumoural activity was most likely caused by a 
specific response generated by the genetically modified human HLA-restricted CD8+ 
T cells and was not the result of a non-specific alloreactivity [278, 279]. The success 
of this model demonstrates that the generation of humanized organoids can open up 
new vistas for the translation of research findings in preclinical animal models of 
tumour immunology.  
4.5 CONVERGENCE OF TISSUE ENGINEERING AND CANCER 
RESEARCH 
Current literature has presented increasing evidence that processes such as 
tumour initiation, progression and metastasis are not only the result of genetic or 
epigenetic alterations but are indeed initiated and maintained by factors provided by 
the microenvironment [26, 78, 280, 281]. A paradigm shift has taken place where 
tumours are not anymore seen as a mere conglomerate of homogenous cancer cells 
but rather as organs with a composition at least as intricate as non-diseased organ 
systems [282]. As it is important to have a profound knowledge about how distinct 
cellular and acellular components affect disease development when treating organ or 
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 tissue failure, it is likewise essential to understand the pathophysiology of the tumour 
with its different specialized cell types and extracellular components. To ultimately 
leave the view that tumours consist of cancer cells only [282], it is important to 
dissect the roles of the tumour microenvironment for tumour initiation, progression 
and metastasis.  
The extracellular matrix (ECM) has long been identified as a three-dimensional 
structure that influences cellular function and maintains tissue architecture. It is not 
only an inert “ground substance” in which cells and important biological factors such 
as hormones, nutrients and growth factors are embedded but rather a responsive 
structure that determines mechanical tissue properties and guides cellular functions 
and biochemical processes. Fortunately, researchers have become aware that the 
ECM does not only regulate physiological processes within healthy tissues or organs 
but also significantly influences pathological processes such as tissue regeneration 
after trauma and tumourigenesis. This makes the limitations of conventional two-
dimensional (2D) cell culture experiments easy to understand. Within this context, 
the tissue engineering tool box makes it possible to probe the importance not only of 
microenvironmental cellular cues but also of three-dimensional (3D) structural 
variables for cancer development under reproducible conditions [112]. 
Our group has previously demonstrated that tumour cells cultured in three-
dimensional matrices exhibit different morphological features and biological 
functions compared to cells grown in monolayer cultures [26, 225, 283-286]. While 
there are increasing numbers of 3D models investigating tumour growth, there are 
only very few analysing processes involved in tumour immunology (reviewed in 
detail in [287]). Interestingly, these few studies have demonstrated that 3D culture of 
cancer cells results in down-regulation of tumour-associated antigens and MHC class 
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 I molecules when compared to conventional monolayer cultures [288-291]. This in 
turn leads to a reduced capacity of cytotoxic T lymphocytes to recognize malignant 
cell clones. The observed impaired immune response in 3D cultures is also mediated 
by the increased production of lactic acid in multilayered architecture suppressing the 
proliferation of cytotoxic T cells and differentiation of monocytes towards dendritic 
cells [289, 292]. Taken together, 3D culture models have demonstrated that tumour 
cell escape mechanisms are mediated by hierarchical structures provided by the 
microenvironment.   
There is no doubt that these tissue engineered in vitro models can provide 
significant insights into the interdependence of tumour immunological processes and 
the surrounding milieu, thereby affecting response to therapy. However, these 
platforms certainly have limitations and many important questions remain 
unanswered even with 3D in vitro models. Though they may be suitable to answer 
specific biological questions under reproducible conditions, they are so far only able 
to analyse single steps of the complex disease cascade depending on the cellular and 
architectural repertoire available. Moreover, most 3D culture platforms are naturally 
derived which makes it hard to define their composition in a way to reliably exclude 
batch-to-batch variation [293].  
Validated animal models need to be developed side by side with in vitro model 
platforms providing the opportunity to investigate the multi-cellular interactions and 
dynamic multistep processes involved in cancerogenesis. We have previously shown 
that the technological toolbox developed for TE&RM applications can be used to 
humanize xenograft models of tumour entities such as prostate [294, 295],  breast 
[226, 296] and ovarian [283] cancer. TE&RM strategies can be also used to increase 
the value of existing models of tumour immunology by incorporation of human cell 
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 and extracellular matrix systems to engineer a functionally defined humanized 
stroma before transplantation of human haematopoietic cells or cancer cells [26].  
This allows not only to test the efficacy of certain drugs against human cancer cells 
but also to determine their safety profile and effects on healthy human cells or 
tissues. As shown in the BLT model, humanized organoids can be engineered and 
provide a humanized stroma which makes it possible to supply human transplanted 
cells with factors that are essential for their engraftment and proliferation. This 
allows investigating the behaviour of human cells within their specific niches [295]. 
The latter is of utmost importance as recent literature suggests that some elements of 
the mutual interaction between human cells and their microenvironment are species-
specific [297]. As shown by Rongvaux et al., the level of conservation between 
humans and mice is highly variable for different chemokines and adhesion molecules 
[97]. While the amino acid sequence of some human proteins is highly similar to the 
ones found in mice, some others exhibit only low or even no homology [97]. 
However, even if the protein of interest shares the same amino-acid sequence 
between humans and the model organism, there is the possibility that there is no 
direct correlation between the functional cross-reactivity of proteins of both species. 
This correlation can only be guaranteed if both the protein expressing cell and the 
target cell are of human origin.  
4.6 FUTURE DIRECTIONS 
As outlined above, even in the BLT model there are several limitations that 
prevent high throughput testing of novel drug candidates or targeted cell therapies. 
Advancements are under way and include the transgenic expression of HLA antigens 
to support the development of HLA-restricted T cells and the knock-out of murine 
MHC I and II molecules to decrease the risk for GvHD [95]. Though, the 
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 introduction of human transgenes encoding for human cytokines has been 
demonstrated to be successful in increasing engraftment rates, this has resulted in 
supraphysiological concentrations of these cytokines leading to artificial effects such 
as rapid exhaustion of HSCs [298]. A new way to solve these problems and develop 
a better functioning humanized immune system within mice is the generation of 
peripheral humanized lymphoid organs that can provide species-specific factors 
necessary for the maintenance of human HSCs without the need for genetic 
manipulations. Recent innovations in TE&RM made it indeed possible to engineer 
such ectopic lymphoid constructs in mice.  
Lee et al. [299] implanted polycrylamide hydrogels loaded with human 
BMSCs subcutaneously into IL-2rγnull mice. The implants induced vascularised 
haematopoietic tissue formation and were able to attract transplanted human 
haematopoietic progenitors and leukemic cells, however the engineered constructs 
did not recapitulate the physiological niche morphology since the transplantation of 
human BMSCs did not result in any bone formation. Moreover, the authors failed to 
prove whether the human cells were able to survive and secrete extracellular matrix 
proteins after transplantation into the host [299]. Groen et al. [300] demonstrated that 
subcutaneous implantation of calcium phosphate particles seeded with human MSCs 
resulted in ectopic bone formation and development of a HSC niche in RAG-/-γc-/- 
mice. The authors showed that transplanted human CD34+ and myeloma cells were 
able to home to these osseous constructs but failed to analyse whether the 
transplanted cells can differentiate into different haematopoietic lineages and develop 
a functional bone marrow compartment [300]. Though these studies intended to 
investigate species-specific microenvironmental cues between the human niche and 
human haematopoietic cells, they provide no evidence whether the transplanted 
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 human mesenchymal cells survive and contribute to the niche formation [299, 300]. 
Recently, we were able to demonstrate that a humanized organ bone can be 
engineered that recapitulates both the function and morphology of the 
haematopoietic stem cell niches [295, 296] and is supportive of the maintenance of 
transplanted human haematopoietic stem and progenitor cells (Figure 4.2). With this 
scaffold-based tissue engineering approach we can transplant a large variety of vital 
human cells of different origin tissue and differentiation stages after undergoing an 
in-process control to guarantee sufficient quality and quantity of not only the cells 
seeded onto the scaffolds before implantation but also the ECM secreted. More 
importantly, after in vivo bone formation it is possible to precisely quantify the level 
of chimerism and determine to what degree the transplanted human mesenchymal 
cells contribute to the niche formation [295, 296].  
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Figure 4.2. Tissue engineering of a humanized haematopoietic organ to recapitulate tumour-
immunological processes involved in bone metastasis. (A): Human mesenchymal progenitor cells are 
seeded on tubular bioresorbable composite scaffolds. After in vitro culture and production of human 
extracellular matrix components, the constructs are filled with fibrin glue and recombinant human 
bone morphogenetic protein (rhBMP-7) and subcutaneously implanted into the flanks of 2rγnull mice. 
 (B): Micro-CT analyses show that the tissue engineered constructs recapitulate the morphological 
features of a physiological organ bone with a cortex like outer structure and an inner trabecular 
network. Histology (H&E) demonstrates that intertrabecular spaces are filled with haematopoietic cell 
systems indicating that the organ is functional. (C): Immunostaining for human-specific collagen I 
(hsCol-1) demonstrates that the transplanted human mesenchymal cells are capable of producing 
human extracellular matrix components (human matrix brown, murine pale blue). Transplanted 
A 
B 
C 
D 
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 human mesenchymal cells survive and are incorporated into the newly formed organ bone as indicated 
by human-specific staining for Nuclear Mitotic Apparatus Protein-1 (hsNuMa) (human cells brown, 
murine cells blue). Transplanted human CD34+ cells can engraft the animal after myeloablative 
irradiation and develop a humanized bone marrow compartment within the chimeric ossicles as shown 
by staining for human-specific CD45 (hsCD45) (human cells brown, murine cells blue). (d): Human 
cancer cells can be injected directly into the humanized engineered organs or inoculated into the 
vascular system of the host to recapitulate the bone metastatic cascade. Histological analysis (H&E) 
and human-specific immunostaining for NuMa demonstrate the replacement of the physiological bone 
marrow compartment by the human cancer cells (human cells brown, murine cells blue). 
Multinucleated cells positive for tartrate resistant acid phosphatase (TRAP, red) represent osteoclasts 
indicating osteolysis. [scale bars: 50µm].   
The convergence of this validated tissue engineering concept with other 
established platforms such as the BLT model could be particularly useful to study the 
behaviour of human primary or secondary bone tumours or haematologic 
malignancies within their native microenvironment under influence of human 
immune cells. Expanding on these promising results that are motivating a paradigm 
shift in the field of cancer research, we are currently working on the establishment of 
a humanized orthotopic cancer microenvironment to recapitulate all hallmarks of 
human cancer from the primary tumour to the overt bone metastasis. Such fully-
humanized orthotopic xenograft models of cancer will significantly improve our 
understanding of the relevant biological processes and will provide a preclinical 
platform to investigate potential therapeutics at multiple intervention points of the 
metastatic cascade from the primary tumour to the overt metastasis.  
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 5.1 ABSTRACT 
Advances in tissue engineering have resulted in a versatile tool-box to 
specifically design a tailored microenvironment for haematopoietic stem cells 
(HSCs) in order to study diseases that develop within this setting. However, current 
in vivo models fail to recapitulate the biological processes seen in humans. Here we 
describe a highly reproducible method to engineer humanized bone constructs that 
are able to recapitulate the morphological features and biological functions of the 
HSC niches. Transplantation of biodegradable composite scaffolds seeded with 
human mesenchymal progenitor cells and loaded with rhBMP-7 resulted in the 
development of a chimeric bone organ including a large number of human 
mesenchymal cells which were shown to be metabolically active and capable of 
establishing a humanized microenvironment supportive of the homing and 
maintenance of human HSCs. The ability to tissue engineer a morphologically intact 
and functional large-volume bone organ with a humanized bone marrow 
compartment will help to further elucidate physiological or pathological interactions 
between human HSCs and their native niches. This will foster the translation of 
innovative personalized medicine approaches that have the potential of altering our 
understanding and therapy of human diseases.  
5.2 INTRODUCTION 
Multiple cellular players within the organ bone tightly control the maintenance, 
differentiation and proliferation of haematopoietic stem cells (HSCs) [301]. The 
components of this control mechanism form a complex and discrete functional unit 
called the HSC niche. According to the original concept of this niche, 
haematopoiesis is not possible without the regulating influence of specific 
microdomains of the bone marrow structure, even though HSCs per se possess the 
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 intrinsic capacity of self-renewal, multi-potency and long-term reconstitution [46]. 
The endosteal [48, 49], mesenchymal [50, 51] and vascular systems [52] have been 
identified as the main regulating components of the HSC niches, nevertheless the 
concept of the niche embodies the physical entity of all its single constituents [302]. 
In the last years, researchers have become more aware of the fact that the niche itself 
can be a driver for pathogenesis, particularly in bone metastatic disease or leukemia 
[303, 304]. This has led to a plethora of new investigative approaches to target not 
only the replicating cancer cells but also their microenvironment [305]. A fortiori, the 
characterisation of the cells and extracellular cues that regulate human HSC function 
is essential in order to elucidate the pathophysiology of diseases that develop within 
this microenvironment. 
Over the last decade, several in vivo models have been developed that use 
tissue engineering concepts to mimic the physiological conditions of a functionally 
intact organ bone. Using these technologies, it is possible to create a tailored niche 
for HSCs in mice [62, 306-310]. However, most previous studies lack a 
comprehensive analysis of the viability of the transplanted cells, not to mention that 
they fail to prove whether the cells are indeed functional after transplantation into the 
host [299, 300]. Moreover, some of these studies show none or only small amounts 
of mineralized tissue formation – not a fully regenerated organ bone – and often the 
newly formed bone and marrow compartment is interspersed with large volumes of 
scaffold material, which interferes with the development of a coherent physiological 
tissue network [299, 300]. Importantly, most current models investigating 
haematopoietic niche physiology fail to recapitulate the processes seen in humans as 
they analyse the behaviour and function of murine – and not human – HSCs within 
their niches [309-311].  
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 To move the field forward, firstly bone engineering models are needed that 
more closely recapitulate both the morphological and functional features of a human 
bone organ and allow to transplant a significant amount of HSCs obtained from a 
single engineered bone construct to perform multiple reconstitution assays [309]; and 
secondly more advanced humanized mouse models are necessary to study the 
interactions between human HSCs and their human niches in vivo [213, 226].  
We have recently shown that it is feasible to engineer a vital and 
morphologically intact humanized bone organ within an immuno-compromised 
murine host by transplantation of bio-degradable tubular composite scaffolds seeded 
with human mesenchymal progenitor cells (MPCs) and loaded with recombinant 
human bone morphogenetic protein 7 (rhBMP-7) [295, 296]. In the present study we 
demonstrate that these humanized tissue engineered bone constructs (TEBCs) host a 
fully functional haematopoietic system and recapitulate not only the morphology but 
also the function of a physiological bone organ. We show, to our knowledge for the 
first time, that a morphologically intact and large-volume humanized bone organ is 
supportive of the lodgement and maintenance of human HSCs.  After transplantation 
into mice via the retro-orbital plexus, human HSCs preferentially home to the 
humanized ossicles, resulting in a higher level of bone marrow humanization than in 
the mouse femur.  This tissue engineering platform makes it possible to unravel the 
interactions between human HSCs and their native niche within a murine host.  
5.3 MATERIALS AND METHODS 
Scaffold preparation and primary cell culture: Tubular medical-grade 
polycaprolactone (mPCL) scaffolds were produced by melt-electrospinning, which 
has been previously described in detail by our group [216, 295]. mPCL tubes were 
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 coated with calcium phosphate (CaP) following an in-house protocol to promote cell 
adhesion, osteogenic differentiation in vitro and bone formation in vivo [312].  
Isolation and culture of human and mouse cells: Approval by the human ethics 
committee of the Queensland University of Technology and the Prince Charles 
Hospital Brisbane, Australia (Approval number: 060/232) was obtained before 
initiation of this study. Human cells were isolated from pelvic cancellous bone 
fragments and marrow of an otherwise healthy male patient who underwent total hip 
replacement. Written informed consent for sample collection was obtained from the 
donor in accordance with the World Medical Association’s Declaration of Helsinki. 
Mesenchymal progenitor cells were isolated and cultured as previously described by 
our group [218]. To isolate haematopoietic cells, bone fragments were eliminated 
through a 40 µm cell strainer (BD Bioscience, USA). After one wash with 200 mL of 
PBS containing 2% FCS and 2 mM EDTA, cells were resuspended in 20 mL IMDM 
(Life Technologies, Australia) supplemented with 10% FCS and underlayered with 
20 mL Ficoll Paque Plus (GE Healthcare, Australia) in a 50 mL tube. After spinning 
at 400 g, 30 min no break at 18°C, mononucleated cells were harvested, washed in 
50 mL magnetic activated cell sorting buffer (MACS, Miltenyi Biotec, Australia). 
Pelleted cells were incubated with human CD 34 magnetic selection beads using the 
Miltenyi CD34+ selection kit (Miltenyi Biotec, Cat# 130-046-702) and separated 
using the Miltenyi AutoMACS Pro Separator (Miltenyi Biotec, Cat# 130-092-545). 
CD34+ cells were counted and resuspended in media (IMDM + 20% heat inactivated 
FCS + Penicillin-Strepromycin-Glutamine, Life Technologies) containing 10 ng/mL 
recombinant human Stem Cell Factor (rhSCF, Biolegend, Cat# 573902) and 
incubated overnight at 4°C on rotor. FACS analysis on an aliquot with PE-
conjugated CD34 antibody showed that more than 90% of the cells were CD34+. 
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 After 24h, cells were washed, counted, centrifuged and resuspended in saline 
supplemented with 2% FCS.  
 All animal studies were conducted in conformity with the Australian Code of 
Practise for the Care and Use of Animals for Scientific Purposes and approved by the 
ethics committees of the University of Queensland (approval number: 510/09) and 
the Queensland University of Technology (approval number: 130/025). C57BL/6 
B6.SJL-Ptprca Pep3bBoyJ mice were purchased from the Animal Resources Centre 
(Perth, Australia). NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice and C57BL/6-Tg(UBC-
GFP)30Sca transgenic mice (ubcGFP) expressing GFP were derived from an in-
house breeding colony at the Mater Research Institute. Animals used were female 
and 6-8 weeks of age. Plastic adherent mouse MPCs were isolated from the femora 
of specified mouse strains. Animals were sacrificed by CO2 asphyxiation. After the 
hind limb bones were excised, they were immediately cleaned of all adherent soft 
tissue using a scalpel blade. Bone marrow was flushed out of each individual bone 
using a 21 gauge needle mounted on a 1 mL syringe loaded with PBS containing 2% 
FCS serum and rinsed several times. Empty bones were minced into small pieces and 
bone fragments were washed 3-5 times with PBS containing 2% FCS. Murine MPCs 
were cultured under the same conditions as human MPCs.  Media change was 
performed every 3-4 days. Cellular outgrowth occurred after 6-9 days. Cells were 
expanded to passage 3 for further experiments. 
Cell seeding and characterization of the implanted constructs: Tubular mPCL 
scaffolds were sterilized over night under UV-light and transferred into a 24-well 
plate. After harvesting with 0.25% trypsin and 1mM EDTA, 3 x105 human or mouse 
MPCs were suspended in 40µL media, added onto each scaffold and incubated for 2h 
to allow cell attachment before topping up with 1mL of culture media per well.  
Research paper 2: Tissue engineered humanized bone supports human haematopoiesis in vivo 112 
 After 4 weeks of static culture, the seeded scaffolds were transferred to the vessel of 
a bi-axial rotating bioreactor (QuinXell Technologies, Singapore) filled with 500mL 
of αMEM supplemented with 10% FCS, 10mM β-glycerophosphate, 0.1µM 
dexamethasone and 150µM phosphoascorbic acid for another 4 weeks dynamic cell 
culture to induce cell differentiation and production of extracellular matrix proteins. 
Cell sheets were produced as previously described (Appendix C, Figure C.1) [294]. 
The scaffold/cell constructs were extensively characterized prior to implantation into 
the host animal to assess the quality of the transplanted biological material in terms 
of cell viability and amount of extracellular matrix produced (Appendix C, Figure 
C.2) [295]. Then the constructs were subcutaneously implanted into the right and left 
flank of the mice as shown in Figure C3 (Appendix). 
Flow cytometry: Mice were sacrificed by CO2 asphyxiation, the tissue 
engineered ossicles and mouse femora were removed and immediately placed into 
ice-cold PBS containing 2% FCS. Samples were either further processed for flow 
cytometry analyses or fixed in PBS with 4% paraformaldehyde for 24 h at 4°C for 
histology processing or Micro-CT scanning. For flow cytometry, ossicles were 
gently crushed with a mortar and pestle in ice-cold PBS with 2% FCS and then 
filtered on a 40µm cell strainer. Femoral bone marrow was harvested by flushing the 
bones with PBS containing 2% FCS. Cell suspensions were then spun at 400g for 5 
min at 4°C. Supernatant was removed and cells were resuspended in 1mL PBS 
containing 2% FCS.  
Flow cytometry analyses of the murine haematopoietic system was performed 
as previously described [313]. Aliquots of 1 x 106 bone marrow cells were stained 
with mouse CD11b-PECY7, B220-APCCY7, mouse CD3ε-Pacific Blue, mouse 
CD45.1-PE and mouse CD45.2-APC to identify CD45.2 vs CD45.1 chimerism in 
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 myeloid and lymphoid lineages. Bone marrow cells were also stained with 
biotinylated mouse CD3ε, CD5, B220, CD11b, Gr1, Ter119, streptavidin-
Alexafuor700, anti-Sca1-PECY7, anti-Kit-APC, CD48-PacificBlue and CD150-PE 
to numerate HSPCs. Dead cells were excluded using 7-amino actinomycin D.  
 The humanized haematopoietic system was analyzed with the following 
combinations of antibodies mixed in mouse CD16/32 hybridoma supernatant and 5 
µg/mL purified mouse IgG to block IgG Fc receptors: A) biotinylated huCD33 
(Miltenyi Biotech, Cat# 130-098-916) with streptavidin-PECF594 (BD Bioscience, 
Cat#562284), huCD19-FITC (Biolegend, Cat# 302205), huCD20-FITC (Biolegend, 
Cat# 302304),  huCD38-PECY7 (Biolegend, Cat# 303515), huCD3-Pacific Blue 
(Biolegend, Cat# 300431),huCD34-APC (Biolegend, Cat# 343608), hu/muCD11b-
BV605 (Biolegend, Cat# 115539), huCD45-PE (Biolegend, Cat# 304008) and mouse 
CD45-APCCY7 Biolegend, Cat# 103116200); B) Gr1-FITC (Biolegend, Cat# 
108406), hu/muCD11b-BV605 (Biolegend, Cat# 115539), anti-Sca1-PECY7 
(Biolegend, Cat# 108114), muCD117-APC (Biolegend, Cat# 105812), muCD48-
Pacific Blue (Biolegend, Cat#103418), muCD150-PE (Biolegend, Cat# 115904) and 
muCD45-APCCY7 (Biolegend, Cat#103116). Analysis was gated on viable cells 
following exclusion of dead cells with 7-amino actinomycin D (BD Bioscience, Cat# 
555815). 
Micro-CT: Specimens were analysed with a high-resolution Micro-CT scanner 
(µCT 40, Scanco Medical AG, Switzerland) and scanned at a voxel size of 16µm. 
Samples were evaluated at a threshold of 120, a filter width of 1.0 and filter support 
of 2. Specified samples were decalcified with 10% EDTA (pH 7.4) for 2 months and 
the newly formed vessel network within the TEBC was visualized using a radio-
opaque dye (microfil MV-120 blue, MV diluent solution 1:1; Flowtech, MA, USA) 
Research paper 2: Tissue engineered humanized bone supports human haematopoiesis in vivo 114 
 as described by Bolland et al. [314]. Samples were scanned at a voxel size of 8µm 
and evaluated at a threshold of 100, a filter width of 0.8 and a filter support of 1.0. 
Histology/Immunohistochemistry: Haematoxylin/Eosin (H&E) staining was 
performed on paraffin sections using a standard protocol to visualize tissue 
morphology [222]. For immunohistochemical assessment, sections were 
deparaffinized, re-hydrated and incubated with 3% H2O2 (Sigma-Aldrich) for 30min. 
To target intracellular proteins, 0.1% Triton X-100 in PBS was applied for 6 min. 
Sections were incubated with the primary antibodies in 2% BSA/PBS following the 
respective target retrieval method and having been blocked for 1h in 2% BSA 
(Appendix C, Table C.1). Chromagen development was achieved by incubating 
sections with 3,3-diaminobenzidine (Sigma Aldrich) for 5 min. Sections were then  
counterstained with Mayer’s haematoxylin (Sigma Aldrich) and mounted using 
Eukitt mounting media (Kindler, Germany). Human and mouse bone sections were 
used as positive and negative controls, respectively. Finally, samples were examined 
using an Olympus BX-51 microscope with a DP-70 digital camera and DP controller 
imaging software (Olympus).  
Visualization of the osteo-canalicular network: Specified ossicles were 
embedded in poly(methyl-methacrylate). The resin fills the lacunar-canalicular 
system of the osteocytes, the osteoid and marrow but it does not penetrate the 
inorganic bone phase. With mild acid etching, the mineral phase is removed leaving 
the resin cast behind. A minor finish polish of the embedded sample was achieved by 
sequential wet sanding with 400, 600 and 1200 grit sandpapers. The final polish was 
performed with 1.0 alpha alumina powder using a soft cloth polishing wheel. 
According to the protocol described by Feng et al. [223], the polished faces were 
then etched with 37% phosphoric acid for 2-10 sec, washed with sodium 
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 hypochlorite for 5 min and briefly rinsed with ddH2O. The dried blocks were then 
coated with gold sputter and analyzed with a FEI Quanta 200 SEM.  
Transplantation of ossicle marrow leukocytes in long-term competitive 
repopulation assays: The haematopoietic potential of leukocytes contained in the 
ossicle marrow was tested in competitive transplantations in lethally irradiated mice 
as previously described [313]. Briefly, 8 week old female recipient mice (either 
C57BL/6 or B6.SJL CD45.1+) were lethally irradiated with 2 doses of 5.5 Gy 3 hours 
apart the day prior to transplantation using a Caesium γ source. For transplantations, 
106 leukocytes were extracted from ectopic ossicles mixed with 300,000 femoral 
bone marrow cells from naïve congenic mice (either C57BL/6 or B6.SJL CD45.1+) 
in a volume of 200µL of sterile saline for injection, and then injected into the retro-
orbital sinus as previously described [313]. 16 weeks post-transplantation, blood 
samples were collected from the retro-orbital sinus and GFP, CD45.1 and CD45.2 
expression was measured by flow cytometry in the B-, T- and myeloid lineages. The 
number of repopulating units (RU) per 1x106 ossicle marrow leukocytes was 
calculated using the following formula: 𝑅𝑅𝑅𝑅 =  𝐷𝐷 𝑥𝑥 𝐶𝐶(100−𝐷𝐷), where D is the percentage of 
cells derived from the ossicle marrows amongst B- and myeloid cells, and C is the 
number of competing RU from the bone marrow of congenic mice co-transplanted 
with the ossicle marrow cells (C =1 for 100,000 competing marrow cells) [315, 316].  
Humanization of the ossicle’s marrow: Mice carrying humanized ossicles were 
irradiated with 2.25 Gy using a Caesium γ source. 24h later, mice were transplanted 
with human haematopoietic cells isolated from pelvic bone marrow obtained from a 
patient undergoing hip arthroplasty as described above. To humanize the ossicle’s 
bone marrow, each mouse received 13 x 105 CD34+ cells and 1 x 106 CD34- cells in 
a volume of 200 µL via retro-orbital intravenous injection. 
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 Statistical analyses: Data was analysed with SigmaStat 3.5® software for 
Windows. For descriptive statistics, values were reported as the mean, standard 
deviation and range. If the test statistics followed a normal distribution we used the 
Student’s t-test to evaluate differences between two groups. For non-normally 
distributed data the Mann-Whitney U-test was performed. The level of significance 
was set at p≤ 0.05. 
5.4 RESULTS 
5.4.1 Tissue engineered bone serves as a humanized HSC niche 
Histological and micro-CT analyses revealed that humanized TEBCs had 
morphological and structural similarities to native bone tissue, with well-
differentiated trabeculae forming a network interspersed with bone marrow (Figure 
5.1A-C; Appendix C, Movie C.1). The bone mineral density of the humanized 
TEBCs was comparable to the density of the mouse femora (876.9 ± 52.6 
mgHA/cm3, range 821.9 – 944.5 [TEBCs] vs. 924.4 ± 31.4 mgHA/cm3, range 887.6 
– 974.9 [femora]).  After filling the arterial system of the animal with a radio-opaque 
dye and decalcification of the ossicles for 2 months, micro-CT analysis and 
visualisation of the vascular tree indicated that not only the outer part of the TEBC 
but also its centre was well vascularised (Appendix C, Movie C.2). The cellular 
composition of the marrow included haematopoietic cells of various lineages and 
differentiation stages. Haematopoietic cell clusters consisting of erythrocytes, 
lymphocytes, granulocytes and von Willebrand factor-positive megakaryocytes 
accumulated at the margins of well preserved expanded sinusoids. The newly formed 
bone was viable as indicated by an abundance of well-preserved, morphologically 
intact osteocytes within the lacunae. The presence of cuboidal cells consistent with 
osteoblasts and tartrate-resistant acid phosphatase-positive osteoclasts in resorption 
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 pits, both found on the surface of the newly formed bone matrix, indicated an active 
remodelling process (Figure 5.1C).  
 Marrow was extracted from specified humanized TEBCs (n=6) and 
corresponding mouse femora and further analysed by flow cytometry (Figure 5.1D) 
which showed that the average leukocyte number in the humanized TEBCs was 
comparable to the one found in the mouse marrow (10.4 ± 5.8 x 106, range 3.9 – 19.5 
[TEBCs] vs. 15.7 ± 2.5 x 106, range 10.7 – 17.4 [femora]). The ossicles contained 
phenotypically defined mouse CD11b+ granulocytes and monocytes and all 
populations of mouse haematopoietic stem and progenitor cells (HSPCs).  Indeed, 
lineage-negative Kit+ Sca1+ (LKS+) mouse HSPCs were abundant and further 
subdivided into LKS+ CD48+ lineage-restricted progenitors and LKS+ CD48- CD150- 
multipotent progenitors in proportion comparable to that observed in femoral bone 
marrow of the same mice. Interestingly, the proportion of LKS+ CD48- CD150+ 
mouse HSCs was significantly higher in the mouse femora than in the humanized 
ossicles. No staining for CD3+ or B220+ was performed as NSG mice lack mature B 
and T cells [136].  
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Figure 5.1. Humanized tissue engineered bone constructs (hTEBCs) recapitulate the morphological 
characteristics and cellular bone marrow composition of a physiological organ bone. (A) Experimental 
outline: Human mesenchymal progenitor cells (MPCs) were isolated from human cancellous bone 
chips and cultured on scaffolds under osteogenic conditions to induce differentiation and production 
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 of extracellular matrix proteins. After 8 weeks of culture, scaffolds were implanted into NSG mice 
(strain: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (n = 6, 2 scaffolds per mouse). Ten-weeks post 
implantation, humanized ossicles and mouse femora were collected to extract bone marrow cells for 
flow cytometry. (B) Necropsy showed that the implanted constructs were surrounded by a highly-
vascularised layer of dense connective tissue mimicking periosteum. After careful resection of this 
tissue, the ossicle’s cortical shell was visible. The constructs were filled with blood as indicated by 
their dark red colour. Micro-CT analysis demonstrated the physiological morphology of the 
humanized TEBCs. [scale bar: 1mm]. (C) Histological analyses (H&E) showed that the trabecular 
spaces of the ossicle were filled with bone marrow. Bone-lining osteoblasts were located at the surface 
of the trabeculae and osteocytes were scattered within the bony matrix. The bone marrow included 
well preserved expanded sinusoids filled with erythrocytes and haematopoietic cell clusters of 
different lineages such as erythrocytes, lymphocytes and granulocytes. Staining for tartrate resistant 
acid phosphatase (TRAP, red) confirmed the presence of osteoclasts degrading the bone matrix. 
Megakaryocytes were identified as parasinusoidal cells with a large amount of cytoplasm, 
multilobulated nuclei and positive staining for von Willebrand Factor (vWF, brown). [scale bars: 
100μm]. (D) Flow cytometry analysis demonstrated the presence of phenotypic HSCs (LKS+ CD48- 
CD150+), multipotent progenitors (LKS+ CD48- CD150-) and lineage restricted progenitors (LKS+ 
CD48 +) in the humanized ossicle and mouse femora 10 weeks post-implantation [humanized ossicles 
are represented by the bright plots, mouse femora by the dark plots]. 
 To determine the species-origin of the cells assimilated into the bone tissue, 
immuno-staining with human-specific antibodies was performed. A large proportion 
of the cells within the bone matrix, the cartilage and the fibrous tissue was found to 
be of human origin (Figure 5.2A). These cells were shown to be metabolically active 
and capable of developing a humanized bone microenvironment. Extracellular matrix 
proteins within the newly formed bone were positive for human-specific collagen 
type-I and osteocalcin (Figure 5.2B). Cell bodies and filopodiae of osteocytes within 
the humanized bone were visualized by acid etching of hard-tissue embedded 
samples. Scanning electron microscopy (SEM) demonstrated a high degree of 
interconnecting cytoplasmatic extensions, suggesting a functional syncytial 
humanized osteocyte network (Figure 5.2C). 
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Figure 5.2. Human bone cells within the TEBCs are metabolically active and contribute to the 
development of the HSC microenvironment. (A) Cells positive for human nuclear mitotic apparatus 1 
(huNuMa; brown stain) were abundantly scattered within the bone matrix (top panel). Cuboidal cells 
on the surface of bone trabeculae -thus equivalent to osteoblasts- were shown to be largely of human 
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 origin (left high power view, white arrows) demonstrating that the human osteoblasts are actively 
contributing to the production of bone matrix components. Cartilage islands in the centre of the 
construct also contained human cells (right high power view). All tissues incorporated mouse cells 
(blue stain, black arrows) indicating that the newly formed organ is a chimera between both species. 
The bone marrow cells were shown to be exclusively of murine origin. (B) Large parts of the 
extracellular matrix proteins were human-derived as shown by positive staining for human-specific 
collagen type-I (huCol-I, brown) and osteocalcin (huOC, brown). (C) Acid etching of resin-embedded 
ossicles demonstrated that the human cells were embedded within an intact and functional osteocyte 
syncytium. This syncytium was closely associated to the vascular system (vessel marked with 
asterisk). [scale bars: 50μm]. 
5.4.2 The marrow of tissue engineered ossicles is functional 
In the next experiment we tested whether the haematopoietic system within the 
TEBCs is functional. To be able to track the origin of transplanted haematopoietic 
cells in long-term reconstitution assays, we used a congenic transplantation system 
using the C57BL/6 strain that expresses the CD45.2 antigen and the B6.SJL congenic 
strain that expresses the CD45.1 antigen on leukocytes. For this experiment we 
didn’t use NSG mice as a congenic transplantation system which allows 
differentiation between donor and host cells is not available for this strain. On the 
other hand, we have demonstrated that immuno-competent strains such as the 
C57BL/6 don’t allow the development of a humanized organ bone (data not shown). 
Consequently, we seeded scaffolds with MPCs isolated from femora of CD57BL/6 
(CD45.2+) mice as described for human MPCs before. Then they were implanted 
into the flanks of B6.SJL recipients expressing the CD45.1 antigen (Figure 5.3A). 
Flow cytometry of the ossicle bone marrow revealed 28.8 ± 4.7% B cells, 7.6 ± 1.7% 
T cells and 33.0 ± 7.0% myeloid cells (Figure 5.3B) which is much closer to skeletal 
bone marrow (20-30%, 60-70%, 5-10% respectively) than blood (60%, 20%, 20%) 
values. All leukocytes contained in TEBC marrows expressed the CD45.1 antigen 
with no CD45.2+ leukocytes, demonstrating that all haematopoietic cells contained in 
the ossicle marrows were derived from the B6.SJL recipients (Figure 5.3B). As 
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 observed in the xenogenic assay, the ossicle marrow again contained all populations 
of HSPCs in composition and proportion similar to that found in femora of mice 
[317] (Appendix C, Figure.C4A). There were no histo-morphological differences 
between murine TEBCs and the humanized TEBCs (Appendix C, Figure.C4B).   
 To further prove that HSCs contained in the marrow of these ossicles were 
functional, marrow cells were transplanted in a competitive repopulation assay into 
lethally irradiated congenic recipients. To this end, TEBC marrow cells from 5 
different ossicles were pooled and aliquots of 1x106 ossicle marrow cells (CD45.1+) 
were mixed with 300,000 bone marrow cells from naïve untreated C57BL/6 
(CD45.2+) adult congenic mice and transplanted into lethally irradiated C57BL/6 
recipients. Sixteen weeks post-transplantation, blood leukocytes were stained for 
CD45.1 and CD45.2 antigens. CD45.1 chimerism was detected in myeloid, B and T 
cells of all recipients (Figure 5.3C) demonstrating that the marrow contained in 
ectopic ossicles is functional with self-renewing HSCs capable of long-term multi-
lineage haematopoietic reconstitution in a competitive setting.  
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Figure 5.3. The marrow contained in ectopic ossicles is host-derived and contains functional HSCs. 
(A) Experimental outline: Mouse MPCs were isolated from femora of C57BL/6 CD45.2+ donors and 
cultured on the scaffolds. Following osteogenic culture, scaffolds were implanted into congenic 
B6.SJL CD45.1+ recipients. Ten weeks post-implantation, ossicles were collected and crushed to 
extract ectopic bone marrow cells for flow cytometry analyses. Aliquots of ectopic bone marrow cells 
were subsequently tested in a long-term competitive repopulation assay in competition with 3x105 
marrow cells from untreated C57/BL/6 mice. (B) Proportion of CD11b+ myeloid cells, B220+ B cells 
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 and CD3+ T cells in ossicle bone marrows and proportion of myeloid cells, B cells and T cells  
expressing the CD45.2 donor and CD45.1 recipient antigens 10 weeks post implantation. (C) Long-
term competitive repopulation assay demonstrating that ectopic ossicle marrow contains functional 
HSCs. Scatter-plots showing expression of CD45.1 and CD45.2 antigens on myeloid (CD11b+), B 
(B220+) and T (CD3+) cells in a typical recipient mouse. Diagrams on the bottom row show 
percentage of CD45.1+ cells amongst myeloid, B and T cells. Each dot represents a recipient mouse. 
Black dots represent values from mice transplanted with ossicle marrow; white dots are values from 
control recipients that were transplanted with competing cells only. The dotted line shows background 
values derived from control mice. 
 In order to determine the origin of mesenchymal cells that had been integrated 
into the mineralized matrix of the ossicles and in its marrow, MPCs were isolated 
from the femora of ubcGFP transgenic mice that overexpress GFP in all tissues under 
the control of the human ubiquitin C gene promoter (Figure 5.4A). Scaffolds were 
seeded with MPCs expressing GFP as detected by fluorescence microscopy (Figure 
5.4B) and cultured as described above. Ten weeks post-implantation into syngeneic 
C57BL/6 mice, TEBCs were removed. Immunohistochemistry for GFP was 
performed to determine the origin of the bone forming cells within the ossicles. 
Immunostaining of ectopic implants clearly demonstrated that large areas of the 
mineralized ossicles contained donor-derived GFP+ osteocytes. In particular, 
cuboidal cells at the interface between the bone matrix and its marrow, thus with the 
location and morphology of osteoblasts, were GFP+. As expected, GFP expression 
was not detected in endothelial cells forming blood vessels or in the ossicle bone 
marrow (Figure 5.4B). This experiment confirms the results obtained in the 
xenogenic transplantation assay.  
 To quantify the HSC content in the marrow of each individual ossicle, we 
performed long-term competitive repopulation assays with three recipient mice per 
ossicle following the experimental strategy shown in Figure 5.4a. Triplicates of 106 
leukocytes from four individual ossicles were mixed with 200,000 femoral bone 
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 marrow cells from congenic B6.SJL CD45.1+ mice and transplanted into 3 lethally 
irradiated B6.SJL mice per ossicle. Blood chimerism 16 weeks post-transplantation 
demonstrated robust competitive CD45.2+ repopulation in myeloid, B- and T-
lineages demonstrating that the marrow from all ossicles contained long-term 
competitive repopulating HSCs. Based on the percentage of CD45.2+ cells in the B- 
and myeloid lineages, we calculated that ossicles contained 13.5±9.5 repopulating 
units per 1x106 cells, which is very close to the frequency observed in the femoral 
marrow (by definition, one RU per 1x105 cells) (Figure 5.4C). Therefore, 
quantification by long-term competitive repopulation assays demonstrated that the 
ossicle bone marrow contained host-derived HSCs in equivalent frequencies to that 
of femoral marrow in adult mice.  
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 Figure 5.4. Osteocytes and osteoblasts in ectopic ossicles are mainly donor-derived. (A) Experimental 
outline: MPCs were isolated from femora of ubcGFP CD45.2+ donors, and cultured on the scaffolds. 
Following additional culture under osteogenic conditions, scaffolds were implanted into syngeneic 
C57BL/6 CD45.2+ recipients. 10 weeks post-implantation, ossicles were collected and analysed for 
GFP expression by immunohistochemistry. Aliquots of ectopic bone marrow cells were subsequently 
tested in a long-term competitive repopulation assay in competition with 2x105 marrow cells from 
congenic B6.SJL CD45.1+ mice. (B) Epifluorescence of cell-seeded scaffold before implantation 
showing that all cells are GFP-positive (left panel). Immunohistochemistry on ossicle sections with 
GFP antibodies (right panel, GFP+ cells are stained brown). Note the absence of GFP+ cells in the 
marrow counterstained with haematoxylin. (C) Long-term competitive repopulation assays with the 
bone marrow from 4 individual ectopic ossicles (os1 – os4). The percentage of CD45.2+ GFP-negative 
host derived myeloid, B- and T-cells and the number of repopulating units (RU) per 1x106 marrow 
cells is shown for each individual ossicle. [scale bars: 50 μm]. 
5.4.3 Tissue engineered bone supports human haematopoiesis in vivo 
Finally, we tested whether humanized ossicles support the engraftment and 
maintenance of transplanted human HSCs (Figure 5.5A).  Scaffolds were seeded 
with human MPCs and subcutaneously implanted into NSG mice as described above. 
After 10 weeks of bone formation, mice were irradiated with 2.25 Gy. 24h later, they 
received human CD34+ cells by retro-orbital intravenous injection. After 5 weeks, 
the experiment was terminated and the frequency of human haematopoietic stem and 
progenitor cells within the humanized bone and the mouse femur was analysed by 
flow cytometry. Immunohistochemical analyses demonstrated the presence of human 
CD45+ and CD 34+ cells within the ossicle’s bone marrow and mouse femur. CD34+ 
cells were mainly located adjacent to sinusoids, whereas CD45+ cells were scattered 
throughout the bone marrow (Figure 5.5B). Flow cytometry revealed stable 
engraftment for human haematopoietic progenitors (huCD45+ CD34+) and 
haematopoietic stem cells (huCD45+ CD34+ CD38-) in both the mouse femur and the 
humanized ossicle, respectively (Figure 5.5C). Interestingly, we observed a 
significantly higher proportion of huCD45+ CD34+ cells and huCD45+ CD34+ CD38- 
HSCs in the humanized ossicle than in the mouse femur. Human T (huCD45+ CD3+) 
Research paper 2: Tissue engineered humanized bone supports human haematopoiesis in vivo 127 
 and B cells (huCD45+ CD19+ CD20+) were abundant in both the humanized ossicle 
and the mouse femur.  
 
Figure 5.5. Human HSCs engraft predominantly within the humanized bone microenvironment. (A) 
Experimental outline: Human MPCs and human haematopoietic cells were isolated from human 
cancellous bone chips. Humanized bone constructs were engineered within NSG mice (n = 6, 2 
scaffolds per mouse) as described before. Ten weeks post implantation, mice carrying humanized 
Research paper 2: Tissue engineered humanized bone supports human haematopoiesis in vivo 128 
 ossicles were irradiated with 2.25 Gy. 24 hours later, they were transplanted with 13 x 105 CD34+ 
cells and 1 x 106 CD34- cells via the retro-orbital venous plexus. After 5 weeks, mice were euthanized 
to harvest humanized ossicles and mouse femora. (B) Immunohistochemical staining for human CD45 
demonstrated that large numbers of leukocytes within the bone marrow of the humanized ossicle and 
the mouse femur were of human origin (huCD45; brown stain). Only few cells were found to be 
positive for human CD34 (huCD34; brown stain). Haematopoietic progenitors were identified as cells 
that stained positive for both huCD45 and huCD34 on serial sections (white arrows). Endothelial cells 
were negative for huCD34 indicating that they are of murine origin. [scale bars: 20 μm; staining for 
huCD45 and CD34 was performed on serial sections 4 μm apart from each other] (C) Flow cytometry 
analysis demonstrated the presence of phenotypic human haematopoietic progenitors (huCD45+ 
CD34+), HSCs (huCD45+ CD34+ CD38-), B (huCD45+ CD19+ CD20+) and T cells (huCD45+ CD3-) in 
the ossicle and femur bone marrow 5 weeks post-transplantation [humanized ossicles are represented 
by the bright plots, mouse femora by the dark plots]. 
5.5 DISCUSSION 
Recent advancements in tissue engineering and stem cell biology provided the 
regenerative medicine community with the opportunity to establish a toolbox 
necessary to create in vivo niches for HSCs [299, 300, 309-311]. Scotti  et al.[309] 
used collagen type-I meshes seeded with human MSCs and cultured them under 
chondrogenic conditions before subcutaneous implantation into nude C57BL/6 mice. 
The engineered hypertrophic cartilage constructs were remodelled into a bone organ, 
which was shown to host a similar proportion of haematopoietic progenitors as the 
mouse femur. After congenic transplantation of the ossicle’s bone marrow cells into 
lethally irradiated recipients, stable long-term reconstitution was achieved [309]. 
Torisawa et al.[311] placed a mixture of murine demineralised bone powder, 
collagen-I, BMP-2 and BMP-4 into a polymer carrier and implanted this construct 
subcutaneously into CD-1 mice. The cellular composition of the engineered bone 
marrow was comparable to the one found in the femora of the mice. The ossicles 
were positioned within a microfluidic porous device (“lab-on-chip”) and perfused 
with culture media in vitro for 4 days. Reconstitution assays demonstrated that the 
engineered ossicles contained functional and self-renewing mouse HSCs [311]. 
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 Groen et al. [300] tried to reconstruct the human haematopoetic niche by 
subcutaneous transplantation of calcium phosphate particles seeded with human 
MSCs into RAG-/-γc-/- mice. Though they observed new bone formation around the 
calcium phosphate particles after 8 weeks, they were not able to prove whether the 
newly formed osseous constructs were of human origin [300].  
 Prima facie, these platforms might provide new insights into the complex 
mutual interactions between HSCs and their niches. However, as they do not account 
for the obvious differences between murine and human cells [62, 309-311] or don’t 
mimic the morphological and functional features of the human niche [299, 300], 
these model systems - strictly speaking - do not allow a translation of preclinical 
findings from bench to bedside [26, 97]. Relying solely on such models makes it 
difficult to predict results in human medicine [97].  
 The application of in regenerative medicine rooted strategies to bioengineer a 
humanized organ bone with a functional humanized haematopoietic system within a 
mouse makes it possible to explore the full potential of current model systems and 
will open up new vistas for the treatment of haematopoietic disorders or 
malignancies. In our study, we demonstrated that it is feasible to engineer humanized 
bone constructs in vivo that are capable of recapitulating both the morphological 
features and biological functions of the human HSC niche. Humanized tissue 
engineered bone forms a functional unit, which is able to self-organize and to support 
human haematopoiesis. Furthermore, our observations suggest that the mutual 
interactions between HSCs and their microenvironment might be species-specific.  
  In our experiments, we used a standardized and reproducible in vitro bone 
engineering protocol which allows an in-process control of the seeded cells and their 
matrix products before implantation into the animal (Appendix C, Figure.C1 & 
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 Figure C2). Most other studies lack this validation step [62, 300, 310, 311].  
However, due to the utilization of human primary cells, the development of a highly 
reproducible in vitro protocol before implantation of these constructs into animals is 
a conditio sine qua non to specifically answer questions about any disease 
development within the HSC niche in the future.  
  Comprehensive immunostaining for human cells and matrix proteins 
demonstrated that the human cells incorporated into the construct were indeed 
metabolically active and contributed significantly to the niche formation. Moreover, 
osteocytes were characterised by a high degree of interconnecting osteocytic 
processes suggesting a functional syncytium. This differs from previous ectopic bone 
models that did not prove whether the implanted human cells are functional and able 
to generate human matrix proteins [62, 299, 300, 309, 310].  
 In order to prove that the tissue engineered chimeric organ serves as a 
humanized niche for murine HSCs, the bone marrow of the ossicles and mouse 
femora was analysed using flow cytometry. Indeed, the proportion of  murine 
lineage-negative Kit+ Sca1+ (LKS+) progenitors, LKS+ CD48+ lineage-restricted and 
LKS+ CD48- CD150- multipotent progenitors in the ossicles were comparable to that 
observed in femora of the same mice. However, the proportion of LKS+ CD48- 
CD150+ HSCs was significantly higher in the mouse bones than in the humanized 
ossicles.  
 For NSG mice, a congenic system that allows tracing of cells in long-term 
reconstitution assays is not available yet. Therefore, a congenic transplantation assay 
was used to demonstrate that the ossicle bone marrow is fully functional. As seen in 
the humanized transplantation system, the proportion of leukocytes and HSPCs in the 
murine tissue engineered ossicles closely resembled the cellular composition found 
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 in the marrow of the mouse femora. Via competitive long-term reconstitution assays 
we demonstrated that the marrow of ectopic ossicles was functional and contained 
self-renewing HSCs capable of long-term multi-lineage haematopoietic 
reconstitution. We calculated that ossicles contained 13.5 ± 9.5 repopulating units 
per 106 cells, which is very close to the frequency observed in the femora of mice as 
one RU is defined as the number of long-term competitive HSCs contained in 105 
bone marrow leukocytes. In summary, these findings suggest that TEBCs can 
establish a physiological bone organ capable of maintaining a functional 
haematopoietic system. 
 In the final step of our experiments we aimed to develop a humanized bone 
marrow compartment within the humanized ossicles. After irradiation of NSG mice 
carrying humanized TEBCs, stable engraftment of transplanted HSPCs was observed 
in the mouse organs and humanized ossicles. Interestingly, the proportion of human 
leukocytes was not significantly different between the mouse skeletal marrow and 
the humanized ossicle marrow. However, the proportion of human HSPCs was 
significantly higher in the humanized TEBCs suggesting that we have successfully 
reconstituted an ectopic humanized HSC niche. On the other hand, we have shown 
that the proportion of murine HSCs was significantly higher in the mouse femoral 
marrow than in the humanized TEBC marrow, whereas the proportion of murine 
leukocytes was comparable between both niches. These observations might be 
explained by the lack of species cross-reactivity of many important factors that 
mediate stem cell migration, survival and proliferation [97]. It has been shown that 
murine IL-3 and granulocyte monocyte colony-stimulating factor (GM-CSF) do not 
bind to human receptors and that mouse stem cell factor (SCF, kit ligand) binds only 
poorly to human stem cell factor receptor (c-kit) [100, 101]. Our novel tissue 
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 engineering approach is a first step towards the development of a tailored humanized 
niche that could potentially include different human cell types such as mesenchymal 
or endothelial cells and thereby provide essential soluble factors for the maintenance 
and survival of transplanted human HSCs.  
5.6 CONCLUSION 
Up to date models should ideally account for interspecies incompatibilities 
between stem cells and their niches in order to reliably predict results in human 
medicine and to adequately model processes that highly depend on factors provided 
by the microenvironment such as tumour initiation, progression and metastasis [26, 
78, 280, 281]. Eventually, the unique humanized mouse model presented here allows 
deciphering the mutual interactions between human HSCs and their native 
microenvironment in vivo which paves the way to unravel the etiopathogenesis of a 
large number of diseases such as bone metastasis or haematopoietic malignancies 
where mouse models suggest that the mesenchymal or osteogenic microenvironment 
may drive the development of malignant haematopoietic clones [318-320]. This 
humanized platform could help to shape the future of personalized medicine by 
developing patient-specific therapeutic strategies that target not only the tumour cell 
alone but also the interactions between malignant cells and the tumour stroma [321].  
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 Chapter 6: Summary and future work 
6.1 SYNOPSIS AND SIGNIFICANCE 
Discrepancies between the results of preclinical studies and clinical trials have 
highlighted the strong need for more clinically relevant disease models [92]. Recent 
studies have demonstrated that these discrepancies are in large parts due to 
interspecies differences between humans and the surrogate model system mouse 
[322]. Significant differences between these two species exist at both the genetic and 
the cellular level. Therefore, it is not enough to rely on transgeneic mouse models 
only [90]. Modern disease models have to account for both the genetic and cellular 
differences to reliably predict results in human medicine. This is why researchers 
around the world wish for preclinical models “in which human immune cells and 
other cells can be manipulated” [322].  
One such model that could potentially satisfy this demand was developed in 
this PhD project. The comprehensive data set presented here demonstrates that it is 
possible to engineer a morphologically and functionally intact humanized ossicle in 
vivo that incorporates a fully functional haematopoietic system including 
haematopoietic stem and progenitor cells. In Aim 1 of this PhD project we have 
shown that this tissue engineered humanized bone organ can serve as a target site for 
osteotropic human prostate cancer cells inoculated via the left cardiac ventricle. Once 
metastasized to the bone, the cells were able to proliferate and form metastatic 
lesions making it for the first time possible to study the interactions between human 
prostate cancer cells and vital human bone in vivo. In Aim 2 it was demonstrated that 
the tissue engineered humanized bone organ hosts a functionally defined 
haematopoietic system and can serve as a tailored microenvironment supportive of 
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 the lodgement and maintenance of transplanted human HSCs. More importantly, we 
were able to show that this humanized organ was capable of human haematopoiesis 
resulting in the generation of human immune cells. Interestingly, the proportion of 
transplanted human HSCs was found to be significantly higher in the humanized 
bone microenvironment than in the mouse femora. On the other hand, the proportion 
of murine HSCs was significantly higher in the mouse bones than in the humanized 
ossicles. These observations might be explained by the species-specific chemokine 
repertoire provided by the murine or humanized microenvironment and at the same 
time highlights the need for disease models that account for these differences. The 
unique humanized platform developed in Aim 2 allows unravelling the interactions 
between human HSCs and their native niche within a murine host and could be a 
highly valuable preclinical animal model that can be utilized to develop novel 
therapeutic strategies against a panel of human diseases such as haematopoietic 
disorders or malignancies, inter alia.   
The experiments presented in this thesis are the first steps toward the 
development of individualized, patient-specific diagnostic and therapeutic disease 
models. While traditional preclinical xenograft models – strictly speaking – did only 
allow for testing the effects of novel drug candidates on diseased human cells, the 
newly developed and characterized model allows for testing drugs that target not 
only the cancer cell itself but also the species-specific interactions between malignant 
cells and their microenvironment. From a translational medicine point of view, this 
might open up new vistas for the treatment of patients suffering from diseases such 
as bone metastases, primary bone tumours or haematopoietic malignancies.  
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 6.2 FUTURE PERSPECTIVES  
The materials and results presented in this PhD project are the basis for a new 
set of experiments planned in the near future. The established model allows 
answering a plethora of research questions. Some refinements of the model are 
already under way and are being undertaken in the Hutmacher laboratory or in other 
institutes in a collaborative effort.  
To more closely recapitulate the clinical scenario of primary tumour growth 
within a xenograft model, researchers tried to enable organotypical interactions 
between human tumour cells and the surrounding human stroma by humanizing the 
primary tumour microenvironment [26, 226]. This has already resulted in the 
development of humanized orthotopic models of breast cancer [121, 124, 162, 323, 
324]. However, so far no group has been able to detect spontaneous metastases in 
bone after orthotopic injection of human prostate cancer cells. As reviewed in detail 
in chapter 2, this could be related to either a short observation period, to a relative 
paucity of blood flow at the primary site of implantation or to the missing species-
specific signals from the human milieu necessary to kick-start the metastatic process 
[213]. Therefore, we hypothesize that a humanized prostate microenvironment can 
provide the factors needed for human cancer cells to enter the metastatic cascade and 
eventually develop overt bone metastases. Combining this approach with the 
humanized tissue engineered bone model described in chapter 3, would enable us to 
establish a fully humanized orthotopic model of prostate cancer bone metastasis 
recapitulating all hallmarks of cancer from the primary prostate tumour to overt bone 
metastases. With this unique platform we will be able to test novel treatment 
strategies at multiple intervention points of the metastatic cascade. These ideas are 
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 beyond the scope of the presented thesis but are part of a grant application that has 
been accepted by Worldwide Cancer Research.  
The metastatic extravasation and invasion of cancer cells into the stroma of the 
secondary tumour site is a key step in the development of bone metastasis [325]. 
Though, this step has been extensively studied in various preclinical platforms, the 
main biological processes and mechanisms remain largely elusive as most in vivo 
models allow an analysis at pre-defined endpoints only. Improvements in intravital 
multiphoton microscopy (IVM) make it now possible to dynamically study these 
steps of the bone metastatic cascade in multiple spatial and sequential dimensions 
[326, 327]. However, so far, there are only very few studies using IVM techniques to 
study processes involved in bone metastasis. Dreau et al. [328] placed calvarial bone 
fragments of syngeneic neonates into dorsal skin-fold chambers carried by CB6 
mice. After 3 days, 2 x 105 4T1 murine mammary carcinoma cells were injected into 
the chamber. Changes in vascularisation were monitored over the next 18 days by 
IVM. The authors demonstrated that vascularisation of the tumours was significantly 
reduced upon treatment with Bosentan, an endothelin-1 antagonist. Tumour growth 
and metastasis to the bone was assessed by means of histology but not by IVM [328]. 
Reeves et al. [329] transplanted single metatarsal bone fragments obtained from 
newborn mice into SCID mice that were carrying dorsal skin-fold chambers. After 
intracardiac injection of 1 x 105 PC3 cells labelled with green fluorescent protein 
(GFP), the number of cells homing to the implanted bone was monitored for 3 weeks 
via IVM. The first cells were detected in the implanted bone 3 days after intracardiac 
injection with a significant increase in numbers between days 11 and 17. Treatment 
with zoledronic acid or GLPG0187, a non-peptide RGD αν-integrin antagonist, 
significantly reduced the number of cells found within the bone [329, 330]. While 
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 these studies analysed the changes of vascularity involved in tumourigenesis and the 
cancer cell numbers within the bone, they were not able to monitor processes such as 
intraosseous tumour growth and osteolysis. More importantly, no humanized model 
of bone metastasis using IVM has been described so far. Therefore, in collaboration 
with the Friedl laboratory at the MD Anderson Cancer Centre in Houston, 
Texas/USA we are currently working on the establishment of a scaffold-based 
technology that makes it possible to grow humanized bone within a dorsal skin-fold 
chamber and eventually monitor the interactions between human prostate cancer 
cells and the bone microenvironment. Preliminary results have shown that it is 
indeed possible to analyse human tumour growth and invasion and reactive 
remodelling of the humanized stroma in real-time. These experiments have been 
presented at the AACR Annual Meeting 2014 in San Diego, California/USA and are 
published as an abstract in Cancer Research [331]. Future work with this model will 
be focussed on the testing of novel drug candidates. Furthermore, we plan to 
combine the platform described in chapter 5 with IVM modalities to assess the 
migratory behaviour and homing of human HSCs within their niches in real-time. 
This would allow for studying the localisation of HSCs within the bone marrow and 
eventually uncover microdomains necessary for the maintenance or mobilization of 
HSCs.  
The model presented in this thesis is not only suitable to study secondary 
tumours or haematopoietic malignancies within their native microenvironment but 
could also serve as a humanized platform for research on primary bone tumours such 
as osteosarcoma or giant cell tumours.  These tumour entities affect mainly children 
and adolescents and grow predominantly in areas such as the metaphysis or epiphysis 
of long bones where longitudinal bone growth takes place via endochondral 
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 ossification [332]. As shown in chapter 3, we are able to recapitulate certain 
developmental stages of bone growth with our model. Immunostaining for collagen 
type II revealed the presence of hypertrophic hyaline cartilage clusters within the 
tissue engineered bone constructs indicating endochondral ossification [295]. In 
preliminary studies, we have injected luciferase labelled human osteosarcoma cells 
(Saos-2) into tissue engineered bone organs grown in NOD/Scid mice and were able 
to recapitulate typical features of human osteosarcoma growth and pulmonary 
metastasis. This work was presented at the German Congress for Orthopaedics and 
Trauma in Berlin in 2014 [333].  
So far, our humanized tissue engineered bone constructs have been implanted 
subcutaneously only. However, it is well known that significant differences exist in 
the biochemical and mechanical microenviroenment between ectopic and orthotopic 
bone regenerates [334]. At the orthotopic site, implanted tissue engineered constructs 
are exposed to significantly higher loads and strains than at the ectopic site. Via 
mechanotransduction and initiation of specific signalling events, this leads to a 
significantly higher bone remodelling rate and eventually to a higher bone mineral 
density and bone volume fraction [334-336]. As environmental mechanical signals 
do also influence migration and proliferation of cancer cells [337, 338] an orthotopic 
model would be desirable that allows for human bone tumour growth within 
humanized bone integrated into the murine skeleton. One such model is currently 
being developed in our group.  
Our road map of how to create clinically relevant and personalized disease 
models for patients suffering from prostate cancer bone metastasis has recently been 
presented in a review article published in Advanced Drugs and Delivery Reviews [5 
year IF: 15.271, JCR journal ranking 4/256 in pharmacology & pharmacy] [26]. 
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 Another article on the topic is currently under revision in the journal “Current 
Opinion in Biotechnology” [5 year IF: 8.466, JCR journal ranking 2/78 in 
biochemical research methods] [91]. Our aim is to engineer three-dimensional 
systems by integrating the patient’s own cells and stromal elements to generate 
patient-specific models that recapitulate specific stages of a disease in vivo and 
eventually develop more personalized treatment strategies [91] (Figure 6.1).  
 
Figure 6.1. Development of an individualized patient-specific model of prostate cancer bone 
metastasis to test novel drug candidates. As described in chapter 3 of this thesis, a humanized organ 
bone can be engineered within an immuno-incompetent murine host by utilizing the patient’s own 
mesenchymal cells. This organ can then serve as a target site for cancer cells isolated from the 
patient’s prostate tumour. Novel drug candidates can subsequently be tested in a humanized setting 
and if successful be translated into the clinic. Figure adapted and reprinted from Loessner, Holzapfel 
et. Clements, © 2014, with kind permission from Elsevier. 
Summary and future work 140 
 6.3 PUBLICATIONS  
Project related journal articles: 
-  Holzapfel BM, Thibaudeau L, Hesami P, Taubenberger A, Holzapfel NP, 
Mayer-Wagner S, Power C, Clements J, Russell P, Hutmacher DW. 
Humanised xenograft models of bone metastasis revisited: novel insights into 
species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis 
Rev. 2013; 32: 129-45. 
-  Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, 
Crawford R, Ling MT, Clements JA, Russell PJ, Hutmacher DW. Species-
specific homing mechanisms of human prostate cancer metastasis in tissue 
engineered bone. Biomaterials. 2014; 35:4108-15. 
- Holzapfel BM, Wagner F, Thibaudeau L, Levesque J-P, Hutmacher DW. 
Humanized models of tumour immunology in the 21st century: Convergence of 
cancer research and tissue engineering. Stem Cells. 2015. [Epub ahead of 
print]. 
- Holzapfel BM, Hutmacher DW, Nowlan B, Barbier V, Thibaudeau L, 
Theodoropoulos C, Hooper JD, Loessner D, Clements JA, Russell PJ, Pettit 
AR, Winkler JG, Levesque J-P. Tissue engineered bone supports human 
haematopoiesis in vivo. Biomaterials. 2015. [Epub ahead of print]. 
- Loessner D, Holzapfel BM, Clements JA. Engineered microenvironments 
provide new insights into ovarian and prostate cancer progression and drug 
responses. Adv Drug Deliv Rev. 2014. [Epub ahead of print]. 
- Hutmacher DW, Holzapfel BM, De-Juan Pardo E, Loessner D, Pereira B, 
Ellem S, Risbridger G. Convergence of regenerative medicine and systems 
Summary and future work 141 
 biology to develop clinically relevant models of human diseases. Curr Opin 
Biotechnol. 2015. [in Revision]. 
Project related conference proceedings: 
- Holzapfel BM, Thibaudeau L, Loessner D, Clements JA, Russell PJ, 
Hutmacher DW. Engineering of functional human bone and marrow within a 
murine host can offer bone metastasis research the clinically relevant macro-
and microenvironment. Nature – CNIO Cancer symposium on frontiers in 
tumour heterogeneity and plasticity. Madrid, Spain. 27.-30.10.2013. Poster 
Presentation.  
- Holzapfel BM, Thibaudeau L, Russell PJ, Hutmacher DW. Humanized animal 
models of prostate cancer bone metastasis – a new method to investigate 
species-specific mechanisms of cancer cell osteotropism. The TERMIS – 
Americas Annual Conference & Exhibition. Atlanta, Georgia, U.S.A. 10.-
13.11.2013. Poster Presentation. 
- Holzapfel BM, Thibaudeau L, Russell PJ, Clements JA, Hutmacher DW. 
Humanized in vivo models of prostate cancer bone metastasis. Australian – 
Canadian Prostate Cancer Research Alliance Symposium, Port Douglas, 
Queensland, Australia. 14.-18.08.2013. Oral presentation.  
- Holzapfel BM. Basic Research Award Presentation: Species-specific homing 
mechanisms of human prostate cancer metastasis in tissue engineered bone. 
German Congress for Orthopaedics and Trauma.  Berlin, Germany. 28. - 
31.10.2014. Oral Presentation.  
- Holzapfel BM, Clements JA, Russell PJ, Levesque JP, Hutmacher DW. Tissue 
engineered humanized bone supporting human haematopoiesis as a model 
Summary and future work 142 
 system for bone metastasis research. Oz MRS, Australian Metastasis Research 
Society Meeting. Melbourne, Victoria, Australia. 01.12.2014. Poster 
Presentation.  
Non-project related journal articles: 
- Thibaudeau L, Taubenberger AV, Theodoropoulos C, Holzapfel BM, Ramuz 
O, Straub M, Hutmacher DW. New mechanistic insights of integrin β1 in 
breast cancer bone colonization. Oncotarget. 2015; 6:332-44.  
- Kaemmerer E, Melchels FP, Holzapfel BM, Meckel T, Hutmacher DW, 
Loessner D. Gelatine methacrylamide-based hydrogels: an alternative three-
dimensional cancer cell culture system. Acta Biomater. 2014; 10:2551-62. 
- Holzapfel BM, Pilge H, Prodinger PM, Toepfer A, Mayer-Wagner S, 
Hutmacher DW, von Eisenhart-Rothe R, Rudert M, Gradinger R, Rechl H. 
Customised osteotomy guides and endoprosthetic reconstruction for 
periacetabular tumours. Int Orthop. 2014; 38: 1435-42. 
- Holzapfel BM, Reichert JC, Schantz JT, Gbureck U, Rackwitz L, Noeth U, 
Jakob F, Rudert M, Groll J, Hutmacher DW. How smart do biomaterials need 
to be? A translational science and clinical point of view. Adv Drug Reliv Rev. 
2013; 65: 581-603. 
Non-project related conference proceedings: 
- Holzapfel BM, Wagner F, Winkler S, Graessel S, Rudert M, Grifka J, 
Hutmacher DW. A humanized animal model to dissect species-specific 
mechanisms of human osteosarcoma growth and metastasis. German Congress 
for Orthopaedics and Trauma.  Berlin, Germany. 28. - 31.10.2014. Oral 
Presentation. 
Summary and future work 143 
 - Dondossola E, Alexander S, Alexander S, Holzapfel BM, Logothetis CJ, 
Hutmacher DW, Friedl P. A humanized bone model for preclinical intravital 
multiphoton microscopy of prostate cancer lesions. Gordon Research 
Conference: Translating Signaling Mechanisms into Therapy. Galveston, 
Texas, U.S.A. 26.-31.01.2014.  Oral Presentation.  
- Dondossola, Alexander S, Alexander S, Holzapfel BM, Logothetis CJ, 
Hutmacher DW, Friedl P. A humanized bone model for preclinical monitoring 
of prostate cancer lesions by intravital multiphoton microscopy. 105th meeting 
of the American Association for Cancer Research. San Diego, CA, U.S.A., 05.-
09.04.2014. Poster Presentation.  
- Thibaudeau L, Taubenberger A, Holzapfel BM, Hutmacher DW. Investigating 
the role of Beta 1 integrin in breast cancer bone metastasis using in vitro and in 
vivo tissue engineered bone models. The TERMIS-Americas 2013 Annual 
Conference & Exposition. Atlanta, Georgia, U.S.A. 10.-13.11.2013.  
  
Summary and future work 144 
 Appendices  
Appendix A 
Supplementary data for chapter 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 145 
 Table A.1. Humanised xenograft models of breast cancer (literature overview). 
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 Table A.2. Humanised xenograft models of prostate cancer (literature overview). 
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 Appendix B 
Supplementary data for chapter 3 
Movie B.1. Dynamic culture of the human MPC-seeded scaffolds under osteogenic conditions within 
the vessel of a bi-axial bioreactor. Movie B.1 can be downloaded from the publisher’s webpage under: 
http://www.sciencedirect.com/science/article/pii/S0142961214000921#mmc1  
Movie B2. Animated, three-dimensional µCT reconstruction of a representative tissue engineered 
bone construct harvested 14 weeks after transplantation demonstrating its morphological similarity to 
physiological bone. Movie B.2 can be downloaded from the the publisher’s webpage under: 
http://www.sciencedirect.com/science/article/pii/S0142961214000921#mmc2  
Figure B.1. Morphological similarities between tissue engineered bone constructs and mouse bones. 
Histological analysis (H&E) demonstrated that tissue engineered bone constructs (D–F) have 
morphological and structural similarities to femora (A–C) of age-matched control mice. Both are 
characterized by an outer cortical shell surrounding a trabecular network. Bone marrow spaces are 
filled with an abundance of haematopoietic cell clusters of several differentiation stages including 
well-expanded sinusoids indicating a high proliferative capacity. 
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 Appendix C 
Supplementary data for chapter 5 
Table C.1. Summary of antibodies used for immunohistochemical analyses.  
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Figure C.1. MPCs were capable of producing mineralized extracellular matrix in vitro after osteogenic 
induction. (A) Proliferating MPCs form dense cell sheets in vitro. To produce mineralized matrices, 
MPCs were seeded at 3000 cells/cm2. Mineralization was induced for 28 days with α-MEM/10% FBS 
supplemented with 50 μg/mL ascorbate-2-phosphate, 10 mm β-glycerophosphate, 0.1 μm 
dexamethasone (Sigma Aldrich). (B) After 4 weeks of culture under osteogenic conditions, 
mineralization was visualized via Alizarin red staining. (C) Bright field microscopy showed a high 
amount of mineralization (red). (D) Fluorescent staining of mesenchymal cells (nuclei in blue, cell 
bodies in red) with staining of the matrix component fibronectin (green, stained with secondary 
antibody AlexaFluor488). 
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Figure C.2. Characterisation of the scaffolds seeded with human MPCs prior to implantation into the 
murine host. (A) Medical-grade polycaprolactone with a molecular weight of 50 kDa was used to 
produce tubular scaffolds by melt electrospinning. The scaffolds used were 8mm long with a diameter 
of 6mm. (B) Light microscopy during culture showing scaffold fibres (arrows) coated with CaP 
particles and osteoblasts (asterisk) covering the surface of the fibre and adhering preferentially at 
crossing fibres. (C) Prior to implantation, 2 mm disks were stamped out of the scaffolds by using a 
disposable biopsy punch and were used for further analyses. (D) Scanning electron microscopy 
demonstrated that the seeded cells had formed dense sheets overgrowing the open spaces between the 
fibres (arrow). (E) Fluorescent staining revealed the typical osteoblast-like cell morphology with a 
spindle-shaped, elongated cell body with thin filopodiae. (F) Life-dead staining indicated that >90% 
of the seeded cells on the scaffolds were viable before implantation. 
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Figure C.3. Scaffold implantation. (A) Before implantation, the hollow cell seeded scaffolds were 
filled with rhBMP-7 (Stryker Biotech, Hopkinton, MA, USA) embedded in fibrin glue (TISSEELTM 
kit, Baxxter Healthcare, Australia). 30µg of rhBMP-7 in 30µL PBS was mixed with 30µL of thrombin 
and injected into the tube. After adding a mineralized MPC matrix into the construct, 30µL fibrinogen 
was injected to allow for polymerisation. This enables a passive release of the rhBMP-7 through fibrin 
degradation and constrains bone formation to the scaffold boundaries. (B-D) An incision of 
approximately 5mm was made on each flank of the animal and two subcutaneous pockets were 
created via blunt dissection. The pocket size was adjusted to the scaffold dimensions. Care was taken 
to implant the scaffolds only after polymerisation of the fibrin glue. This made it possible to maintain 
the tubular form of the scaffold after implantation. Wounds were closed with resorbable sutures. 
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Figure C.4. (A) Flow cytometry analysis demonstrated the presence of phenotypic HSCs (LKS+ 
CD48- CD150+), multipotent progenitors (LKS+ CD48- CD150-), lineage restricted progenitors 
(LKS+ CD48 +) and myeloid progenitors (LKS-) in the ossicle bone marrows 10 weeks post-
implantation. Gating strategies and numbers of HSCs and HPCs are shown per ossicle (each dot 
represents the value from one separate ossicle, the average is represented by a bar). (B) Histo-
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 morphological analyses of murine TEBCs revealed no differences to humanized TEBCs. The murine 
ossicles contained all bone marrow cell types that have been found in the humanized ossicles and 
native mouse bones, respectively. Immunohistochemistry revealed a high number of megakaryocytes 
stained positive for von Willebrand Factor (vWF, brown). Staining for tartrate resistant acid 
phosphatase (TRAP, red) confirmed the presence of osteoclasts actively degrading the bone matrix. 
Newly formed matrix proteins were visualized by staining for collagen type-I (Col-I, brown). The 
bone matrix, osteocytes and osteoblasts were shown to be positive for the late-stage bone marker 
osteocalcin (OC, brown). [scale bars: 50μm]. 
Movie C.1. Animated, three-dimensional micro-CT reconstruction of a representative tissue 
engineered bone construct harvested 10 weeks after transplantation demonstrating its morphological 
similarity to physiological bone. Movie C.1 can be requested from the author of this thesis.  
Movie C.2. Animated, three-dimensional micro-CT reconstruction of the vascular system supporting 
the tissue engineered bone construct. The vascular tree was filled with a radio-opaque dye (microfil 
MV-120 blue, MV diluent solution 1:1) and the sample was decalcified for 2 months prior to 
scanning. Movie C.2 can be requested from the author of this thesis.  
 
 
 
 
 
Appendices 154 
 Bibliography 
1. Colemanf RE. Metastatic bone disease: clinical features, pathophysiology and 
treatment strategies. Cancer Treat Rev. 2001;27:165-176. 
2. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J 
Clin. 2011;61:69-90. 
3. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588-
1594. 
4. Galasko CS. The anatomy and pathways of skeletal metastases. In: Weiss L, 
Gilbert, A. , ed. Bone metastases. Boston: GK Hall; 1981:49-63. 
5. Coleman RE, Rubens RD. The clinical course of bone metastases from breast 
cancer. Br J Cancer. 1987;55:61-66. 
6. Li S, Peng Y, Weinhandl ED et al. Estimated number of prevalent cases of 
metastatic bone disease in the US adult population. Clin Epidemiol. 
2012;4:87-93. 
7. Nozue M, Oshiro Y, Kurata M et al. Treatment and prognosis in colorectal 
cancer patients with bone metastasis. Oncol Rep. 2002;9:109-112. 
8. Zekri J, Ahmed N, Coleman RE et al. The skeletal metastatic complications 
of renal cell carcinoma. Int J Oncol. 2001;19:379-382. 
9. Hansen BH, Keller J, Laitinen M et al. The Scandinavian Sarcoma Group 
Skeletal Metastasis Register. Survival after surgery for bone metastases in the 
pelvis and extremities. Acta Orthop Scand Suppl. 2004;75:11-15. 
10. Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of 
disease in bone in patients with androgen-independent prostate cancer. J Clin 
Oncol. 1999;17:948-957. 
11. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with 
metastatic prostate cancer based on extent of disease on initial bone scan. 
Cancer. 1988;61:195-202. 
12. Rudert M, Holzapfel, B.M. Operative Behandlungsoptionen von 
Knochenmetastasen. In: Stenzl A, Fehm, T., Hofbauer, L.C., Jakob, F., ed. 
Knochenmetastasen: Springer, Berlin, Heidelberg; 2014:105-115. 
13. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and 
biology of circulating tumor cells. Breast Cancer Res. 2011;13:228. 
14. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev 
Clin Oncol. 2009;6:339-351. 
15. Janni W, Rack B, Schindlbeck C et al. The persistence of isolated tumor cells 
in bone marrow from patients with breast carcinoma predicts an increased 
risk for recurrence. Cancer. 2005;103:884-891. 
16. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow 
micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802. 
17. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: 
challenges and perspectives. Trends Mol Med. 2010;16:398-406. 
18. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the 
U.S. Cancer. 2007;109:2334-2342. 
19. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality 
worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J 
Cancer. 2014. 
Bibliography  155 
 
 20. Clemons MJ, Dranitsaris G, Ooi WS et al. Phase II trial evaluating the 
palliative benefit of second-line zoledronic acid in breast cancer patients with 
either a skeletal-related event or progressive bone metastases despite first-line 
bisphosphonate therapy. J Clin Oncol. 2006;24:4895-4900. 
21. Weinfurt KP, Castel LD, Li Y et al. Health-related quality of life among 
patients with breast cancer receiving zoledronic acid or pamidronate 
disodium for metastatic bone lesions. Med Care. 2004;42:164-175. 
22. Weinfurt KP, Trucco SM, Willke RJ et al. Measuring agreement between 
patient and proxy responses to multidimensional health-related quality-of-life 
measures in clinical trials. An application of psychometric profile analysis. J 
Clin Epidemiol. 2002;55:608-618. 
23. Saad F, Lipton A, Cook R et al. Pathologic fractures correlate with reduced 
survival in patients with malignant bone disease. Cancer. 2007;110:1860-
1867. 
24. Holzapfel BM, Pilge H, Toepfer A et al. [Proximal tibial replacement and 
alloplastic reconstruction of the extensor mechanism after bone tumor 
resection]. Oper Orthop Traumatol. 2012;24:247-262. 
25. Rudert M, Holzapfel BM, Pilge H et al. [Partial pelvic resection (internal 
hemipelvectomy) and endoprosthetic replacement in periacetabular tumors]. 
Oper Orthop Traumatol. 2012;24:196-214. 
26. Loessner D, Holzapfel BM, Clements JA. Engineered microenvironments 
provide new insights into ovarian and prostate cancer progression and drug 
responses. Adv Drug Deliv Rev. 2014; 79-80:193-213. 
27. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment 
to cancer metastasis. Surg Oncol Clin N Am. 2001;10:257-269, vii-viiii. 
28. Paget S. The distribution of secondary growths in cancer of the breast. 
Lancet. 1889;1:571-573. 
29. Halperin EC, Schmidt-Ulrich, R.K., Perez, C.A., Brady, L.W., . The 
discipline of radiation oncology. In: Perez CA, Brady, L.W., Halperin E.C., 
Schmidt-Ulrich, R.K., ed. Principles and Practice of Radiation Oncology, 4th 
ed. Philadelphia: Lippincott Williams & Wilkins; 2004:1-95. 
30. Ewing J. A treatise on tumors. In: Ewing J, ed. Neoplastic Disease, 3rd ed. 
Philadelphia: WB Saunders; 1928:77-89. 
31. Lucke B, Breedis C, Woo ZP et al. Differential growth of metastatic tumors 
in liver and lung; experiments with rabbit V2 carcinoma. Cancer Res. 
1952;12:734-738. 
32. Zeidman I, Buss JM. Transpulmonary passage of tumor cell emboli. Cancer 
Res. 1952;12:731-733. 
33. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 
1973;242:148-149. 
34. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within 
a malignant tumor. Science. 1977;197:893-895. 
35. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic 
patterns of B16 melanoma. Cancer Res. 1980;40:2281-2287. 
36. Schackert G, Fidler IJ. Development of in vivo models for studies of brain 
metastasis. Int J Cancer. 1988;41:589-594. 
37. Pilgrim HI. The kinetics of the organ-specific metastasis of a transplantable 
reticuloendothelial tumor. Cancer Res. 1969;29:1200-1205. 
Bibliography  156 
 
 38. Tarin D, Price JE, Kettlewell MG et al. Mechanisms of human tumor 
metastasis studied in patients with peritoneovenous shunts. Cancer Res. 
1984;44:3584-3592. 
39. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis 
revisited. Nat Rev Cancer. 2003;3:453-458. 
40. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-
eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990;50:6130-
6138. 
41. Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. 
Science. 1968;161:54-56. 
42. Maniatis A, Tavassoli M, Crosby WH. Origin of osteogenic precursor cells in 
extramedullary marrow implants. Blood. 1971;38:569-575. 
43. Friedenstein AJ. Bone marrow osteogenic stem cells. In: Cohn DV, Glorieux, 
F.H., Martin, T.J., ed. Calcium regulation and bone metabolism. Cambridge: 
Elsevier; 1990:353-361. 
44. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic 
precursors. Ciba Found Symp. 1988;136:42-60. 
45. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641-650. 
46. Schofield R. The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood Cells. 1978;4:7-25. 
47. Bianco P. Bone and the haematopoietic niche: a tale of two stem cells. Blood. 
2011;117:5281-5288. 
48. Gong JK. Endosteal marrow: a rich source of haematopoietic stem cells. 
Science. 1978;199:1443-1445. 
49. Zhang J, Niu C, Ye L et al. Identification of the haematopoietic stem cell 
niche and control of the niche size. Nature. 2003;425:836-841. 
50. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid 
progenitors occupy distinct bone marrow niches. Nature. 2013;495:231-235. 
51. Greenbaum A, Hsu YM, Day RB et al. CXCL12 in early mesenchymal 
progenitors is required for haematopoietic stem-cell maintenance. Nature. 
2013;495:227-230. 
52. Kiel MJ, Yilmaz OH, Iwashita T et al. SLAM family receptors distinguish 
haematopoietic stem and progenitor cells and reveal endothelial niches for 
stem cells. Cell. 2005;121:1109-1121. 
53. Li W, Johnson SA, Shelley WC et al. Haematopoietic stem cell repopulating 
ability can be maintained in vitro by some primary endothelial cells. Exp 
Haematol. 2004;32:1226-1237. 
54. Begg SK, Radley JM, Pollard JW et al. Delayed haematopoietic development 
in osteopetrotic (op/op) mice. J Exp Med. 1993;177:237-242. 
55. Lowell CA, Niwa M, Soriano P et al. Deficiency of the Hck and Src tyrosine 
kinases results in extreme levels of extramedullary haematopoiesis. Blood. 
1996;87:1780-1792. 
56. Nilsson SK, Bertoncello I. Age-related changes in extramedullary 
haematopoiesis in the spleen of normal and perturbed osteopetrotic (op/op) 
mice. Exp Haematol. 1994;22:377-383. 
57. Visnjic D, Kalajzic Z, Rowe DW et al. Haematopoiesis is severely altered in 
mice with an induced osteoblast deficiency. Blood. 2004;103:3258-3264. 
58. Taichman RS, Emerson SG. Human osteoblasts support haematopoiesis 
through the production of granulocyte colony-stimulating factor. J Exp Med. 
1994;179:1677-1682. 
Bibliography  157 
 
 59. Marusic A, Kalinowski JF, Jastrzebski S et al. Production of leukemia 
inhibitory factor mRNA and protein by malignant and immortalized bone 
cells. J Bone Miner Res. 1993;8:617-624. 
60. Deguchi K, Yagi H, Inada M et al. Excessive extramedullary haematopoiesis 
in Cbfa1-deficient mice with a congenital lack of bone marrow. Biochem 
Biophys Res Commun. 1999;255:352-359. 
61. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the 
haematopoietic stem cell niche. Nature. 2003;425:841-846. 
62. Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in 
bone marrow sinusoids can organize a haematopoietic microenvironment. 
Cell. 2007;131:324-336. 
63. Corselli M, Chin CJ, Parekh C et al. Perivascular support of human 
haematopoietic stem/progenitor cells. Blood. 2013;121:2891-2901. 
64. Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and 
haematopoietic stem cells form a unique bone marrow niche. Nature. 
2010;466:829-834. 
65. Avecilla ST, Hattori K, Heissig B et al. Chemokine-mediated interaction of 
haematopoietic progenitors with the bone marrow vascular niche is required 
for thrombopoiesis. Nat Med. 2004;10:64-71. 
66. Winkler IG, Barbier V, Nowlan B et al. Vascular niche E-selectin regulates 
haematopoietic stem cell dormancy, self renewal and chemoresistance. Nat 
Med. 2012;18:1651-1657. 
67. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 
2004;350:1655-1664. 
68. Kahn D, Weiner GJ, Ben-Haim S et al. Positron emission tomographic 
measurement of bone marrow blood flow to the pelvis and lumbar vertebrae 
in young normal adults. Blood. 1994;83:958-963. 
69. Wang C, Shen Y. Study on the distribution features of bone metastases in 
prostate cancer. Nucl Med Commun. 2012;33:379-383. 
70. Morgan JW, Adcock KA, Donohue RE. Distribution of skeletal metastases in 
prostatic and lung cancer. Mechanisms of skeletal metastases. Urology. 
1990;36:31-34. 
71. Koizumi M, Yoshimoto M, Kasumi F et al. Comparison between solitary and 
multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol. 
2003;14:1234-1240. 
72. Pittas AG, Adler M, Fazzari M et al. Bone metastases from thyroid 
carcinoma: clinical characteristics and prognostic variables in one hundred 
forty-six patients. Thyroid. 2000;10:261-268. 
73. Lipton A, Colombo-Berra A, Bukowski RM et al. Skeletal complications in 
patients with bone metastases from renal cell carcinoma and therapeutic 
benefits of zoledronic acid. Clin Cancer Res. 2004;10:6397S-6403S. 
74. Wels J, Kaplan RN, Rafii S et al. Migratory neighbors and distant invaders: 
tumor-associated niche cells. Genes Dev. 2008;22:559-574. 
75. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis 
and bone-marrow myelopoiesis in mice lacking the CXC chemokine 
PBSF/SDF-1. Nature. 1996;382:635-638. 
76. Levesque JP, Hendy J, Takamatsu Y et al. Disruption of the 
CXCR4/CXCL12 chemotactic interaction during haematopoietic stem cell 
mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 
2003;111:187-196. 
Bibliography  158 
 
 77. Sun YX, Wang J, Shelburne CE et al. Expression of CXCR4 and CXCL12 
(SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 
2003;89:462-473. 
78. Shiozawa Y, Pedersen EA, Havens AM et al. Human prostate cancer 
metastases target the haematopoietic stem cell niche to establish footholds in 
mouse bone marrow. J Clin Invest. 2011;121:1298-1312. 
79. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize 
haematopoietic stem cells poorly. Blood. 2011;118:4530-4540. 
80. Domanska UM, Timmer-Bosscha H, Nagengast WB et al. CXCR4 inhibition 
with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. 
Neoplasia. 2012;14:709-718. 
81. Nervi B, Ramirez P, Rettig MP et al. Chemosensitization of acute myeloid 
leukemia (AML) following mobilization by the CXCR4 antagonist 
AMD3100. Blood. 2009;113:6206-6214. 
82. Schuettpelz LG, Link DC. Niche competition and cancer metastasis to bone. 
J Clin Invest. 2011;121:1253-1255. 
83. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 
2011;331:1559-1564. 
84. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. 
Cancer Res. 2006;66:11089-11093. 
85. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic 
bone marrow progenitors initiate the pre-metastatic niche. Nature. 
2005;438:820-827. 
86. Krause DS. Regulation of haematopoietic stem cell fate. Oncogene. 
2002;21:3262-3269. 
87. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic 
progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci 
U S A. 1993;90:9374-9378. 
88. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common 
ground. Cancer Metastasis Rev. 2013;32:449-464. 
89. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev 
Cancer. 2009;9:285-293. 
90. Couzin-Frankel J. The littlest patient. Science. 2014;346:24-27. 
91. Hutmacher DW, Holzapfel, B.M., De-Juan-Pardo, E., Loessner, D., Pereira, 
B., Ellem, S., Risbridger, G. Convergence of regenerative medicine and 
systems biology to develop clinically relevant models of human diseases. 
Current opinion in biotechnology [in Revision]. 2015. 
92. Perrin S. Preclinical research: Make mouse studies work. Nature. 
2014;507:423-425. 
93. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D 
productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug 
Discov. 2010;9:203-214. 
94. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study 
human diseases. Curr Opin Endocrinol Diabetes Obes. 2010;17:120-125. 
95. Shultz LD, Brehm MA, Garcia-Martinez JV et al. Humanized mice for 
immune system investigation: progress, promise and challenges. Nat Rev 
Immunol. 2012;12:786-798. 
96. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational 
biomedical research. Nat Rev Immunol. 2007;7:118-130. 
Bibliography  159 
 
 97. Rongvaux A, Takizawa H, Strowig T et al. Human haemato-lymphoid system 
mice: current use and future potential for medicine. Annu Rev Immunol. 
2013;31:635-674. 
98. Cosgun KN, Rahmig S, Mende N et al. Kit regulates HSC engraftment across 
the human-mouse species barrier. Cell Stem Cell. 2014;15:227-238. 
99. Burkhardt AM, Zlotnik A. Translating translational research: mouse models 
of human disease. Cell Mol Immunol. 2013;10:373-374. 
100. Auffray I, Dubart A, Izac B et al. A murine stromal cell line promotes the 
proliferation of the human factor-dependent leukemic cell line UT-7. Exp 
Haematol. 1994;22:417-424. 
101. Jiang X, Gurel O, Mendiaz EA et al. Structure of the active core of human 
stem cell factor and analysis of binding to its receptor kit. Embo J. 
2000;19:3192-3203. 
102. Lacey DL, Boyle WJ, Simonet WS et al. Bench to bedside: elucidation of the 
OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev 
Drug Discov. 2012;11:401-419. 
103. Kostenuik PJ, Nguyen HQ, McCabe J et al. Denosumab, a fully human 
monoclonal antibody to RANKL, inhibits bone resorption and increases 
BMD in knock-in mice that express chimeric (murine/human) RANKL. J 
Bone Miner Res. 2009;24:182-195. 
104. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial 
of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 
2006;355:1018-1028. 
105. Hanke T. Lessons from TGN1412. Lancet. 2006;368:1569-1570; author 
reply 1570. 
106. Pallardy M, Hunig T. Primate testing of TGN1412: right target, wrong cell. 
Br J Pharmacol. 2010;161:509-511. 
107. Blum HE. Advances in individualized and regenerative medicine. Adv Med 
Sci. 2014;59:7-12. 
108. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in 
breast and prostate cancers. Endocr Relat Cancer. 2004;11:207-224. 
109. Fizazi K, Albiges L, Massard C et al. Novel and bone-targeted agents for 
CRPC. Ann Oncol. 2012;23 Suppl 10:x264-x267. 
110. Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ. Progress in the 
treatment of bone metastases in cancer patients. Expert Opin Investig 
Drugs. 2012;21:785-795. 
111. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents 
for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474. 
112. Hutmacher DW. Biomaterials offer cancer research the third dimension. Nat 
Mater. 2010;9:90-93. 
113. Rosol TJ, Tannehill-Gregg SH, LeRoy BE et al. Animal models of bone 
metastasis. Cancer. 2003;97:748-757. 
114. Welch DR. Technical considerations for studying cancer metastasis in vivo. 
Clin Exp Metastasis. 1997;15:272-306. 
115. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and 
beyond. Cancer Metastasis Rev. 2007;26:489-502. 
116. Nicolson GL. Cancer metastasis: tumor cell and host organ properties 
important in metastasis to specific secondary sites. Biochim Biophys Acta. 
1988;948:175-224. 
Bibliography  160 
 
 117. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis 
formation. Bone. 2011;48:37-43. 
118. Goldstein RH, Weinberg RA, Rosenblatt M. Of mice and (wo)men: mouse 
models of breast cancer metastasis to bone. J Bone Miner Res. 2010;25:431-
436. 
119. Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. J 
Urol. 2005;174:820-826. 
120. Richmond A, Su Y. Mouse xenograft models vs GEM models for human 
cancer therapeutics. Dis Model Mech. 2008;1:78-82. 
121. Kuperwasser C, Dessain S, Bierbaum BE et al. A mouse model of human 
breast cancer metastasis to human bone. Cancer Res. 2005;65:6130-6138. 
122. Nemeth JA, Harb JF, Barroso U, Jr. et al. Severe combined immunodeficient-
hu model of human prostate cancer metastasis to human bone. Cancer Res. 
1999;59:1987-1993. 
123. Yonou H, Yokose T, Kamijo T et al. Establishment of a novel species- and 
tissue-specific metastasis model of human prostate cancer in humanized non-
obese diabetic/severe combined immunodeficient mice engrafted with human 
adult lung and bone. Cancer Res. 2001;61:2177-2182. 
124. Xia TS, Wang GZ, Ding Q et al. Bone metastasis in a novel breast cancer 
mouse model containing human breast and human bone. Breast Cancer Res 
Treat. 2012;132:471-486. 
125. Kuperwasser C, Chavarria T, Wu M et al. Reconstruction of functionally 
normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S 
A. 2004;101:4966-4971. 
126. Ganick DJ, Sarnwick RD, Shahidi NT et al. Inability of intravenously 
injected monocellular suspensions of human bone marrow to establish in the 
nude mouse. Int Arch Allergy Appl Immunol. 1980;62:330-333. 
127. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency 
mutation in the mouse. Nature. 1983;301:527-530. 
128. Kyoizumi S, Baum CM, Kaneshima H et al. Implantation and maintenance of 
functional human bone marrow in SCID-hu mice. Blood. 1992;79:1704-
1711. 
129. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem 
cell engraftment. Stem Cells. 1998;16:166-177. 
130. Shultz LD, Schweitzer PA, Christianson SW et al. Multiple defects in innate 
and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 
1995;154:180-191. 
131. Boynton E, Aubin J, Gross A et al. Human osteoblasts survive and deposit 
new bone when human bone is implanted in SCID mouse. Bone. 
1996;18:321-326. 
132. Christianson SW, Greiner DL, Schweitzer IB et al. Role of natural killer cells 
on engraftment of human lymphoid cells and on metastasis of human T-
lymphoblastoid leukemia cells in C57BL/6J-scid mice and in C57BL/6J-scid 
bg mice. Cell Immunol. 1996;171:186-199. 
133. Prochazka M, Gaskins HR, Shultz LD et al. The nonobese diabetic scid 
mouse: model for spontaneous thymomagenesis associated with 
immunodeficiency. Proc Natl Acad Sci U S A. 1992;89:3290-3294. 
134. Meyerrose TE, Herrbrich P, Hess DA et al. Immune-deficient mouse models 
for analysis of human stem cells. Biotechniques. 2003;35:1262-1272. 
Bibliography  161 
 
 135. Nakamura Y, Ito M, Yamamoto T et al. Engraftment of 
NOD/SCID/gammac(null) mice with multilineage neoplastic cells from 
patients with juvenile myelomonocytic leukaemia. Br J Haematol. 
2005;130:51-57. 
136. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid 
cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with 
mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477-6489. 
137. Ishikawa F, Yasukawa M, Lyons B et al. Development of functional human 
blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) 
mice. Blood. 2005;106:1565-1573. 
138. Ito R, Takahashi T, Katano I et al. Current advances in humanized mouse 
models. Cell Mol Immunol. 2012;9:208-214. 
139. Shultz LD, Saito Y, Najima Y et al. Generation of functional human T-cell 
subsets with HLA-restricted immune responses in HLA class I expressing 
NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A. 
2010;107:13022-13027. 
140. Shtivelman E, Namikawa R. Species-specific metastasis of human tumor 
cells in the severe combined immunodeficiency mouse engrafted with human 
tissue. Proc Natl Acad Sci U S A. 1995;92:4661-4665. 
141. Banerjee S, Hussain M, Wang Z et al. In vitro and in vivo molecular evidence 
for better therapeutic efficacy of ABT-627 and taxotere combination in 
prostate cancer. Cancer Res. 2007;67:3818-3826. 
142. Deng X, He G, Levine A et al. Adenovirus-mediated expression of TIMP-1 
and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. 
Int J Cancer. 2008;122:209-218. 
143. Nie D, Nemeth J, Qiao Y et al. Increased metastatic potential in human 
prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. 
Clin Exp Metastasis. 2003;20:657-663. 
144. Carbonell F, Calvo W, Fliedner TM. Cellular composition of human fetal 
bone marrow. Histologic study in methacrylate sections. Acta Anat (Basel). 
1982;113:371-375. 
145. LeBien TW, Wormann B, Villablanca JG et al. Multiparameter flow 
cytometric analysis of human fetal bone marrow B cells. Leukemia. 
1990;4:354-358. 
146. Villablanca JG, Anderson JM, Moseley M et al. Differentiation of normal 
human pre-B cells in vitro. J Exp Med. 1990;172:325-334. 
147. Christensen RD, Harper TE, Rothstein G. Granulocyte-macrophage 
progenitor cells in term and preterm neonates. J Pediatr. 1986;109:1047-
1051. 
148. Emerson SG, Thomas S, Ferrara JL et al. Developmental regulation of 
erythropoiesis by haematopoietic growth factors: analysis on populations of 
BFU-E from bone marrow, peripheral blood, and fetal liver. Blood. 
1989;74:49-55. 
149. Ikuta K, Kina T, MacNeil I et al. A developmental switch in thymic 
lymphocyte maturation potential occurs at the level of haematopoietic stem 
cells. Cell. 1990;62:863-874. 
150. Goya M, Miyamoto S, Nagai K et al. Growth inhibition of human prostate 
cancer cells in human adult bone implanted into nonobese diabetic/severe 
combined immunodeficient mice by a ligand-specific antibody to human 
insulin-like growth factors. Cancer Res. 2004;64:6252-6258. 
Bibliography  162 
 
 151. Ling LJ, Wang S, Liu XA et al. A novel mouse model of human breast cancer 
stem-like cells with high CD44+CD24-/lower phenotype metastasis to human 
bone. Chin Med J (Engl). 2008;121:1980-1986. 
152. Sangai T, Fujimoto H, Miyamoto S et al. Roles of osteoclasts and bone-
derived IGFs in the survival and growth of human breast cancer cells in 
human adult bone implanted into nonobese diabetic/severe combined 
immunodeficient mice. Clin Exp Metastasis. 2008;25:401-410. 
153. Yang W, Lam P, Kitching R et al. Breast cancer metastasis in a human bone 
NOD/SCID mouse model. Cancer Biol Ther. 2007;6:1289-1294. 
154. Yonou H, Ochiai A, Goya M et al. Intraosseous growth of human prostate 
cancer in implanted adult human bone: relationship of prostate cancer cells to 
osteoclasts in osteoblastic metastatic lesions. Prostate. 2004;58:406-413. 
155. Lam P, Yang W, Amemiya Y et al. A human bone NOD/SCID mouse model 
to distinguish metastatic potential in primary breast cancers. Cancer Biol 
Ther. 2009;8:1010-1017. 
156. Liu S, Goldstein RH, Scepansky EM et al. Inhibition of rho-associated kinase 
signaling prevents breast cancer metastasis to human bone. Cancer Res. 
2009;69:8742-8751. 
157. Amemiya Y, Yang W, Benatar T et al. Insulin like growth factor binding 
protein-7 reduces growth of human breast cancer cells and xenografted 
tumors. Breast Cancer Res Treat. 2011;126:373-384. 
158. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by 
mice with severe combined immune deficiency (SCID). Evidence that natural 
killer cells can mediate the specificity of marrow graft rejection. J Exp Med. 
1987;165:1212-1217. 
159. Heike Y, Ohira T, Takahashi M et al. Long-term human haematopoiesis in 
SCID-hu mice bearing transplanted fragments of adult bone and bone marrow 
cells. Blood. 1995;86:524-530. 
160. Sandhu JS, Clark BR, Boynton EL et al. Human haematopoiesis in SCID 
mice implanted with human adult cancellous bone. Blood. 1996;88:1973-
1982. 
161. Hubin F, Humblet C, Belaid Z et al. Maintenance of functional human 
cancellous bone and human haematopoiesis in NOD/SCID mice. Cell 
Transplant. 2004;13:823-831. 
162. Xia TS, Wang J, Yin H et al. Human tissue-specific microenvironment: an 
essential requirement for mouse models of breast cancer. Oncol Rep. 
2010;24:203-211. 
163. Waitches G, Zawin JK, Poznanski AK. Sequence and rate of bone marrow 
conversion in the femora of children as seen on MR imaging: are accepted 
standards accurate? AJR Am J Roentgenol. 1994;162:1399-1406. 
164. Atkinson HR. Bone marrow distribution as a factor in estimating radiation to 
the blood-forming organ: a survey of present knowledge. J Coll Radiol 
Australas. 1962;6:149-154. 
165. Ellis RE. The distribution of active bone marrow in the adult. Phys Med 
Biol. 1961;5:255-258. 
166. Hayman JA, Callahan JW, Herschtal A et al. Distribution of proliferating 
bone marrow in adult cancer patients determined using FLT-PET imaging. 
Int J Radiat Oncol Biol Phys. 2011;79:847-852. 
167. Laor T, Jaramillo D. MR imaging insights into skeletal maturation: what is 
normal? Radiology. 2009;250:28-38. 
Bibliography  163 
 
 168. Hutmacher DW, Loessner D, Rizzi S et al. Can tissue engineering concepts 
advance tumor biology research? Trends Biotechnol. 2010;28:125-133. 
169. Moreau JE, Anderson K, Mauney JR et al. Tissue-engineered bone serves as 
a target for metastasis of human breast cancer in a mouse model. Cancer 
Res. 2007;67:10304-10308. 
170. Schuster J, Zhang J, Longo M. A novel human osteoblast-derived severe 
combined immunodeficiency mouse model of bone metastasis. J Neurosurg 
Spine. 2006;4:388-391. 
171. Hutmacher DW, Horch RE, Loessner D et al. Translating tissue engineering 
technology platforms into cancer research. J Cell Mol Med. 2009;13:1417-
1427. 
172. Goldstein RH, Reagan MR, Anderson K et al. Human bone marrow-derived 
MSCs can home to orthotopic breast cancer tumors and promote bone 
metastasis. Cancer Res. 2010;70:10044-10050. 
173. Moreau J, Anderson KM, Mauney JR et al. Studies of osteotropism on both 
sides of the breast cancer-bone interaction. Ann N Y Acad Sci. 
2007;1117:328-344. 
174. Yu H, VandeVord PJ, Mao L et al. Improved tissue-engineered bone 
regeneration by endothelial cell mediated vascularization. Biomaterials. 
2009;30:508-517. 
175. Holzapfel BM, Reichert JC, Schantz JT et al. How smart do biomaterials 
need to be? A translational science and clinical point of view. Adv Drug 
Deliv Rev. 2012; 65(4): 581-603. 
176. Hutmacher DW, Schantz JT, Lam CX et al. State of the art and future 
directions of scaffold-based bone engineering from a biomaterials 
perspective. J Tissue Eng Regen Med. 2007;1:245-260. 
177. Probst FA, Hutmacher DW, Muller DF et al. [Calvarial reconstruction by 
customized bioactive implant]. Handchir Mikrochir Plast Chir. 
2010;42:369-373. 
178. Reichert JC, Cipitria A, Epari DR et al. A tissue engineering solution for 
segmental defect regeneration in load-bearing long bones. Sci Transl Med. 
2012;4:141ra193. 
179. Reichert JC, Epari DR, Wullschleger ME et al. Establishment of a preclinical 
ovine model for tibial segmental bone defect repair by applying bone tissue 
engineering strategies. Tissue Eng Part B Rev. 2010;16:93-104. 
180. Bauerle T, Adwan H, Kiessling F et al. Characterization of a rat model with 
site-specific bone metastasis induced by MDA-MB-231 breast cancer cells 
and its application to the effects of an antibody against bone sialoprotein. Int 
J Cancer. 2005;115:177-186. 
181. Bauerle T, Peterschmitt J, Hilbig H et al. Treatment of bone metastasis 
induced by MDA-MB-231 breast cancer cells with an antibody against bone 
sialoprotein. Int J Oncol. 2006;28:573-583. 
182. Neudert M, Fischer C, Krempien B et al. Site-specific human breast cancer 
(MDA-MB-231) metastases in nude rats: model characterisation and in vivo 
effects of ibandronate on tumour growth. Int J Cancer. 2003;107:468-477. 
183. Halpern J, Lynch CC, Fleming J et al. The application of a murine bone 
bioreactor as a model of tumor: bone interaction. Clin Exp Metastasis. 
2006;23:345-356. 
Bibliography  164 
 
 184. Tamura H, Ishii S, Ikeda T et al. The Relationship between Urinary 
Pyridinoline, Deoxypyridinoline and Bone Metastasis in a Rat Breast Cancer 
Model. Breast Cancer. 1999;6:23-28. 
185. Tamura H, Ishii S, Ikeda T et al. Therapeutic efficacy of pamidronate in 
combination with chemotherapy to bone metastasis of breast cancer in a rat 
model. Surg Oncol. 1996;5:141-147. 
186. Mayevski A. Ischemia in the brain: the effects of carotid artery ligation and 
decapitation on the energy state of the awake and anesthetized rat. Brain 
Research. 1978;140:217-230. 
187. Yoneda T, Williams PJ, Hiraga T et al. A bone-seeking clone exhibits 
different biological properties from the MDA-MB-231 parental human breast 
cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner 
Res. 2001;16:1486-1495. 
188. Goodale D, Phay C, Postenka CO et al. Characterization of tumor cell 
dissemination patterns in preclinical models of cancer metastasis using flow 
cytometry and laser scanning cytometry. Cytometry A. 2009;75:344-355. 
189. Havens AM, Pedersen EA, Shiozawa Y et al. An in vivo mouse model for 
human prostate cancer metastasis. Neoplasia. 2008;10:371-380. 
190. Thalmann GN, Anezinis PE, Chang SM et al. Androgen-independent cancer 
progression and bone metastasis in the LNCaP model of human prostate 
cancer. Cancer Res. 1994;54:2577-2581. 
191. Tsingotjidou AS, Ahluwalia R, Zhang X et al. A metastatic human prostate 
cancer model using intraprostatic implantation of tumor produced by PC-3 
neolacZ transfected cells. Int J Oncol. 2003;23:1569-1574. 
192. Al Nakouzi N, Bawa O, Le Pape A et al. The IGR-CaP1 xenograft model 
recapitulates mixed osteolytic/blastic bone lesions observed in metastatic 
prostate cancer. Neoplasia. 2012;14:376-387. 
193. An Z, Wang X, Geller J et al. Surgical orthotopic implantation allows high 
lung and lymph node metastatic expression of human prostate carcinoma cell 
line PC-3 in nude mice. Prostate. 1998;34:169-174. 
194. Rembrink K, Romijn JC, van der Kwast TH et al. Orthotopic implantation of 
human prostate cancer cell lines: a clinically relevant animal model for 
metastatic prostate cancer. Prostate. 1997;31:168-174. 
195. Nemeth JA, Yousif R, Herzog M et al. Matrix metalloproteinase activity, 
bone matrix turnover, and tumor cell proliferation in prostate cancer bone 
metastasis. J Natl Cancer Inst. 2002;94:17-25. 
196. Yonou H, Kanomata N, Goya M et al. Osteoprotegerin/osteoclastogenesis 
inhibitory factor decreases human prostate cancer burden in human adult 
bone implanted into nonobese diabetic/severe combined immunodeficient 
mice. Cancer Res. 2003;63:2096-2102. 
197. Sutton EJ, Henning TD, Pichler BJ et al. Cell tracking with optical imaging. 
Eur Radiol. 2008;18:2021-2032. 
198. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of 
mammary adenocarcinoma. Cancer Res. 1975;35:512-516. 
199. Weiss L. Metastatic inefficiency. Adv Cancer Res. 1990;54:159-211. 
200. Welch DR. Do we need to redefine a cancer metastasis and staging 
definitions? Breast Dis. 2006;26:3-12. 
201. Tentler JJ, Tan AC, Weekes CD et al. Patient-derived tumour xenografts as 
models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338-
350. 
Bibliography  165 
 
 202. Daniel VC, Marchionni L, Hierman JS et al. A primary xenograft model of 
small-cell lung cancer reveals irreversible changes in gene expression 
imposed by culture in vitro. Cancer Res. 2009;69:3364-3373. 
203. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J 
Clin. 2013;63:11-30. 
204. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate 
cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-583. 
205. Norgaard M, Jensen AO, Jacobsen JB et al. Skeletal related events, bone 
metastasis and survival of prostate cancer: a population based cohort study in 
Denmark (1999 to 2007). J Urol. 2010;184:162-167. 
206. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid 
for the prevention of skeletal complications in patients with metastatic 
hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 
207. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging 
therapeutic strategies. Nat Rev Clin Oncol. 2011;8:357-368. 
208. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or 
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 
2004;351:1502-1512. 
209. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-
resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:12-23. 
210. Cleeland CS, Body JJ, Stopeck A et al. Pain outcomes in patients with 
advanced breast cancer and bone metastases: results from a randomized, 
double-blind study of denosumab and zoledronic acid. Cancer. 
2013;119:832-838. 
211. Lawrence MG, Taylor RA, Toivanen R et al. A preclinical xenograft model 
of prostate cancer using human tumors. Nat Protoc. 2013;8:836-848. 
212. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus 
human cells: modelling human cancer in mice. Nat Rev Cancer. 2003;3:952-
959. 
213. Holzapfel BM, Thibaudeau L, Hesami P et al. Humanised xenograft models 
of bone metastasis revisited: novel insights into species-specific mechanisms 
of cancer cell osteotropism. Cancer Metastasis Rev. 2013;32:129-145. 
214. Holzapfel BM, Chhaya MP, Melchels FP et al. Can bone tissue engineering 
contribute to therapy concepts after resection of musculoskeletal sarcoma? 
Sarcoma. 2013;2013:153640. 
215. Zaman MH. The role of engineering approaches in analysing cancer invasion 
and metastasis. Nat Rev Cancer. 2013;13:596-603. 
216. Brown TD, Slotosch A, Thibaudeau L et al. Design and fabrication of tubular 
scaffolds via direct writing in a melt electrospinning mode. Biointerphases. 
2012;7:13. 
217. Vaquette C, Ivanovski S, Hamlet SM et al. Effect of culture conditions and 
calcium phosphate coating on ectopic bone formation. Biomaterials. 2013. 
218. Reichert JC, Quent VM, Burke LJ et al. Mineralized human primary 
osteoblast matrices as a model system to analyse interactions of prostate 
cancer cells with the bone microenvironment. Biomaterials. 2010;31:7928-
7936. 
219. Singh H, Teoh SH, Low HT et al. Flow modelling within a scaffold under the 
influence of uni-axial and bi-axial bioreactor rotation. J Biotechnol. 
2005;119:181-196. 
Bibliography  166 
 
 220. Kaighn ME, Narayan KS, Ohnuki Y et al. Establishment and characterization 
of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23. 
221. Bouxsein ML, Boyd SK, Christiansen BA et al. Guidelines for assessment of 
bone microstructure in rodents using micro-computed tomography. J Bone 
Miner Res. 2010;25:1468-1486. 
222. Haas AR, Tuan RS. Chondrogenic differentiation of murine C3H10T1/2 
multipotential mesenchymal cells: II. Stimulation by bone morphogenetic 
protein-2 requires modulation of N-cadherin expression and function. 
Differentiation. 1999;64:77-89. 
223. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and 
osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat 
Genet. 2006;38:1310-1315. 
224. Tannous O, Stall AC, Griffith C et al. Heterotopic bone formation about the 
hip undergoes endochondral ossification: a rabbit model. Clin Orthop Relat 
Res. 2013;471:1584-1592. 
225. Clark AK, Taubenberger AV, Taylor RA et al. A bioengineered 
microenvironment to quantitatively measure the tumorigenic properties of 
cancer-associated fibroblasts in human prostate cancer. Biomaterials. 
2013;34:4777-4785. 
226. Thibaudeau L, Quent VM, Holzapfel BM et al. Mimicking breast cancer-
induced bone metastasis in vivo: current transplantation models and advanced 
humanized strategies. Cancer Metastasis Rev. 2014; 33(2-3):721-35. 
227. Macchiarini F, Manz MG, Palucka AK et al. Humanized mice: are we there 
yet? J Exp Med. 2005;202:1307-1311. 
228. Davies G. What is a Humanized Mouse? Remaking the Species and Spaces of 
Translational Medicine. Body & Society. 2012;18:126-155. 
229. Karpowicz P, Cohen CB, van der Kooy D. It is ethical to transplant human 
stem cells into nonhuman embryos. Nat Med. 2004;10:331-335. 
230. Flanagan SP. 'Nude', a new hairless gene with pleiotropic effects in the 
mouse. Genet Res. 1966;8:295-309. 
231. Lapidot T, Pflumio F, Doedens M et al. Cytokine stimulation of multilineage 
haematopoiesis from immature human cells engrafted in SCID mice. Science. 
1992;255:1137-1141. 
232. Mosier DE, Gulizia RJ, Baird SM et al. Transfer of a functional human 
immune system to mice with severe combined immunodeficiency. Nature. 
1988;335:256-259. 
233. McCune JM, Namikawa R, Kaneshima H et al. The SCID-hu mouse: murine 
model for the analysis of human haematolymphoid differentiation and 
function. Science. 1988;241:1632-1639. 
234. Makino S, Kunimoto K, Muraoka Y et al. Breeding of a non-obese, diabetic 
strain of mice. Jikken Dobutsu. 1980;29:1-13. 
235. Mombaerts P, Iacomini J, Johnson RS et al. RAG-1-deficient mice have no 
mature B and T lymphocytes. Cell. 1992;68:869-877. 
236. Shinkai Y, Rathbun G, Lam KP et al. RAG-2-deficient mice lack mature 
lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 
1992;68:855-867. 
237. Banuelos SJ, Shultz LD, Greiner DL et al. Rejection of human islets and 
human HLA-A2.1 transgenic mouse islets by alloreactive human 
lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) 
mice. Clin Immunol. 2004;112:273-283. 
Bibliography  167 
 
 238. Palucka AK, Gatlin J, Blanck JP et al. Human dendritic cell subsets in 
NOD/SCID mice engrafted with CD34+ haematopoietic progenitors. Blood. 
2003;102:3302-3310. 
239. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol. 
2001;1:200-208. 
240. Goldman JP, Blundell MP, Lopes L et al. Enhanced human cell engraftment 
in mice deficient in RAG2 and the common cytokine receptor gamma chain. 
Br J Haematol. 1998;103:335-342. 
241. Hiramatsu H, Nishikomori R, Heike T et al. Complete reconstitution of 
human lymphocytes from cord blood CD34+ cells using the 
NOD/SCID/gammacnull mice model. Blood. 2003;102:873-880. 
242. Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human 
adaptive immune system in cord blood cell-transplanted mice. Science. 
2004;304:104-107. 
243. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by 
single human melanoma cells. Nature. 2008;456:593-598. 
244. Wege AK, Ernst W, Eckl J et al. Humanized tumor mice--a new model to 
study and manipulate the immune response in advanced cancer therapy. Int J 
Cancer. 2011;129:2194-2206. 
245. Wulf-Goldenberg A, Eckert K, Fichtner I. Intrahepatically transplanted 
human cord blood cells reduce SW480 tumor growth in the presence of 
bispecific EpCAM/CD3 antibody. Cytotherapy. 2011;13:108-113. 
246. Seitz G, Pfeiffer M, Fuchs J et al. Establishment of a rhabdomyosarcoma 
xenograft model in human-adapted mice. Oncol Rep. 2010;24:1067-1072. 
247. Wege AK, Schmidt M, Ueberham E et al. Co-transplantation of human 
haematopoietic stem cells and human breast cancer cells in NSG mice: a 
novel approach to generate tumor cell specific human antibodies. MAbs. 
2014;6:968-977. 
248. King MA, Covassin L, Brehm MA et al. Human peripheral blood leucocyte 
non-obese diabetic-severe combined immunodeficiency interleukin-2 
receptor gamma chain gene mouse model of xenogeneic graft-versus-host-
like disease and the role of host major histocompatibility complex. Clin Exp 
Immunol. 2009;157:104-118. 
249. Abate-Daga D, Lagisetty KH, Tran E et al. A Novel Chimeric Antigen 
Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in 
a Humanized Mouse Model of Pancreatic Cancer. Hum Gene Ther. 2014. 
250. Guichelaar T, Emmelot ME, Rozemuller H et al. Human regulatory T cells do 
not suppress the antitumor immunity in the bone marrow: a role for bone 
marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res. 
2013;19:1467-1475. 
251. Ito A, Ishida T, Yano H et al. Defucosylated anti-CCR4 monoclonal antibody 
exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing 
humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer 
Immunol Immunother. 2009;58:1195-1206. 
252. McCormack E, Adams KJ, Hassan NJ et al. Bi-specific TCR-anti CD3 
redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. 
Cancer Immunol Immunother. 2013;62:773-785. 
253. Hudecek M, Lupo-Stanghellini MT, Kosasih PL et al. Receptor affinity and 
extracellular domain modifications affect tumor recognition by ROR1-
Bibliography  168 
 
 specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19:3153-
3164. 
254. Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, 
and antitumor activity of CAR-engineered T cells is enhanced by 
costimulatory signaling through CD137 (4-1BB). Cancer Res. 
2011;71:4617-4627. 
255. Kloss CC, Condomines M, Cartellieri M et al. Combinatorial antigen 
recognition with balanced signaling promotes selective tumor eradication by 
engineered T cells. Nat Biotechnol. 2013;31:71-75. 
256. Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in 
promoting human T cell-mediated rejection of systemic lymphoma in 
immunodeficient mice. Blood. 2010;115:3508-3519. 
257. Abate-Daga D, Speiser DE, Chinnasamy N et al. Development of a T cell 
receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis 
antigen SSX2 for adoptive immunotherapy of cancer. PLoS One. 
2014;9:e93321. 
258. Tanner A, Taylor SE, Decottignies W et al. Humanized mice as a model to 
study human haematopoietic stem cell transplantation. Stem Cells Dev. 
2014;23:76-82. 
259. Werner-Klein M, Proske J, Werno C et al. Immune humanization of 
immunodeficient mice using diagnostic bone marrow aspirates from 
carcinoma patients. PLoS One. 2014;9:e97860. 
260. Lang J, Weiss N, Freed BM et al. Generation of haematopoietic humanized 
mice in the newborn BALB/c-Rag2null Il2rgammanull mouse model: a 
multivariable optimization approach. Clin Immunol. 2011;140:102-116. 
261. Legrand N, Weijer K, Spits H. Experimental models to study development 
and function of the human immune system in vivo. J Immunol. 
2006;176:2053-2058. 
262. Kikuchi K, Kondo M. Developmental switch of mouse haematopoietic stem 
cells from fetal to adult type occurs in bone marrow after birth. Proc Natl 
Acad Sci U S A. 2006;103:17852-17857. 
263. Tagawa M, Goto S, Takenaga K et al. Reduced tumorigenicity of human 
gastric carcinoma cells engineered to produce IL-2 in SCID mice 
reconstituted with peripheral blood cells from cancer patients. Cancer Lett. 
1998;123:87-93. 
264. Aspord C, Pedroza-Gonzalez A, Gallegos M et al. Breast cancer instructs 
dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate 
tumor development. J Exp Med. 2007;204:1037-1047. 
265. Brehm MA, Cuthbert A, Yang C et al. Parameters for establishing humanized 
mouse models to study human immunity: analysis of human haematopoietic 
stem cell engraftment in three immunodeficient strains of mice bearing the 
IL2rgamma(null) mutation. Clin Immunol. 2010;135:84-98. 
266. Onoe T, Kalscheuer H, Danzl N et al. Human natural regulatory T cell 
development, suppressive function, and postthymic maturation in a 
humanized mouse model. J Immunol. 2011;187:3895-3903. 
267. Biswas S, Chang H, Sarkis PT et al. Humoral immune responses in 
humanized BLT mice immunized with West Nile virus and HIV-1 envelope 
proteins are largely mediated via human CD5+ B cells. Immunology. 
2011;134:419-433. 
Bibliography  169 
 
 268. Rongvaux A, Willinger T, Martinek J et al. Development and function of 
human innate immune cells in a humanized mouse model. Nat Biotechnol. 
2014;32:364-372. 
269. Rathinam C, Poueymirou WT, Rojas J et al. Efficient differentiation and 
function of human macrophages in humanized CSF-1 mice. Blood. 
2011;118:3119-3128. 
270. Rongvaux A, Willinger T, Takizawa H et al. Human thrombopoietin knockin 
mice efficiently support human haematopoiesis in vivo. Proc Natl Acad Sci 
U S A. 2011;108:2378-2383. 
271. Willinger T, Rongvaux A, Takizawa H et al. Human IL-3/GM-CSF knock-in 
mice support human alveolar macrophage development and human immune 
responses in the lung. Proc Natl Acad Sci U S A. 2011;108:2390-2395. 
272. Billerbeck E, Barry WT, Mu K et al. Development of human CD4+FoxP3+ 
regulatory T cells in human stem cell factor-, granulocyte-macrophage 
colony-stimulating factor-, and interleukin-3-expressing NOD-SCID 
IL2Rgamma(null) humanized mice. Blood. 2011;117:3076-3086. 
273. Covassin L, Laning J, Abdi R et al. Human peripheral blood CD4 T cell-
engrafted non-obese diabetic-scid IL2rgamma(null) H2-Ab1 (tm1Gru) Tg 
(human leucocyte antigen D-related 4) mice: a mouse model of human 
allogeneic graft-versus-host disease. Clin Exp Immunol. 2011;166:269-280. 
274. Takagi S, Saito Y, Hijikata A et al. Membrane-bound human SCF/KL 
promotes in vivo human haematopoietic engraftment and myeloid 
differentiation. Blood. 2012;119:2768-2777. 
275. Brehm MA, Shultz LD, Luban J et al. Overcoming current limitations in 
humanized mouse research. J Infect Dis. 2013;208 Suppl 2:S125-130. 
276. Lan P, Tonomura N, Shimizu A et al. Reconstitution of a functional human 
immune system in immunodeficient mice through combined human fetal 
thymus/liver and CD34+ cell transplantation. Blood. 2006;108:487-492. 
277. Melkus MW, Estes JD, Padgett-Thomas A et al. Humanized mice mount 
specific adaptive and innate immune responses to EBV and TSST-1. Nat 
Med. 2006;12:1316-1322. 
278. Vatakis DN, Koya RC, Nixon CC et al. Antitumor activity from antigen-
specific CD8 T cells generated in vivo from genetically engineered human 
haematopoietic stem cells. Proc Natl Acad Sci U S A. 2011;108:E1408-
1416. 
279. Vatakis DN, Bristol GC, Kim SG et al. Using the BLT humanized mouse as a 
stem cell based gene therapy tumor model. J Vis Exp. 2012:e4181. 
280. Ren G, Zhao X, Wang Y et al. CCR2-dependent recruitment of macrophages 
by tumor-educated mesenchymal stromal cells promotes tumor development 
and is mimicked by TNFalpha. Cell Stem Cell. 2012;11:812-824. 
281. Addadi Y, Moskovits N, Granot D et al. p53 status in stromal fibroblasts 
modulates tumor growth in an SDF1-dependent manner. Cancer Res. 
2010;70:9650-9658. 
282. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144:646-674. 
283. Kaemmerer E, Melchels FP, Holzapfel BM et al. Gelatine methacrylamide-
based hydrogels: an alternative three-dimensional cancer cell culture system. 
Acta Biomater. 2014;10:2551-2562. 
Bibliography  170 
 
 284. Sieh S, Taubenberger AV, Rizzi SC et al. Phenotypic characterization of 
prostate cancer LNCaP cells cultured within a bioengineered 
microenvironment. PLoS One. 2012;7:e40217. 
285. Sieh S, Taubenberger AV, Lehman ML et al. Paracrine interactions between 
LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture 
reflect molecular changes during bone metastasis. Bone. 2014;63:121-131. 
286. Taubenberger AV. In vitro microenvironments to study breast cancer bone 
colonisation. Adv Drug Deliv Rev. 2014;79-80C:135-144. 
287. Hirt C, Papadimitropoulos A, Mele V et al. "In vitro" 3D models of tumor-
immune system interaction. Adv Drug Deliv Rev. 2014. 
288. Feder-Mengus C, Ghosh S, Weber WP et al. Multiple mechanisms underlie 
defective recognition of melanoma cells cultured in three-dimensional 
architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer. 
2007;96:1072-1082. 
289. Fischer K, Hoffmann P, Voelkl S et al. Inhibitory effect of tumor cell-derived 
lactic acid on human T cells. Blood. 2007;109:3812-3819. 
290. Ghosh S, Rosenthal R, Zajac P et al. Culture of melanoma cells in 3-
dimensional architectures results in impaired immunorecognition by 
cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated 
antigen. Ann Surg. 2005;242:851-857, discussion 858. 
291. Dangles-Marie V, Richon S, El-Behi M et al. A three-dimensional tumor cell 
defect in activating autologous CTLs is associated with inefficient antigen 
presentation correlated with heat shock protein-70 down-regulation. Cancer 
Res. 2003;63:3682-3687. 
292. Gottfried E, Kunz-Schughart LA, Ebner S et al. Tumor-derived lactic acid 
modulates dendritic cell activation and antigen expression. Blood. 
2006;107:2013-2021. 
293. Ranga A, Gobaa S, Okawa Y et al. 3D niche microarrays for systems-level 
analyses of cell fate. Nat Commun. 2014;5:4324. 
294. Hesami P, Holzapfel B, Taubenberger A et al. A humanized tissue-
engineered in vivo model to dissect interactions between human prostate 
cancer cells and human bone. Clin Exp Metastasis. 2014:1-12. 
295. Holzapfel BM, Wagner F, Loessner D et al. Species-specific homing 
mechanisms of human prostate cancer metastasis in tissue engineered bone. 
Biomaterials. 2014;35:4108-4115. 
296. Thibaudeau L, Taubenberger AV, Holzapfel BM et al. A tissue-engineered 
humanized xenograft model of human breast cancer metastasis to bone. Dis 
Model Mech. 2014;7:299-309. 
297. Parmar H, Cunha GR. Epithelial-stromal interactions in the mouse and 
human mammary gland in vivo. Endocr Relat Cancer. 2004;11:437-458. 
298. Nicolini FE, Cashman JD, Hogge DE et al. NOD/SCID mice engineered to 
express human IL-3, GM-CSF and Steel factor constitutively mobilize 
engrafted human progenitors and compromise human stem cell regeneration. 
Leukemia. 2004;18:341-347. 
299. Lee J, Li M, Milwid J et al. Implantable microenvironments to attract 
haematopoietic stem/cancer cells. Proc Natl Acad Sci U S A. 
2012;109:19638-19643. 
300. Groen RW, Noort WA, Raymakers RA et al. Reconstructing the human 
haematopoietic niche in immunodeficient mice: opportunities for studying 
primary multiple myeloma. Blood. 2012;120:e9-e16. 
Bibliography  171 
 
 301. Levesque JP, Helwani FM, Winkler IG. The endosteal 'osteoblastic' niche and 
its role in haematopoietic stem cell homing and mobilization. Leukemia. 
2010;24:1979-1992. 
302. Nakamura-Ishizu A, Suda T. Haematopoietic stem cell niche: an interplay 
among a repertoire of multiple functional niches. Biochim Biophys Acta. 
2013;1830:2404-2409. 
303. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour 
stroma promote breast cancer metastasis. Nature. 2007;449:557-563. 
304. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current 
concepts and therapeutic opportunities. Blood. 2009;114:1150-1157. 
305. Camacho DF, Pienta KJ. A multi-targeted approach to treating bone 
metastases. Cancer Metastasis Rev. 2014. 
306. Krebsbach PH, Kuznetsov SA, Satomura K et al. Bone formation in vivo: 
comparison of osteogenesis by transplanted mouse and human marrow 
stromal fibroblasts. Transplantation. 1997;63:1059-1069. 
307. Kuznetsov SA, Krebsbach PH, Satomura K et al. Single-colony derived 
strains of human marrow stromal fibroblasts form bone after transplantation 
in vivo. J Bone Miner Res. 1997;12:1335-1347. 
308. Miura Y, Gao Z, Miura M et al. Mesenchymal stem cell-organized bone 
marrow elements: an alternative haematopoietic progenitor resource. Stem 
Cells. 2006;24:2428-2436. 
309. Scotti C, Piccinini E, Takizawa H et al. Engineering of a functional bone 
organ through endochondral ossification. Proc Natl Acad Sci U S A. 
2013;110:3997-4002. 
310. Song J, Kiel MJ, Wang Z et al. An in vivo model to study and manipulate the 
haematopoietic stem cell niche. Blood. 2010;115:2592-2600. 
311. Torisawa YS, Spina CS, Mammoto T et al. Bone marrow-on-a-chip replicates 
haematopoietic niche physiology in vitro. Nat Methods. 2014. 
312. Vaquette C, Ivanovski S, Hamlet SM et al. Effect of culture conditions and 
calcium phosphate coating on ectopic bone formation. Biomaterials. 
2013;34:5538-5551. 
313. Barbier V, Winkler IG, Levesque JP. Mobilization of haematopoietic stem 
cells by depleting bone marrow macrophages. Methods Mol Biol. 
2012;904:117-138. 
314. Bolland BJ, Kanczler JM, Dunlop DG et al. Development of in vivo muCT 
evaluation of neovascularisation in tissue engineered bone constructs. Bone. 
2008;43:195-202. 
315. Purton LE, Scadden DT. Limiting factors in murine haematopoietic stem cell 
assays. Cell Stem Cell. 2007;1:263-270. 
316. Winkler IG, Pettit AR, Raggatt LJ et al. Haematopoietic stem cell mobilizing 
agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of 
action on bone marrow HSC niches and bone formation. Leukemia. 
2012;26:1594-1601. 
317. Winkler IG, Barbier V, Wadley R et al. Positioning of bone marrow 
haematopoietic and stromal cells relative to blood flow in vivo: serially 
reconstituting haematopoietic stem cells reside in distinct nonperfused niches. 
Blood. 2010;116:375-385. 
318. Kode A, Manavalan JS, Mosialou I et al. Leukaemogenesis induced by an 
activating beta-catenin mutation in osteoblasts. Nature. 2014;506:240-244. 
Bibliography  172 
 
 319. Raaijmakers MH, Mukherjee S, Guo S et al. Bone progenitor dysfunction 
induces myelodysplasia and secondary leukaemia. Nature. 2010;464:852-
857. 
320. Walkley CR, Olsen GH, Dworkin S et al. A microenvironment-induced 
myeloproliferative syndrome caused by retinoic acid receptor gamma 
deficiency. Cell. 2007;129:1097-1110. 
321. Levesque JP, Winkler IG, Rasko JE. Nichotherapy for stem cells: there goes 
the neighborhood. Bioessays. 2013;35:183-190. 
322. Reed JC, Herold KC. Thinking bedside at the bench: the NOD mouse model 
of T1DM. Nat Rev Endocrinol. 2015. 
323. Wang J, Xia TS, Liu XA et al. A novel orthotopic and metastatic mouse 
model of breast cancer in human mammary microenvironment. Breast 
Cancer Res Treat. 2010;120:337-344. 
324. Proia DA, Kuperwasser C. Reconstruction of human mammary tissues in a 
mouse model. Nat Protoc. 2006;1:206-214. 
325. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity 
and reciprocity. Cell. 2011;147:992-1009. 
326. Alexander S, Koehl GE, Hirschberg M et al. Dynamic imaging of cancer 
growth and invasion: a modified skin-fold chamber model. Histochem Cell 
Biol. 2008;130:1147-1154. 
327. Alexander S, Weigelin B, Winkler F et al. Preclinical intravital microscopy of 
the tumour-stroma interface: invasion, metastasis, and therapy response. 
Curr Opin Cell Biol. 2013;25:659-671. 
328. Dreau D, Karaa A, Culberson C et al. Bosentan inhibits tumor vascularization 
and bone metastasis in an immunocompetent skin-fold chamber model of 
breast carcinoma cell metastasis. Clin Exp Metastasis. 2006;23:41-53. 
329. Reeves KJ, Hurrell JE, Cecchini M et al. Prostate cancer cells home to bone 
using a novel in vivo model: Modulation by the integrin antagonist 
GLPG0187. Int J Cancer. 2015;136:1731-1740. 
330. Reeves KJ, van der Pluijm, G., Cecchini, M.G., Eaton, C.L., Hamdy, F.C., 
Brown, N.J. P1: A new in vivo model of prostate cancer metastasis to bone. 
IX international meeting on cancer induced bone disease. Bone. 2010;47:282. 
331. Dondossola E, Alexander, S., Alexander, S., Holzapfel, B.M., Logothetis, 
C.J., Hutmacher, D.W., Friedl, P. A humanized bone model for preclinical 
monitoring of prostate cancer lesions by intravital multiphoton microscopy. 
In: Proceedings of the 105th Annual Meeting of the American Association for 
Cancer Research. Cancer Res. 2014;74:4941. 
332. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, 
and treatment strategies. Clin Adv Haematol Oncol. 2010;8:705-718. 
333. Holzapfel B, Wagner, F., Winkler, S., Graessel, S., Rudert, M., Grifka, J., 
Hutmacher, D.W. A humanized animal model to dissect species-specific 
mechanisms of human osteosarcoma growth and metastasis. Deutscher 
Kongress fuer Orthopaedie und Unfallchirurgie. Berlin, Germany; 2014. 
334. Scott MA, Levi B, Askarinam A et al. Brief review of models of ectopic bone 
formation. Stem Cells Dev. 2012;21:655-667. 
335. Chan MW, Hinz B, McCulloch CA. Mechanical induction of gene expression 
in connective tissue cells. Methods Cell Biol. 2010;98:178-205. 
336. Epari DR, Duda GN, Thompson MS. Mechanobiology of bone healing and 
regeneration: in vivo models. Proc Inst Mech Eng H. 2010;224:1543-1553. 
Bibliography  173 
 
 337. Harland B, Walcott S, Sun SX. Adhesion dynamics and durotaxis in 
migrating cells. Phys Biol. 2011;8:015011. 
338. Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nat Rev Mol 
Cell Biol. 2009;10:63-73. 
 
 
Bibliography  174 
 
